

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/002380

International filing date: 26 January 2005 (26.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/539,245
Filing date: 26 January 2004 (26.01.2004)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1297276

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 17, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/539,245

FILING DATE: *January 26, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/02380*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 C.F.R. § 1.53(c).

	Docket Number	21108.0042U1	Type a Plus Sign (+) inside this box	+															
INVENTOR(s)																			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (City and Either State or Foreign Country)																
Yule	David	I.	33 Corral Drive, Penfield, New York 14526 (Citizenship: British)																
Wagner, II	Larry		276 Glen Ellyn Way, Rochester, New York 14618 (Citizenship: USA)																
TITLE OF INVENTION (500 characters max)																			
INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR MUTANTS AND USES THEREOF																			
CORRESPONDENCE ADDRESS																			
Customer Number 23859																			
ENCLOSED APPLICATION PARTS (Check All That Apply)																			
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%;"><input checked="" type="checkbox"/> Provisional Application Title Page</td> <td style="width: 20%; text-align: right;"><i>Number of Pages</i></td> <td style="width: 30%; text-align: right;">[1]</td> </tr> <tr> <td><input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)</td> <td style="text-align: right;"><i>Number of Pages</i></td> <td style="text-align: right;">[54]</td> </tr> <tr> <td><input checked="" type="checkbox"/> Drawing(s)</td> <td style="text-align: right;"><i>Number of Sheets</i></td> <td style="text-align: right;">[16]</td> </tr> <tr> <td colspan="3"><input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time</td> </tr> <tr> <td colspan="3"><input checked="" type="checkbox"/> Other (specify): <u>Sequence Listing (Paper Copy) [122 Pages] and Diskette</u></td> </tr> </table>					<input checked="" type="checkbox"/> Provisional Application Title Page	<i>Number of Pages</i>	[1]	<input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)	<i>Number of Pages</i>	[54]	<input checked="" type="checkbox"/> Drawing(s)	<i>Number of Sheets</i>	[16]	<input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time			<input checked="" type="checkbox"/> Other (specify): <u>Sequence Listing (Paper Copy) [122 Pages] and Diskette</u>		
<input checked="" type="checkbox"/> Provisional Application Title Page	<i>Number of Pages</i>	[1]																	
<input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract)	<i>Number of Pages</i>	[54]																	
<input checked="" type="checkbox"/> Drawing(s)	<i>Number of Sheets</i>	[16]																	
<input checked="" type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time																			
<input checked="" type="checkbox"/> Other (specify): <u>Sequence Listing (Paper Copy) [122 Pages] and Diskette</u>																			

 31355 U.S. PTO
60/539245

012604

16562 U.S. PTO
012604

METHOD PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (Check One)	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR § 1.27.	FILING FEE AMOUNT \$ 80.00
<input checked="" type="checkbox"/> A Credit Card Payment Form PTO-2038 is enclosed to cover the filing fees.	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.	
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number _____.	
<input type="checkbox"/> The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. _____.	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

- ☐ No.
- ☒ Yes. The name of the U.S. Government agency and the Government contract number are:
National Institutes of Health, RO1-DK54568; RO1-DE14756 and PO1-DE13539

Respectfully submitted,

Signature Gwendolyn D. Spratt Date January 26, 2004
Typed or Printed Name: Gwendolyn D. Spratt
Registration No. 36,016

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10	
I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 992 076 722 US, in an envelope addressed to: MAIL STOP PROVISIONAL PATENT APPLICATION , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
<u>Michael Laird</u>	<u>1/26/04</u>
Michael Laird	Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
YULE et al.)	Art Unit: Unassigned
)	
Application No. Unassigned)	Examiner: Unassigned
)	
Filing Date: Concurrently)	Confirmation No. Unassigned
)	
For: INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR)	
MUTANTS AND USES THEREOF)	

AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME
AS INCORPORATING PETITION FOR EXTENSION OF TIME

Mail Stop PROVISIONAL PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

Pursuant to 37 C.F.R. § 1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time for the appropriate length of time.

ATTORNEY DOCKET NO. 21108.0042U1
PATENT

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Gwendolyn D. Spratt
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EL 992 076 722 US, in an envelope addressed to: Mail Stop **PROVISIONAL PATENT APPLICATION**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.



Michael Laird

1/26/04

Date

Express Mail No. EL 992 076 722 US

Attorney Docket No. 21108.0042U1

UTILITY PATENT - PROVISIONAL FILING

PROVISIONAL APPLICATION FOR LETTERS PATENT

TO ALL WHOM IT MAY CONCERN:

Be it known that we, David I. Yule and Larry Wagner, II, residing respectively at 33 Corral Drive, Penfield, New York 14526 and 276 Glen Ellyn Way, Rochester, New York 14618 have invented new and useful improvements in

INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR MUTANTS AND USES THEREOF

for which the following is a specification.

INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR MUTANTS AND USES THEREOF

This invention was made with government support under Grants RO1-DK54568; RO1-
5 DE14756 and PO1-DE13539 awarded by the National Institutes of Health. The government
has certain rights in the invention.

I. BACKGROUND OF THE INVENTION

1. Inositol 1,4,5-trisphosphate receptors are ubiquitous ligand-gated ion channels
10 localized to the endoplasmic reticulum which function to couple activation of cell surface
receptors to intracellular Ca^{2+} release [1]. Genes have been identified which encode three
distinct proteins of molecular weight ~ 300 kDa and have been named the type 1,2 and 3
InsP₃R [2-5]. Notably, the type-1 receptor gene is alternatively spliced to yield additional
variants of the receptor, which have specific tissue distribution [6, 7]. The functional
15 channel is a tetramer, consisting of a binding site for InsP₃ in the N-terminus of each subunit
[8, 9], and a single calcium permeable pore, formed from six transmembrane spanning
helices located towards the C-terminus of each subunit [10, 11]. Between these regions is a
~1600 amino acid cytoplasmic loop which is termed the regulatory and coupling domain.

2. This regulation of InsP₃R, together with the complement of InsP₃R types and the
20 sub-cellular localization of the channel, are thought to be the major determinants of the
spatio-temporal characteristics of agonist-evoked Ca^{2+} signals [13, 14]. These particular
characteristics likely contribute to the fidelity and specificity associated with activation of
 Ca^{2+} -dependent effectors. The most important regulator of InsP₃-induced Ca^{2+} release is
 Ca^{2+} itself [12, 15-17], however, numerous factors including adenine nucleotides [18, 19],
25 protein interactions [12, 20] and phosphorylation by various kinases can significantly
influence InsP₃R function [7, 21-31]. In particular, since all InsP₃R subtypes are
phosphorylated by cAMP and cGMP-dependent protein kinases (PKA and PKG) [7, 21-23,
25, 26, 28, 29, 32-41], the InsP₃R may represent an important nexus for cross-talk between
these distinct signaling pathways. Indeed, cyclic nucleotide-dependent kinase-induced
30 phosphorylation of InsP₃R is proposed to be important in such diverse physiological and
pathophysiological processes as synaptic plasticity [23], remodeling following neurotoxic
insult [39], smooth muscle contractility [36, 37] and fluid secretion [29].

II. BRIEF DESCRIPTION OF THE DRAWINGS

3. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.

4. Figure 1 shows the phosphorylation of S1755 results in enhanced Ca^{2+} release by $\text{S}2^+$ $\text{InsP}_3\text{R-1}$. In Figure 1A, DT40 3ko cells shown in the inset were transfected with M3 receptor, HcRed and $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ as described below. Fura-2 loaded cells were stimulated with 50 nM Carbadol (CCh) to increase $[\text{Ca}^{2+}]_i$. A $[\text{Ca}^{2+}]_i$ increase was only evoked in cells expressing HcRed, and thus presumably M3 receptor and $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ (compare black trace vs. gray trace from cells indicated in the inset). Treatment with 20 μM forskolin, to raise cAMP levels and activate PKA, resulted in a markedly enhanced CCh-induced $[\text{Ca}^{2+}]_i$ signal. After removal of forskolin a subsequent exposure to CCh resulted in a $[\text{Ca}^{2+}]_i$ increase similar to control. In Figure 1B, a similar experimental paradigm was utilized in DT-40 3ko cells expressing S1589A $\text{S}2^+$ $\text{InsP}_3\text{R-1}$. Stimulation with CCh following 20 μM forskolin also resulted in a markedly enhanced $[\text{Ca}^{2+}]_i$ increase relative to a control stimulation. Figure 1C shows that in cells expressing S1755A $\text{S}2^+$ $\text{InsP}_3\text{R-1}$, forskolin treatment did not result in an enhanced signal. Figure 1D shows pooled data from the number of cells indicated for each construct, showing the normalized fold increase in initial $[\text{Ca}^{2+}]_i$ peak over control resulting from forskolin treatment of cells expressing $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ and serine to alanine mutants. Forskolin treatment resulted in CCh responses in Wild type and S1589A $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ cells being significantly different from S1755A $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ expressing cells. Cartoon inset depicts the $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ regulatory and coupling domain. The black shaded region represents the S2 splice region. The functionally important phosphorylation of S1755 is indicated by a gray circle.

5. Figure 2 shows the potentiation of Ca^{2+} release by forskolin after flash photolysis of ciInsP_3PM . DT-40 3ko cells expressing $\text{S}2^+$ $\text{InsP}_3\text{R-1}$ were loaded with the visible wavelength Ca^{2+} indicator Fluo-4 and the cell permeable caged InsP_3 analog $\text{ciInsP}_3\text{-PM}$ as described below. Figure 2A shows minimal photolysis of InsP_3 was evoked by a brief UV flash, (~ 0.5 msec indicated by the arrows) resulting in a small increase in $[\text{Ca}^{2+}]_i$. A subsequent, identical flash of UV light 5 min. later fails to evoke a larger increase in $[\text{Ca}^{2+}]_i$, although increasing the duration of the flash to 5 ms evokes a significantly larger increase in $[\text{Ca}^{2+}]_i$ (arrow, "max uncage"). In Figure 2B, an identical protocol was followed except the second minimal uncaging was performed following 5 min. treatment with 10 μM forskolin.

This treatment resulted in a significantly larger increase in $[Ca^{2+}]_i$ when compared to the initial uncaging. Figure 2C shows pooled data comparing normalized fold increase for the first and second uncaging in the presence or absence of forskolin. Treatment with forskolin results in a statistically significant increase in the second response.

6. Figure 3 shows both S1589 and S1755 are functionally important PKA phosphorylation sites in $S2^- InsP_3R-1$. A similar experimental paradigm as described in fig. 1 was utilized to assess the consequences and functionally important phosphorylation sites in $S2^- InsP_3R-1$. Figure 3A shows treatment of wild type $S2^- InsP_3R-1$ with forskolin resulted in enhanced CCh stimulated Ca^{2+} release with respect to a control CCh stimulation. Figure 3B shows a similar potentiation was observed with S1589A $S2^- InsP_3R-1$ expressing cells. Figure 3C shows a similar enhanced $[Ca^{2+}]_i$ signal was observed following forskolin treatment in S1755A $S2^- InsP_3R-1$ expressing cells. Figure 3D shows that no effect of forskolin treatment was observed in double mutant S1589A/S1755A $S2^- InsP_3R-1$ expressing cells. Figure 3E shows pooled data for the number of cells indicated for each construct. The filled bars indicate data for the particular construct obtained using the low affinity Ca^{2+} indicator Fura-2FF. Normalized fold increase is only significantly altered in the double mutant. Cartoon inset depicts the functionally important phosphorylation of S1589 and S1755, indicated by gray circles.

7. Figure 4 shows the phosphorylation of S1755 by PKG results in enhanced Ca^{2+} release by $S2^+ InsP_3R-1$. A similar experimental paradigm utilized for experiments presented in fig. 1 was performed to assess the effects and site(s) of phosphorylation by PKG on $S2^+ InsP_3R-1$. Figure 4A shows treatment with 10 μM 8-Br cGMP to specifically activate PKG results in a marked potentiation of CCh-evoked Ca^{2+} release when compared to control CCh stimulation in the absence of PKG activation. Figure 4B shows a similar potentiation of Ca^{2+} release following PKG activation was observed in cells expressing S1589A $S2^+ InsP_3R-1$. Figure 4C shows that PKG activation does not enhance Ca^{2+} release by S1755A $S2^+ InsP_3R-1$. Figure 4D shows that PKG does not inhibit CCh-induced Ca^{2+} release by S1755A $S2^+ InsP_3R-1$. Figure 4E shows pooled data for the number of cells indicated for each construct. Normalized fold increase by S1755A $S2^+ InsP_3R-1$ was significantly different from both wild-type and S1589A $S2^+ InsP_3R-1$. Cartoon inset depicts the functionally important phosphorylation of S1755, indicated by a gray circle.

8. Figure 5 shows that treatment with PKI inhibits forskolin but not 8-Br cGMP-induced potentiation. Cells expressing $S2^+ InsP_3R-1$ were treated for 30 mins with myr-PKI(14-22) prior to assessing the effects of activating PKA or PKG. Figure 5A shows that

PKI treatment completely abolishes the forskolin-induced enhancement of Ca^{2+} release. Figure 5B shows that PKI does not affect the 8-Br cGMP-induced enhancement of Ca^{2+} release. Figure 5C shows the results of pooled data.

9. Figure 6 shows PKG activation is without effect on Ca^{2+} release by $\text{S2}^- \text{InsP}_3\text{R-1}$. A similar experimental paradigm used in experiments depicted in fig. 1 was utilized to assess the effects of PKG phosphorylation of $\text{S2}^- \text{InsP}_3\text{R-1}$. Figure 6A shows that PKG activation has no effect on CCh-evoked Ca^{2+} release by wild-type $\text{S2}^- \text{InsP}_3\text{R-1}$. Figure 6B shows that similarly no effect was observed in S1589A $\text{S2}^- \text{InsP}_3\text{R-1}$ expressing cells. Figure 6C shows that no effect was observed in S1755A $\text{S2}^- \text{InsP}_3\text{R-1}$ expressing cells. Figure 6D shows pooled data for the number of cells indicated for each construct. Cartoon depicts absence of phosphorylation by PKG.

10. Figure 7 shows in Figure 7A that ATP treatment of fura-2 loaded mouse parotid acinar cells, in the presence of La^{3+} to block Ca^{2+} entry (isolating P2Y receptors) results in an increase in $[\text{Ca}^{2+}]_i$. The $[\text{Ca}^{2+}]_i$ is markedly enhanced by incubation with forskolin.

15 Figure 7B shows that CCh treatment of human parotid acinar cells results in an increase in $[\text{Ca}^{2+}]_i$ which is potentiated by forskolin treatment. Representative traces from >4 experiments and >3 preparations of tissue.

11. Figure 8A depicts representative traces showing that mutation of both functional phosphorylation sites in the short form of $\text{InsP}_3\text{R-1}$ to glutamate residues results in a receptor which is apparently more sensitive to InsP_3 as revealed by increased sensitivity to CCh. Figure 8B shows the pooled data illustrating that the S1589E/S1755E mutant $\text{InsP}_3\text{R-1}$ is approximately 7.5 fold more sensitive than the wild type $\text{S2}^- \text{InsP}_3\text{R-1}$ and approximately 35 fold more sensitive than the S1589A/S1755A nonphosphorylatable $\text{S2}^- \text{InsP}_3\text{R-1}$.

25 12. Figure 9 shows single channel records from an isolated Cos-7 cell nucleus patched on several occasions. K^+ is the charge carrier, holding potential was +20 mV. Channel activity is observed only when InsP_3 is present in the pipette. Note in the final trace several channels appear to be present. Representative of 7 experiments.

13. Figure 10 shows a cartoon depicting the proposed structure of the InsP_3R .

30 14. Figure 11 depicts the regulatory and coupling domain of the $\text{InsP}_3\text{R-1}$; showing the phosphorylation sites at S1589 and S1755. In addition the location of the S2 splice site is shown.

15. Figure 12A shows that single mutation of S1589E in $\text{S2}^+ \text{InsP}_3\text{R}$ has little effect on the potentiation of Ca^{2+} signaling seen upon phosphorylation of the receptor, confirming in

the S2+ variant of the receptor that this site is not functional. Figure 12B/C show that stimulation of cells expressing the S1755E phosphomimetic mutation are apparently more sensitive to stimulation, and in addition no further enhancement of Ca^{2+} signaling is observed following PKA activation, confirming S1755 as the functionally important site.

16. Figure 13A/B shows that if either S1589 or S1755 is mutated to glutamate individually that no further potentiation by PKA stimulation is observed. Indicating that phosphorylation of individual sites is not functionally additive.

17. Figure 14 shows that $\text{InsP}_3\text{R-III}$ can be phosphorylated in a PKA dependent fashion.

18. Figure 15A shows stimulation of DT40 cells expressing chicken $\text{InsP}_3\text{R-III}$ results in Ca^{2+} oscillations. Figure 15B shows that activation of PKA during these oscillations results in an inhibition of the Ca^{2+} signal, consistent with an effect on the $\text{InsP}_3\text{R-III}$.

19. Figure 16 shows that stimulation of DT-40 3ko transfected with rat $\text{InsP}_3\text{R-III}$ results in Ca^{2+} signals which are inhibited by stimulating PKA.

III. DETAILED DESCRIPTION

20. The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the Examples included therein and to the Figures and their previous and following description.

21. Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that this invention is not limited to specific synthetic methods, specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

Definitions

22. In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

23. As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

24. Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be

understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about”
 5 that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed the “less than or equal to 10” as
 10 well as “greater than or equal to 10” is also disclosed.

25. “Treatment” or “treating” means to administer a composition to a subject with an undesired condition or at risk for the condition. The condition can be any pathogenic disease, autoimmune disease, cancer or inflammatory condition. The effect of the administration of the composition to the subject can have the effect of but is not limited to
 15 reducing the symptoms of the condition, a reduction in the severity of the condition, or the complete ablation of the condition.

26. By “effective amount” is meant a therapeutic amount needed to achieve the desired result or results, e.g., increasing or decreasing Ca^{2+} release, enhancing or blunting physiological functions, altering the qualitative or quantitative nature of the proteins
 20 expressed by cell or tissues, and eliminating or reducing disease causing molecules and/or symptoms.

27. “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

25 28. By “subject” is meant an individual. Preferably, the subject is a mammal such as a primate, and, more preferably, a human. The term “subject” can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.).

29. By “ InsP_3R ” is meant an inositol 1,4,5-triphosphate receptor. Such receptors are
 30 generally the major route of intracellular calcium release in eukaryotic cells and are pivotal for stimulation of calcium dependent effectors. Modulation of calcium release through these receptors has important consequences in a development and in a variety of normal and pathological cellular conditions. There are three major types of InsP_3R : InsP_3R -1, InsP_3R -2, and InsP_3R -3. InsP_3R -1 has two major splice variants: the S2^- and the S2^+ . The S2^- splice

variant of InsP₃R-1 is the short splice variant in which 40 amino acids are excised.

Specifically, residues 1693 to 1732 of the full length variant (ie. S2⁺ or the long splice variant) are excised. The S2⁻ variant is located predominantly in peripheral tissues whereas the S2⁺ variant is present predominantly in the CNS.

5 30. By "homology" is meant the degree of relatedness shared between two or more nucleic acids, peptides, polypeptides or proteins as determined by their sequence structure or function.

31. It is understood that as discussed herein the use of the terms homology and identity mean the same thing as similarity. Thus, for example, if the use of the word homology is
10 used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence
15 similarity regardless of whether they are evolutionarily related or not.

32. In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed genes and proteins herein, is through defining the variants and derivatives in terms of homology to specific known sequences. This identity of particular sequences disclosed herein is also discussed elsewhere herein. In
20 general, variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids, such as genes. For example, the homology can be calculated after aligning the two
25 sequences so that the homology is at its highest level.

33. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. MoL Biol. 48: 443 (1970), by the search
30 for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

34. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used and that in certain instances the results of these various methods may differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

35. For example, as used herein, a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

Mutants

36. The present invention provides mutant receptor proteins of two general categories: phosphomimetic mutant InsP_3 receptors and nonphosphorylatable mutant InsP_3 . By “phosphomimetic” is meant a receptor that has an increased Ca^{2+} release function as compared to the wild-type InsP_3R as a result of amino substitution to mimic phosphorylation. Preferably, the phosphomimetic mutant has a Ca^{2+} release function that is 3, 4, 5, 6, 7, 8, 9, 10 (or any amount in between) times that of the corresponding wild-type receptor. Preferably, the phosphomimetic mutant has a Ca^{2+} release function that is 10, 20,

30, 40 (or any amount in between) times that of the corresponding nonphosphorylatable mutant. By “nonphosphorylatable” mutant is meant a “null” mutant that is not phosphorylated under conditions that cause phosphorylation in the wild-type. The mutants can be derived from InsP₃R-1, either the S2⁻ or the S2⁺ variant; InsP₃R-2; or InsP₃R-3.

5 37. By increased or enhanced Ca²⁺ release function is meant an increase release of calcium following a stimulus that activates the InsP₃R. Such stimuli include, for example, carbachol, an analog of acetylcholine, acting at muscarinic M3 receptors or alternatively, any agonist acting at any one of over one hundred plasma membrane receptors for neurotransmitters, hormones and growth factors coupled to the formation of InsP₃. In
10 addition enhanced Ca²⁺ release can occur following direct activation of InsP₃R with InsP₃ or its analogs.

38. The phosphomimetic mutants are derived by substitution of a serine in a phosphorylation site with a negatively charged amino acid residue. “By substitution of a serine in a phosphorylation site with a different amino acid residue” is meant that serine is
15 removed and the different amino acid residue replaces it. By “a negatively charged amino acid residue” is meant that when incorporated into the protein it provides a net negative charge at the phosphorylation site. Thus, the substitution with the negatively charged amino acid residue neutralizes the positive charge at the site (provided at least by the typical arginine residue at the phosphorylation site). The phosphorylation site can be the strong
20 PKA recognition motif of RXXS (SEQ ID NO:21), in which X represents any amino acid.. The serine residue can be replaced with either aspartate or glutamate. Thus the invention provides a InsP₃R mutant comprising at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site of a wild-type InsP₃R, wherein the mutant has an enhanced Ca²⁺ release function as compared to the wild-type InsP₃R.
25 Preferably the mutant’s Ca²⁺ release function is at least 5 times greater than the Ca²⁺ release function of the wild-type InsP₃R. Preferably the mutant’s Ca²⁺ release function is at least 10 times greater than the Ca²⁺ release function of the wild-type InsP₃R.

39. The invention provides a phosphomimetic InsP₃R-1 mutant, which has enhanced Ca²⁺ release function as compared to the wild-type InsP₃R-1. More specifically, the mutant
30 comprises at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site, wherein the phosphorylation site is selected from residue 1589 or 1755 of a wild-type InsP₃R sequence. As used throughout, the amino acid residues are numbered according to the rat sequences for the full length InsP₃R. Thus, one of skill in the art, can readily align the sequence for human (ATCC Acc. No. NM_002222), mouse (ATCCAcc.

No. NM_010585), or any other species and replace the comparable serine residue with the desired amino acid.

40. Examples of InsP₃R-1 phosphomimetic mutants include those wherein the substitution of serine for the negatively charged amino acid (including either glutamate or aspartate) is at residue 1589. Thus the mutant can comprise the amino acid sequence of SEQ ID NO:1, which corresponds to the short splice variant S1589E; SEQ ID NO:2, which corresponds to the long splice variant for S1589E; SEQ ID NO:3, which corresponds to S1589D in the short splice variant; SEQ ID NO:4, which corresponds to the long splice variant of S1589D.

41. The invention also provides the amino acids of SEQ ID NO:1,2,3,or 4 having one or more conservative amino acid substitutions, wherein the Ca²⁺ release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence of SEQ ID NO:1,2,3,or 4 wherein the Ca²⁺ release function is maintained. Also provided are the comparable S1589E and S1589D mutants for various species.

42. Examples of InsP₃R-1 phosphomimetic mutants include those wherein the substitution of serine for the negatively charged amino acid (including either glutamate or aspartate) is at residue 1755. Thus the mutant can comprise the amino acid sequence of SEQ ID NO:5; which corresponds to the short variant of S1755E; SEQ ID NO:6, which corresponds to the long splice variant of S1755E; SEQ ID NO:7, which corresponds to the short variant of S1755D; and SEQ ID NO:8, which corresponds to the long splice variant of S1755D.

43. The invention also provides the amino acids of SEQ ID NO: 5, 6, 7, and 8 having one or more conservative amino acid substitutions, wherein the Ca²⁺ release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence of SEQ ID NO:5,6,7, or 8, wherein the Ca²⁺ release function is maintained. Also provided are the comparable S1755E and S1755D mutants for various species.

44. The invention also provides a InsP₃R-1 mutant, wherein the substitutions of serine for the negatively charged amino acid is at residues 1589 and 1755. Either glutamate or aspartate is substituted for the two serines, in any combination. Thus, the invention provides a mutant, wherein glutamate is substituted for serine at residues 1589 and 1755;

including for example a mutant comprising the amino acid sequence of SEQ ID NO:9, which corresponds to the S1589E/S1755E mutant of the short splice variant, or SEQ ID NO:10, which corresponds to the S1589E/S1755E mutant of the long splice variant. The invention also provides a mutant, wherein aspartate is substituted for serine at residues 1589 and 1755, including for example a mutant comprising SEQ ID NO:11, which corresponds to S1589D/S1755D of the short splice variant; SEQ ID NO:12, which corresponds to S1589D/S1755D of the long splice variant.

45. The invention also provides the amino acids of SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 having one or more conservative amino acid substitutions, wherein the Ca^{2+} release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence of SEQ ID NO:9, 10, 11, or 12, wherein the Ca^{2+} release function is maintained. Also provided are the comparable S1589E/S1755E and S1589D/S1755D mutants for various species.

46. The invention further provides double mutants, wherein aspartate is substituted for serine at residue 1589 and glutamate is substituted for serine at residue 1755. For example, the invention provides a mutant comprising the amino acid sequence of SEQ ID NO:13, which corresponds to S1589D/S1755E short splice variant; and SEQ ID NO:14, which corresponds to a S1589D/S1755E mutation in the long splice variant. The invention also provides a mutant, wherein glutamate is substituted for serine at residue 1589 and aspartate is substituted for serine at residue 1755; including, for example, a mutant comprising the amino acid of SEQ ID NO:15, which corresponds to a S1589E/S1755D mutant of the short splice variant; and a mutant comprising the amino acid of SEQ ID NO:16, which corresponds to a S1589E/S1755D mutation in the long splice variant.

47. The invention also provides the amino acids of SEQ ID NO: 13, 14, 15, 16, having one or more conservative amino acid substitutions, wherein the Ca^{2+} release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence of SEQ ID NO:13, 14, 15, or 16, wherein the Ca^{2+} release function is maintained. Also provided are the comparable S1589D/S1755E and S1589E/S1755D mutants for various species.

48. Similar to those outlined above for the $\text{InsP}_3\text{R-1}$ mutant, the invention provides phosphomimetic $\text{InsP}_3\text{R-2}$ mutants. More specifically, the mutant comprises at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site,

wherein the phosphorylation site is selected from residues 766, 1772, 1856, 1772, 1856, 2058, or 2227. For example, the sequence of SEQ ID NO:19 can be modified to form S766E, S766D, S1772D, S1772E, S1856E, S1856D, S2058E, S2058D, S2227E, S2227D. Furthermore, any combination of these serine substations can be made to form mutants with two, three, four, or five different substitutions. As for the InsP₃R-1 mutants, the invention further provides substitution InsP₃R-1 mutants wherein the amino acid sequence modified from the wild type sequence, provided herein as SEQ ID NO:19, has one or more conservative amino acids, wherein the Ca²⁺ release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence modified from the wild type sequence (provided herein as SEQ ID NO:19), wherein the Ca²⁺ release function is maintained. Also provided are the comparable InsP₃R-2 mutants for various species designed by aligning the InsP₃R-2 of the species with the rat species and substituting the corresponding amino acid sequence.

49. Similar to those outlined above for the InsP₃R-1 mutant, the invention provides phosphomimetic InsP₃R-3 mutants. More specifically, the mutant comprises at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site, wherein the phosphorylation site is selected from residues 934, 1640, 1834, 2009, 2041, or 2189. For example, the sequence of SEQ ID NO:20 can be modified to form S934E, S934D, S1640D, S1640E, S1834E, S1834D, S2009E, S2009D, S2041E, S2041D, S2189E, or S2189D. Furthermore, any combination of these serine substations can be made to form mutants with two, three, four, five, or six different substitutions. As for the InsP₃R-1 mutants, the invention further provides substitution InsP₃R-1 mutants wherein the amino acid sequence modified from the wild type sequence, provided herein as SEQ ID NO:20, has one or more conservative amino acids, wherein the Ca²⁺ release function is maintained. Also provided are mutants comprising amino acid sequences having at least 80, 85, 90, 95, 96, 97, 98, 99 % (or any amount in between these values) homology to the amino acid sequence modified from the wild type sequence (provided herein as SEQ ID NO:20), wherein the Ca²⁺ release function is maintained. Also provided are the comparable InsP₃R-2 mutants for various species designed by aligning the InsP₃R-2 of the species with the rat species and substituting the corresponding amino acid sequence.

50. The invention also provides mutants that are nonphosphorylatable. Specifically, the invention provides an InsP₃R mutant comprising at least one substitution of serine for an amino acid with an aliphatic side chain at a phosphorylation site of a wild-type InsP₃R,

wherein the mutant is nonphosphorylatable. Preferably, the amino acid with the aliphatic side chain is alanine. The mutant can be a modified InsP₃R-1 (either the long or short splice variant), InsP₃R-2, or InsP₃R-3. Thus, the sequence of SEQ ID NO:17 can be modified at residues 1589 and 1775 to form a null mutant, SEQ ID NO:18 can be modified at S1755 to form a null mutant. Similarly, nonphosphorylatable mutants of InsP₃R-2 can be formed by substituting alanine for any one or more of the residues 766, 1772, 1856, 2058, 2227 of a wild-type InsP₃R-2 sequence or any combination thereof. Nonphosphorylatable mutants of InsP₃R-3 can be formed by substituting alanine for any one or more of the residues 934, 1640, 1834, 2009, 2041, 2189 of a wild-type InsP₃R-3 sequence or any combination thereof. Similar mutants in various species can be derived by aligning the sequence with the rat sequence provided herein and making the null-inducing substitutions provided herein in the corresponding serine residue.

51. As discussed herein there are numerous variants of the InsP₃R protein that are known and herein contemplated. In addition, to the known functional InsP₃R strain variants, there are derivatives and fragments of the InsP₃R proteins that also function in the disclosed methods and compositions. Protein variants and derivatives are well understood to those of skill in the art and can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Immunogenic fusion protein derivatives, such as those described in the examples, are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross-linking *in vitro* or by recombinant cell culture transformed with DNA encoding the fusion. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1

to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 1 and are referred to as conservative substitutions.

TABLE 1:Amino Acid Substitutions

Original Residue Exemplary Conservative Substitutions, others are known in the art.

Ala; Ser
 Arg; Lys; Gln
 Asn; Gln; His
 Asp; Glu
 Cys; Ser
 Gln; Asn, Lys
 Glu; Asp
 Gly; Pro
 His; Asn; Gln
 Ile; Leu; Val
 Leu; Ile; Val
 Lys; Arg; Gln;
 Met; Leu; Ile
 Phe; Met; Leu; Tyr
 Ser; Thr
 Thr; Ser
 Trp; Tyr
 Tyr; Trp; Phe
 Val; Ile; Leu

52. Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by)

an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.

53. For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic polypeptides provided herein.

54. Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.

55. Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

56. It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. For example, SEQ ID NO: 1 sets forth a particular sequence of the "short form" (S2⁻) of InsP₃R-1 (short form S1589E) and SEQ ID NO: 2 sets forth a particular sequence of the "long form" (S2⁺) of InsP₃R-1 protein (long form S1589E). Specifically disclosed are variants of these and other proteins herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins.

57. It is understood that the description of conservative mutations and homology can be combined together in any combination, such as embodiments that have at least 70% homology to a particular sequence wherein the variants are conservative mutations.

58. As this specification discusses various proteins and protein sequences it is understood that the nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence. For example, one of the many nucleic acid sequences that can encode the protein sequence set forth in SEQ ID NO: 18 is set forth in SEQ ID NO: 22. In addition, for example, a disclosed conservative derivative of SEQ ID NO: 1 is shown in SEQ ID NO: 3, where the isoleucine (E) at position 1589 is changed to a valine (D). It is understood that for this mutation all of the nucleic acid sequences that encode this particular derivative of the short form S1589E are also disclosed. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where particular variants of a disclosed protein are disclosed herein, the known nucleic acid sequence that encodes that protein is also known and herein disclosed and described.

59. Also provided are fragments of the proteins described below, wherein the fragments maintain the Ca^{2+} enhancing or reducing function of full length protein. Preferably the fragment will have at least 50% of the enhancing function of the full length correlate or at least a 50% reduction of the Ca^{2+} reducing function.

Nucleic Acids, Vectors and Expression Systems

60. The invention further provides nucleic acids that encode the mutants described herein. Examples of nucleic acids that encode the $\text{InsP}_3\text{R-1}$ wild type receptors can be found at <http://www.ncbi.nlm.nih.gov/HomoloGene/homol.cgi?HID=30927>, including for example rat (ATCC Acc. No. xm_342732); mouse (ATCC Acc. No. nm_010585); human (ATCC Acc. No. nm_002222). Examples of nucleic acids that encode the $\text{InsP}_3\text{R-2}$ wild-type receptors can also be found at the <http://www.ncbi.nlm.nih.gov> site and include, for example, rat (ATCC Acc. No. NM_031046), human (ATCC Acc. No. NM_002223). Examples of nucleic acids that encode the $\text{InsP}_3\text{R-3}$ wild-type receptors can also be found at

the <http://www.ncbi.nlm.nih.gov> site and include, for example, rat (ATCC Acc. No. NM_013138), human (ATCC Acc. No. NM_002224), and mouse (ATCC Acc. No. NM_080553).

61. One of skill in the art could modify these nucleic acid sequences to make the substitutions described herein. For example, the codon for the selected serine is replaced by a codon for glutamate, aspartate, or alanine. Further provided are nucleic acids that comprise a sequence that hybridizes under highly stringent conditions to the various rat, mouse, and human mutants encoding nucleic acids with the selected serine(s) substituted with glutamate, aspartate, or alanine. Preferably these hybridizing nucleic acids do not hybridize to the wild-type encoding nucleic acids.

62. The term hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.

63. Parameters for selective hybridization between two nucleic acid molecules are well known to those of skill in the art. For example, in some embodiments selective hybridization conditions can be defined as stringent or highly stringent hybridization conditions. For example, stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. For example, the conditions of hybridization to achieve selective hybridization may involve hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the T_m. The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as

is known in the art. (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. Methods Enzymol. 1987:154:367, 1987 which is herein incorporated by reference for material at least related to hybridization of nucleic acids). A preferable stringent

5 hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C. Stringency of hybridization and washing, if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for. Likewise, stringency of hybridization and washing, if
10 desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

64. Another way to define selective hybridization is by looking at the amount (percentage) of one of the nucleic acids bound to the other nucleic acid. For example, in
15 some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid. Typically, the non-limiting primer is in for example, 10 or 100 or 1000 fold excess. This type of assay can be performed at under conditions where both the limiting
20 and non-limiting primer are for example, 10 fold or 100 fold or 1000 fold below their k_d , or where only one of the nucleic acid molecules is 10 fold or 100 fold or 1000 fold or where one or both nucleic acid molecules are above their k_d .

65. Another way to define selective hybridization is by looking at the percentage of primer that gets enzymatically manipulated under conditions where hybridization is
25 required to promote the desired enzymatic manipulation. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is
30 DNA extension, then selective hybridization conditions would be when at least about 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer molecules are extended. Preferred conditions also include those suggested by the manufacturer or indicated in the art as being appropriate for the enzyme performing the manipulation.

66. Just as with homology, it is understood that there are a variety of methods herein disclosed for determining the level of hybridization between two nucleic acid molecules. It is understood that these methods and conditions may provide different percentages of hybridization between two nucleic acid molecules, but unless otherwise indicated meeting the parameters of any of the methods would be sufficient. For example if 80% hybridization was required and as long as hybridization occurs within the required parameters in any one of these methods it is considered disclosed herein.

67. It is understood that those of skill in the art understand that if a composition or method meets any one of these criteria for determining hybridization either collectively or singly it is a composition or method that is disclosed herein.

68. Also provided are fragments of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 nucleotides (or any number in between) of the nucleic acids provided herein, wherein the fragment encodes a serine substitution described herein.

69. The invention also provides an expression vector comprising a nucleic acid of the invention wherein the nucleic acid is operable linked to an expression control sequence.

70. The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

71. There are a number of compositions and methods which can be used to deliver nucleic acids to cells, either *in vitro* or *in vivo*. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems. For example, the nucleic acids can be delivered through a number of direct delivery systems such as, electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes. Appropriate means for transfection, including viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA, are described by, for example, Wolff, J. A., et al., *Science*, 247, 1465-1468, (1990); and Wolff, J. A. *Nature*, 352, 815-818, (1991). Such methods are well known in the art and readily adaptable for use with the compositions and methods described herein. In certain cases, the methods will be

modified to specifically function with large DNA molecules. Further, these methods can be used to target certain diseases and cell populations by using the targeting characteristics of the carrier.

72. Transfer vectors can be any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenovirus (Ram et al. Cancer Res. 53:83-88, (1993)).

73. As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as SEQ ID NO: 22 into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. Viral vectors are, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families which share the properties of these viruses which make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retroviruses that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. A preferred embodiment is a viral vector which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens. Preferred vectors of this type will carry coding regions for Interleukin 8 or 10.

74. Viral vectors can have higher transfection (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstructural early genes, structural late genes, an RNA polymerase III transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promotor cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines which have been engineered to express the gene products of the early genes in trans.

75. A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, I.M., Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is
5 incorporated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Patent Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incorporated herein by reference.

76. A retrovirus is essentially a package which has packed into it nucleic acid cargo.
10 The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and
15 env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands
20 during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon
25 replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert.

77. Since the replication machinery and packaging proteins in most retroviral vectors
30 have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into

new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.

78. The construction of replication-defective adenoviruses has been described (Berkner et al., *J. Virology* 61:1213-1220 (1987); Massie et al., *Mol. Cell. Biol.* 6:2872-2883 (1986); Haj-Ahmad et al., *J. Virology* 57:267-274 (1986); Davidson et al., *J. Virology* 61:1226-1239 (1987); Zhang, *BioTechniques* 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, *in vivo* delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, *J. Clin. Invest.* 92:1580-1586 (1993); Kirshenbaum, *J. Clin. Invest.* 92:381-387 (1993); Roessler, *J. Clin. Invest.* 92:1085-1092 (1993); Moullier, *Nature Genetics* 4:154-159 (1993); La Salle, *Science* 259:988-990 (1993); Gomez-Foix, *J. Biol. Chem.* 267:25129-25134 (1992); Rich, *Human Gene Therapy* 4:461-476 (1993); Zabner, *Nature Genetics* 6:75-83 (1994); Guzman, *Circulation Research* 73:1201-1207 (1993); Bout, *Human Gene Therapy* 5:3-10 (1994); Zabner, *Cell* 75:207-216 (1993); Caillaud, *Eur. J. Neuroscience* 5:1287-1291 (1993); and Ragot, *J. Gen. Virology* 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenovirus (Chardonnet and Dales, *Virology* 40:462-477 (1970); Brown and Burlingham, *J. Virology* 12:386-396 (1973); Svensson and Persson, *J. Virology* 55:442-449 (1985); Seth, et al., *J. Virol.* 51:650-655 (1984); Seth, et al., *Mol. Cell. Biol.* 4:1528-1533 (1984); Varga et al., *J. Virology* 65:6061-6070 (1991); Wickham et al., *Cell* 73:309-319 (1993)).

79. A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virions are generated in a cell line such as the human 293 cell line. In another preferred embodiment both the E1 and E3 genes are removed from the adenovirus genome.

80. Another type of viral vector is based on an adeno-associated virus (AAV). This defective parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type

of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the herpes simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.

81. In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus.

82. Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. United States Patent No. 6,261,834 is herein incorporated by reference for material related to the AAV vector.

83. The vectors of the present invention thus provide DNA molecules which are capable of integration into a mammalian chromosome without substantial toxicity.

84. The inserted genes in viral and retroviral usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

85. Molecular genetic experiments with large human herpesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpesviruses (Sun et al., *Nature Genetics* 8: 33-41, 1994; Cotter and Robertson, *Curr Opin Mol Ther* 5: 633-644, 1999). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable. The maintenance of these episomes requires a specific EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently *in vitro*. Herpesvirus amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes.

86. Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia virus vectors.

87. The disclosed compositions can be delivered to the target cells in a variety of ways. For example, the compositions can be delivered through use of a gene gun, electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend in part on the type of cell targeted and whether the delivery is occurring for example *in vivo* or *in vitro*.

88. Thus, the compositions can comprise, in addition to the disclosed vectors for example, lipids such as liposomes (cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes). Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. *Am. J. Resp. Cell. Mol. Biol.* 1:95-100 (1989); Felgner et al. *Proc. Natl. Acad. Sci USA* 84:7413-7417 (1987); U.S. Pat. No.4,897,355. Furthermore, the compound can be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

89. In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), delivery of the compositions to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the nucleic acid or vector of this invention can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

90. The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., *Bioconjugate Chem.*, 2:447-451, (1991); Bagshawe, K.D., *Br. J. Cancer*, 60:275-281, (1989); Bagshawe,

et al., *Br. J. Cancer*, 58:700-703, (1988); Senter, et al., *Bioconjugate Chem.*, 4:3-9, (1993); Battelli, et al., *Cancer Immunol. Immunother.*, 35:421-425, (1992); Pietersz and McKenzie, *Immunolog. Reviews*, 129:57-80, (1992); and Roffler, et al., *Biochem. Pharmacol*, 42:2062-2065, (1991)). These techniques can be used for a variety of other specific cell types. Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., *Cancer Research*, 49:6214-6220, (1989); and Litzinger and Huang, *Biochimica et Biophysica Acta*, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, *DNA and Cell Biology* 10:6, 399-409 (1991)).

91. Nucleic acids that are delivered to cells which are to be integrated into the host cell genome, typically contain integration sequences. These sequences are often viral related sequences, particularly when viral based systems are used. These viral intergration systems can also be incorporated into nucleic acids which are to be delivered using a non-nucleic acid based system of deliver, such as a liposome, so that the nucleic acid contained in the delivery system can be come integrated into the host genome.

92. Other general techniques for integration into the host genome include, for example, systems designed to promote homologous recombination with the host genome. These systems typically rely on sequence flanking the nucleic acid to be expressed that has enough homology with a target sequence within the host cell genome that recombination between the vector nucleic acid and the target nucleic acid takes place, causing the delivered nucleic

acid to be integrated into the host genome. These systems and the methods necessary to promote homologous recombination are known to those of skill in the art.

93. As described above, the compositions can be administered in a pharmaceutically acceptable carrier and can be delivered to the subject's cells *in vivo* and/or *ex vivo* by a
5 variety of mechanisms well known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis and the like).

94. If *ex vivo* methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art. The compositions can be introduced into the cells via any gene transfer mechanism, such as, for example,
10 calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes. The transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or homotopically transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.

95. The invention also provides a cell comprising a vector described herein. Preferably the cultured cell, in the absence of the vector does not express InsP₃Rs. Optionally, the cell is a cultured cell. An example of such a cell is the DT-40 3ko cell. Optionally, the cell further comprises a nucleic acid that encodes an acetylcholine receptor (including for
15 example an M3 receptor). Optionally various labels can be used to identify the cells that are successfully transfected or transformed.
20

96. Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin
25 promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al., *Nature*, 273: 113 (1978)). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a *Hind*III E restriction fragment (Greenway, P.J. et al., *Gene* 18: 355-360 (1982)). Of course, promoters from the host cell or related
30 species also are useful herein.

97. Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al., *Proc. Natl. Acad. Sci.* 78: 993 (1981)) or 3' (Lusky, M.L., et al., *Mol. Cell Bio.* 3: 1108 (1983)) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, J.L. et al., *Cell*

33: 729 (1983)) as well as within the coding sequence itself (Osborne, T.F., et al., *Mol. Cell Bio.* 4: 1293 (1984)). They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression. Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

98. The promotor and/or enhancer may be specifically activated either by light or specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

99. In certain embodiments the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed. In certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is the CMV promoter (650 bases). Other preferred promoters are SV40 promoters, cytomegalovirus (full length promoter), and retroviral vector LTF.

100. It has been shown that all specific regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types such as melanoma cells. The glial fibrillary acetic protein (GFAP) promoter has been used to selectively express genes in cells of glial origin.

101. Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and

transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

102. The viral vectors can include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once delivered is being expressed. Preferred marker genes are the *E. Coli* lacZ gene, which encodes β -galactosidase, and green fluorescent protein.

103. In some embodiments the marker may be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hydromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: CHO DHFR- cells and mouse LTK- cells.

These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media.

104. The second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin, (Southern P. and Berg, P., *J. Molec. Appl. Genet.* 1: 327 (1982)), mycophenolic acid, (Mulligan, R.C. and Berg, P. *Science* 209: 1422 (1980)) or hygromycin, (Sugden, B. et al., *Mol. Cell. Biol.* 5: 410-413 (1985)). The three examples employ bacterial genes under eukaryotic control to convey resistance to the

appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include the neomycin analog G418 and puramycin.

105. The invention further provides methods of using the mutants, nucleic acids, and cells of the invention in various methods of making the mutant receptors, methods of screening
5 for agents that modulate the InsP₃Rs, and methods of treatment.

106. The expression systems described herein can be used to make mutant InsP₃Rs. Thus, the invention provides making mutant InsP₃R-1, InsP₃R-2, InsP₃R-3 or fragments thereof described herein by culturing a cell that expresses the selected mutant or fragments
10 under conditions that allow expression and by isolating the expressed mutant or fragment thereof.

107. The invention further provides a method of screening for an agent that preferentially modulates Ca²⁺ release by phosphorylated InsP₃R, comprising contacting a cell of the invention with the agent to be screened, under conditions that allow Ca²⁺ release; measuring Ca²⁺ release; and comparing the amount of Ca²⁺ release with a control cell. The control cell
15 can comprise an unphosphorylated InsP₃R that is not contacted with the agent to be screened. Conditions that allow calcium release include for example carbachol, acting at muscaric M3 receptors or alternatively, an agonist acting at any one of over one hundred plasma membrane receptors for neurotransmitters, hormones and growth factors coupled to the formation of InsP₃. In addition, enhanced Ca²⁺ release can occur following direct
20 activation of InsP₃R with InsP₃ or its analogs. An increase or decrease in Ca²⁺ release as compared to a control cell indicates an agent that preferentially modulates unphosphorylated InsP₃R. By "modulation" is meant any physiologic effect that increases or decreases InsP₃R stimulated calcium release. Preferably the unphosphorylated InsP₃R is a nonphosphorylatable mutant InsP₃R described herein.

25 108. The invention also provides a method of expressing a mutant InsP₃R in a cell *in vivo*, comprising providing an expression vector described herein; introducing the vector into a cell *in vivo*; maintaining the cell under conditions that permit expression of the mutant InsP₃R by the cell.

109. Also provided herein are methods of treating a subject with reduced Ca²⁺ release,
30 comprising introducing into the subject an expression vector that encodes a phosphomimetic mutant of the invention, under conditions that an amount of the mutant receptor is expressed in an effective amount to enhance Ca²⁺ release. Examples of such diseases include, xerostomia, cystic fibrosis, or a large class of diseases which result from the decreased secretion of hormones, these include but are not limited to, decreased thyroid stimulating

hormone (TSH) secretion from the pituitary or insulin secretion from the pancreas. The former deficiency results in dwarfism and cretinism, the latter diabetes.

110. Optionally the expression vector can be targeted. For example, to treat a subject with a condition like xerostomia, the vector could be targeted to the oral mucosal cells.

5 111. The invention also provides a method of treating a subject with cystic fibrosis, comprising introducing into the subject the expression vector of that expresses a phosphomimetic mutant receptor under conditions that an amount of the mutant receptor is expressed in an effective amount to alleviate the symptoms of cystic fibrosis.

10 **EXAMPLES**

Example 1: Phosphorylation of Type-1 Inositol 1,4,5-Trisphosphate Receptors by Cyclic Nucleotide-dependent Protein Kinases

112. Inositol 1,4,5-trisphosphate receptors (InsP₃R) constitute the major route of intracellular calcium release in eukaryotic cells and as such are pivotal for stimulation of

15 Ca²⁺ dependent effectors important for numerous physiological processes. Modulation of this release has important consequences for defining the particular spatio-temporal characteristics of Ca²⁺ signals. In this study, regulation of Ca²⁺ release by phosphorylation of type-1 InsP₃R (InsP₃R-1) by cAMP (PKA) and cGMP (PKG) dependent protein kinases was investigated in the two major splice variants of InsP₃R-1. InsP₃R-1 were expressed in

20 DT-40 cells devoid of endogenous InsP₃R. In cells expressing the neuronal, S2⁺ splice variant of the InsP₃R-1, Ca²⁺ release was markedly enhanced when either PKA or PKG was activated. The sites of phosphorylation were investigated by mutation of serine residues present in two canonical phosphorylation sites present in the protein. Potentiated Ca²⁺ release was abolished when serine 1755 was mutated to alanine (S1755A) but was

25 unaffected by a similar mutation of serine 1589 (S1589A). These data demonstrate that S1755 is the functionally important residue for phosphoregulation by PKA and PKG in the neuronal variant of the InsP₃R-1. Activation of PKA also resulted in potentiated Ca²⁺ release in cells expressing the non-neuronal, S2⁻ splice variant of the InsP₃R-1. However, the PKA-induced potentiation was still evident in S1589A or S1755A InsP₃R-1 mutants.

30 The effect was abolished in the double (S1589A/S1755A) mutant, indicating both sites are phosphorylated and contribute to the functional effect. Activation of PKG had no effect on Ca²⁺ release in cells expressing the S2⁻ variant of InsP₃R-1. Collectively these data indicated that phosphoregulation of InsP₃R-1 had dramatic effects on Ca²⁺ release and

defined the molecular sites phosphorylated in the major variants expressed in neuronal and peripheral tissues.

113. Most studies of PKA-dependent phosphorylation have been performed on the S2⁺ neuronal type-I InsP₃R, the so called “long-form” of the receptor. In this variant of the InsP₃R-1, serine residues at S1589 and S1755 are phosphorylated by PKA [7, 34, 35], with S1755 being more heavily phosphorylated [34]. In contrast, little consensus exists as to the effect of PKG; *in situ* experiments in cerebellar slices reported S1589 to be preferentially phosphorylated by PKG [35], while other studies suggest that purified InsP₃R-1 protein from the cerebellum was phosphorylated preferentially on S1755 [36].

114. Alternative splicing of the type-1 receptor gene results in the S2⁻ variant of the type-1 InsP₃R where 40 amino acids (amino acids 1693 to 1732) are excised between the two phosphorylation sites [6, 7]. This protein is predominantly expressed in peripheral tissues and interestingly has been reported to be exclusively phosphorylated on S1589 by PKA [7], but on S1755 by PKG [36]. Studies of the functional effects of phosphorylation of the peripheral form have suggested that in contrast to the neuronal form of the receptor, phosphorylation of the “short form” of the InsP₃R-1 results in attenuated Ca²⁺ release [21, 22]. Thus, prior to this invention, the possibility existed that differences in both the sites of phosphorylation and therefore the functional effects of phosphorylation were defined by the particular splice variants expressed in particular tissues.

115. In this study the sites of phosphorylation by PKA and PKG, functionally important for regulation of Ca²⁺ release in the two major splice variants of the InsP₃R-1, were investigated. By expression of mutant InsP₃R-1 in InsP₃R *null* DT-40 cells [42, 43], the studies revealed that phosphorylation of S1755 by PKA or PKG resulted in markedly enhanced Ca²⁺ release for S2⁺ InsP₃R-1. Notably, in S2⁻ InsP₃R expressing cells PKG activation did not markedly alter Ca²⁺ release while PKA phosphorylation of both S1755 and S1589 result in enhanced Ca²⁺ release. Thus, the expression of particular InsP₃R splice variants defined the functional consequences of phosphoregulation by cyclic nucleotide-dependent kinases.

Materials:

116. The acetoxymethylesters of Fura-2, and Fluo-4 were purchased from Molecular Probes (Eugene, Or.). Fura-2FF was purchased from Tefabs (Austin, TX). Cell permeable cyclic nucleotides and forskolin were purchased from Biomol, (Plymouth Meeting, PA). All other chemicals were purchased from Sigma Chemical Company (St. Louis, MO). The

DT-40 cells lacking InsP₃R (DT-40 3ko) were kindly provided by Dr Kurosaki, (Kansai Medical University, Japan) and were maintained as previously described [42-44].

Production of Mutations:

117. The S2⁺ InsP₃R-1 in the expression plasmid pIRES-GFP (Clontech; Palo Alto, CA) was digested with the restriction endonuclease Sal I. The overhang created by digestion was blunted using T4 polymerase. An EcoR I linker was then ligated onto the blunted ends of the construct. The entire receptor DNA was excised from the plasmid using EcoR I and ligated into the plasmid MXT-1. The region containing the S2⁻ splice variant and potential PKA phosphorylation sites was excised from its backbone in pCDNA 3.1+ (Invitrogen; Carlsbad, CA) by Rsr II and Kas I and ligated into the InsP₃R construct in MXT-1. The potential PKA sites, S1589 and S1755, were mutated, individually in both splice variants and together in the S2⁻ splice variant, to alanines using sequential PCR mutagenesis. The outer oligos used for the mutagenesis reaction flanked the restriction sites Rsr II and Kas I. Following mutation, the resulting fragments were cut with Rsr II and Kas I and inserted into the IP₃R-1 backbone at the corresponding sites. The mutations and lack of spurious misincorporations were confirmed by Big Dye fluorescent sequencing. Mutated receptor DNAs were excised from MXT-1 using EcoR I and ligated into the mammalian expression vector pGW (British Biotechnology; Oxford, UK). Orientation was confirmed using restriction enzyme digestion.

Transfection of DT-40 cells:

118. DT-40 cells lacking all three InsP₃ receptor subtypes DT-40 3ko were transfected using electroporation, 350 V and 950 µF. 2 x 10⁷ cells were co-transfected with 25 µg of the InsP₃R cDNA, 25 µg of the muscarinic type 3 (M3) receptor, and 4 µg of the red fluorescent protein plasmid pHcRed1-N1. Cells were incubated with DNA in 500 µl of Optimem media on ice for 10 minutes. The cell / DNA mixture was electroporated, incubated on ice for 30 minutes, brought up to 5 ml with Optimem and placed in a 5 % CO₂ incubator at 39 °C for 5 hours. The cells were then centrifuged and resuspended in 12 ml of complete RPMI media. Transfection efficiency was typically ~20%. Experiments were performed within 32 hours of transfection.

Digital Imaging of [Ca⁺²]_i:

119. Transfected DT-40 3ko cells were washed once in a HEPES-buffered physiological saline solution (HEPES-PSS) containing (in mM) 5.5 glucose, 137 NaCl, 0.56 MgCl₂, 4.7 KCl, 1 Na₂HPO₄, 10 HEPES (pH 7.4), 1.2 CaCl₂ and 1% w/v Bovine Serum Albumin. Cells

were then resuspended in BSA HEPES-PSS with 1 μ M Fura-2 (AM), placed on a 15 mm glass coverslip in a low volume perfusion chamber (Warner Instruments) and allowed to adhere for 30 minutes at room temperature. Cells were perfused continually for 10 minutes with HEPES-PSS before experimentation to allow Fura-2 de-esterification. A field of cells for each experiment was chosen that contained a wide range of transfection efficiency based upon the intensity of red fluorescence emitted when excited at 560 nm. $[Ca^{2+}]_i$ imaging was performed essentially as previously described [28, 29, 41] using an inverted epifluorescence Nikon microscope with a 40X oil immersion objective lens (numerical aperture, 1.3). Cells were excited alternately with light at 340 and 380 nm (± 10 nm bandpass filters, Chroma) using a monochromator (TILL Photonics). Fluorescence images were captured and digitized with a digital camera driven by TILL Photonics software. Images were captured every 2 seconds with an exposure of 35 ms and no binning. 340 / 380 ratio images were calculated online and stored immediately to hard disk. Only data from cells exhibiting an increase in ratio units of less than 0.2 upon stimulation were used for further analysis.

Flash Photolysis:

120. Transfected cells were simultaneously loaded by incubation with the visible wavelength indicator Fluo-4 and a cell permeable form of caged-inositol trisphosphate (ciIP₃/PM) for 30 min. Ci-IP₃/PM is a homologue of cm-IP₃/PM [45] The 2- and 3-hydroxyls of the inositol ring were protected by an isopropylidene group in ci-IP₃/PM, and were protected by a methoxymethylene group in cm-IP₃/PM. Like cm-IP₃/PM, ci-IP₃/PM diffuses across cell membranes and induces internal calcium release upon photo-uncaging. A further period of approximately 30 min was allowed for de-esterification of both dye and cage. Cells were illuminated at 488 ± 10 nm and fluorescence collected through a 525 ± 25 nm band pass filter and captured using the Till Photonics imaging suite. These traces are displayed as $\% \Delta F/F_0$, where F is the recorded fluorescence and F_0 is the mean of the initial 10 sequential frames. Photolytic release was performed as previously described [28, 29, 41] using a pulsed Xenon arc lamp (Till Photonics). A high intensity (0.5-5 msec duration; 80 J) discharge of UV light (360 ± 7.5 nm) was reflected onto the plane of focus using a DM400 dichroic mirror and Nikon X 40 oil immersion objective, 1.3 NA.

Statistical Analysis:

121. The effects of treatment were determined by normalizing the peak change in fluorescence ratio by stimulation following forskolin or 8-Br cGMP exposure to that of stimulation in control HEPES-PSS. Thus, pooled data represents a normalized fold increase

over control for the treated trial. Two tailed heteroscedastic t-tests with P values < 0.05 were considered to have statistical significance.

PKA phosphorylation of S1755 in S2⁺ InsP₃R-1 resulted in enhanced Ca²⁺ release:

122. Experiments were performed in DT-40 3ko cells transfected with S2⁺ InsP₃R-1. Since there are no reports of Gαq coupled receptors expressed in DT-40 cells, initial experiments were performed eliciting [Ca²⁺]_i changes by stimulating the endogenous B cell receptor with α-IgM antibody. This resulted in somewhat irregular Ca²⁺ oscillations, which were not reversible when the antibody was removed making paired analysis of any effects of raising cyclic nucleotides difficult to interpret. Thus, in all further experiments, DT-40 3ko cells were co-transfected with the M3 receptor, and HcRed to facilitate identification of transfected cells (inset fig. 1). Stimulation of M3 receptors with the muscarinic agonist carbachol (CCh), provided a convenient means of stimulating [Ca²⁺]_i changes, presumably through Gαq-induced activation of phospholipase C and production of InsP₃. Stimulation with a low concentration of CCh (25-50 nM) resulted in an increase in [Ca²⁺]_i, which returned to baseline when the agonist was removed. Following 10 min incubation with 20 μM forskolin to maximally raise cAMP, the initial peak in [Ca²⁺]_i elicited by identical CCh treatment was markedly potentiated (fig 1A and pooled data in fig 1D). After washout of forskolin a subsequent stimulation resulted in a [Ca²⁺]_i change comparable to the initial exposure. The potentiation was most marked when threshold elevations in [Ca²⁺]_i were evoked by the initial exposure to CCh and therefore only cells in which the initial CCh treatment evoked a Δ 340/380 ratio of < 0.2 ratio units were included for analysis. These data showed that phosphorylation of the S2⁺ InsP₃R resulted in enhanced Ca²⁺ release by increasing the sensitivity of the receptor to InsP₃. [Ca²⁺]_i changes were never evoked by CCh treatment in cells transfected with only M3 cDNA in the absence of InsP₃R or likewise InsP₃R with no M3 cDNA. Similarly, cells exhibiting no HcRed fluorescence seldom responded to CCh treatment (black trace, fig 1A).

123. To ascertain whether one or both of the serine residues S1589 or S1755 is important for phosphoregulation of the S2⁺ variant of the InsP₃R-1 following PKA activation, individual point mutations were constructed where these serine residues were mutated to alanine (S1589A and S1755A). A similar potentiation of the initial peak of the CCh-induced [Ca²⁺]_i elevation was observed following forskolin treatment in cells expressing S1589A S2⁺ InsP₃R (fig 1B and 1D), however mutation of S1755A resulted in the complete

abrogation of any potentiation upon forskolin treatment (fig 1C and 1D). These data clearly support the assertion that phosphorylation of S1755 is the important event underlying enhanced Ca^{2+} release through the neuronal $\text{InsP}_3\text{R-1}$ following PKA activation. It follows therefore, that phosphorylation of S1589 after 20 μM forskolin treatment (which could reasonably be expected to result in the maximal generation of cAMP) was either not occurring to a significant extent, or perhaps more likely, was functionally not important in modulating Ca^{2+} release.

124. Since the only difference between the experiment in fig 1A and 1C is a conservative point mutation in the $\text{InsP}_3\text{R-1}$, it was assumed that the effects observed on the peak Ca^{2+} signal following forskolin treatment were predominately the results of alteration of Ca^{2+} release. To rule out the possibility that phosphorylation by PKA of other signaling molecules caused the effect, experiments were performed utilizing ciIP_3/PM , a cell permeable form of caged InsP_3 [45] to more directly induce Ca^{2+} release in cells transfected with wild-type S2^+ $\text{InsP}_3\text{R-1}$. Using a brief flash of UV light (~ 0.5 ms, indicated by the arrow in fig 2) small elevations in $[\text{Ca}^{2+}]_i$ could be evoked. Subsequent exposure to UV light never produced an increase larger than that initially evoked, however longer flashes of UV light (5 msec) could evoke larger peak increases (fig 2A; max uncage, indicated by the large arrow-head). No effect of UV light was observed in cells either not loaded with cage, or alternatively not expressing InsP_3R . In contrast, when cells were incubated with 10 μM forskolin for 5 min prior to a second identical exposure to UV light a marked increase in the initial Ca^{2+} peak was evoked (fig 2B and pooled data fig 2C). This potentiation of InsP_3 -induced release was of similar magnitude to that seen for CCh-treated cells exposed to forskolin and supports the notion that the predominant effect of forskolin treatment is to regulate Ca^{2+} release through phosphorylation of InsP_3R .

PKA-induced phosphorylation of S1589 and S1755 were functionally important in the $\text{S2}^- \text{InsP}_3\text{R-1}$:

125. The S2^- variant of the $\text{InsP}_3\text{R-1}$ is predominantly expressed in peripheral tissues and in fetal brain during neuronal development [6, 7]. The $\text{S2}^- \text{InsP}_3\text{R-1}$ has been reported to be phosphorylated by PKA in a number of tissues, including platelets, vas deferens, smooth muscle and hepatocytes [7, 30, 46]. In contrast to the neuronal form of the $\text{InsP}_3\text{R-1}$, studies performed with $\text{S2}^- \text{InsP}_3\text{R-1}$ purified from vas deferens and smooth muscle have demonstrated that the receptor is almost exclusively phosphorylated on S1589 [7]. Reports have also suggested a different functional outcome as a result of PKA activation, since the

majority of studies, for example in megakaryocytes have suggested that phosphorylation results in inhibition of Ca^{2+} release [22]. An important caveat relevant to the interpretation of this functional data, is that in contrast to $\text{InsP}_3\text{R-1}$ in cerebellum (>99% S2^+ $\text{InsP}_3\text{R-1}$), in peripheral tissues multiple InsP_3R types are invariably expressed to varying degrees [47].

5 Thus, unequivocally attributing an effect to an individual homotetrameric receptor was problematic prior to the invention.

126. Similar experimental paradigms were employed to assess the effect of PKA-induced phosphorylation on a homogeneous population of S2^- $\text{InsP}_3\text{R-1}$. In DT-40 3ko cells expressing wild-type S2^- $\text{InsP}_3\text{R-1}$, incubation with 20 μM forskolin for 10 min resulted in a marked potentiation of the initial CCh-induced Ca^{2+} peak (fig 3A, pooled data fig 3E) in a similar fashion to that demonstrated for the S2^+ $\text{InsP}_3\text{R-1}$. In contrast to the S2^+ variant of the $\text{InsP}_3\text{R-1}$, neither single mutation in amino acids corresponding to S1589 or S1755 in S2^+ $\text{InsP}_3\text{R-1}$ resulted in loss of this enhanced Ca^{2+} signal (fig 3C/3D and 3E). These data indicated that both serine residues can be phosphorylated in this form of the receptor and

15 furthermore was consistent with the observation that the peripheral $\text{InsP}_3\text{R-1}$ is more readily phosphorylated by PKA than the neuronal form [7]. However, no potentiation was observed in cells transfected with a double mutant where both serines were mutated to alanine (S1589A/S1755A S2^- $\text{InsP}_3\text{R-1}$), confirming that no additional functionally important phosphorylation sites are present in the S2^- $\text{InsP}_3\text{R-1}$ (fig 3D and 3E).

20 127. The degree of potentiation appeared similar when comparing wild-type to either S1589A or S1755A S2^- $\text{InsP}_3\text{R-1}$; expression of each construct revealed a ~3 fold increase in CCh-induced Ca^{2+} release in the presence of forskolin. These data indicated, that if the assumption is made that phosphorylation of each particular site occurred independently, that phosphorylation of individual sites appeared not to result in an additive effect on Ca^{2+}

25 release. A potential exists, however, that the dye used in these experiments (Fura-2; $\text{kd} \sim 150 \text{ nM}$) is saturated with Ca^{2+} upon CCh exposure in the presence of forskolin, thereby masking any additive effect of phosphorylating both sites. For this reason, similar experiments were performed using the lower affinity Ca^{2+} indicator Fura-2-FF ($\text{kd} \sim 10 \mu\text{M}$). While the degree of potentiation was somewhat greater in cells expressing wild-type

30 S2^- $\text{InsP}_3\text{R-1}$ (~4.5 fold) there was no significant difference in the extent of enhancement when comparing wild-type to S1589A and S1755A expressing cells (Fig 3E; filled bars). These data indicate that while it is possible that Fura-2 measurements may indeed underestimate the degree of PKA-induced enhancement of Ca^{2+} release resulting from PKA

phosphorylation, our data suggests that phosphorylation of individual sites appears not to be functionally additive.

128. To assess if the phosphorylation of a particular site was favored in S2⁻ InsP₃R-1, the minimal concentration of forskolin sufficient to enhance CCh-induced Ca²⁺ release in wild-type vs. S1589A and S1755A mutants was compared. In cells transfected with wild-type S2⁻ InsP₃R-1, 100 nM, 500 nM or 1 μM forskolin failed to enhance the subsequent CCh-induced Ca²⁺ release (3 experiments, >5 cells for each condition). Incubation with 5 μM forskolin resulted in a 1.26 ± 0.21 fold potentiation of Ca²⁺ release (n=6). At this threshold concentration of forskolin a similar degree of potentiation was observed in both S1589A (1.36 ± 25 fold; n=8) and S1755A (1.37 ± 0.26 fold; n=7) S2⁻ InsP₃R-1. Thus, functionally, it appears that a particular site is not obviously subject to preferential phosphoregulation by PKA.

129. These data demonstrated that, in contrast to the S2⁺ variant, both S1589 and S1755 are functionally important phosphorylation substrates in the S2⁻ InsP₃R. This indicates that excision of the 40 amino acids in the S2⁻ form of the InsP₃R-1 either alters the structure of the receptor allowing access to the kinase or perhaps allows the interaction with an accessory protein necessary to confer this effect. The only known structural difference between the splice variants is the insertion of an adenine nucleotide binding site in the S2⁻ InsP₃R-1.

Phosphorylation of S2⁺ InsP₃R-1 by PKG:

130. Similar experiments were performed to assess the effects on Ca²⁺ release of phosphorylating InsP₃R-1 with PKG. Cells transfected with S2⁺ InsP₃R-1 together with M3 receptor and HcRed were stimulated with low, threshold concentrations of CCh (25-50 nM) followed by a 10 min treatment with 10 μM 8-Br cGMP, a specific activator of PKG [48]. Subsequent re-stimulation with an identical concentration of CCh revealed a marked potentiation of the [Ca²⁺]_i change. In a similar fashion to PKA activation, this was manifested as an increase in the CCh-induced initial peak (fig 4A and pooled data fig 4E). Moreover, these data are again consistent with phosphorylation increasing the sensitivity of the InsP₃R to InsP₃, since sub-threshold increases in [Ca²⁺]_i were readily potentiated to substantial increases in [Ca²⁺]_i (fig 4A 4B and 4E).

131. Next, the effect of phosphorylation of S1589 and S1755 in S2⁺ InsP₃R-1 mutants was assessed. In cells transfected with S1589A a similar potentiation by 8-Br cGMP was observed (fig 4B and 4E) while no enhanced [Ca²⁺]_i signal was observed in cells transfected

with S1755A (fig 4C and 4E), strongly indicating that phosphorylation of S1755 by PKG is the important event underlying this potentiation of Ca^{2+} signaling. Although PKG and PKA consensus motifs are similar (RRXS) these data are consistent with reports that S1755 is phosphorylated by PKG and furthermore that phosphorylation by PKG is enhanced by the presence of an aromatic amino acid, 4 amino acids downstream from the phosphorylatable serine as is the case for S1755 in $\text{InsP}_3\text{R-1}$ [49]. Indeed the substantial degree of

potentiation may reflect the favorable nature of this site for phosphorylation by PKG. Although phosphorylation of S1755 appears to be responsible for the potentiated signal, our data thus far does not exclude the possibility that the response of wild-type $\text{S2}^+ \text{InsP}_3\text{R-1}$ is a result of a net phosphorylation of both serines by PKG, with phosphorylation of S1589 actually resulting in inhibited release. Thus, the effect of PKG activation on larger $[\text{Ca}^{2+}]_i$ responses to CCh stimulation was tested in cells transfected with S1589A $\text{InsP}_3\text{R-1}$. Using this paradigm no effect of 10 μM 8-Br cGMP was observed (fig 4D), confirming that either S1589 is not phosphorylated or has no functional consequence in $\text{S2}^+ \text{InsP}_3\text{R-1}$.

132. Although the most likely consequence of 8-Br cGMP treatment was to activate PKG, it was possible that this compound led to cAMP accumulation and activation of PKA indirectly by inhibiting cAMP phosphodiesterase [50]. Additionally, a somewhat less likely scenario was that 8-Br cGMP bound to and activated PKA directly. Experiments were therefore performed to confirm that the potentiation of Ca^{2+} signaling observed with 8-Br cGMP treatment was not the result of PKA activation. Cells transfected with $\text{S2}^+ \text{InsP}_3\text{R-1}$ were preincubated for 30 minutes with the cell-permeable PKA inhibitor, myristoylated PKI. This treatment completely abolished any potentiation of the CCh-induced $[\text{Ca}^{2+}]_i$ elevation after forskolin treatment (fig 5A and pooled data fig 5C). In contrast, similar treatment with PKI did not alter the potentiation induced by 8-Br cGMP treatment (fig 5B/C); this treatment still resulted in a ~20 fold potentiation of the CCh-stimulated $[\text{Ca}^{2+}]_i$ signal (compare fig 4A and fig 5B). These data clearly indicate that treatment with forskolin and 8-Br cGMP resulted in the selective activation of PKA or PKG respectively.

Phosphorylation of $\text{S2}^- \text{InsP}_3\text{R-1}$ by PKG:

133. PKA or PKG phosphorylation of the $\text{S2}^- \text{InsP}_3\text{R-1}$ in megakaryocytes and smooth muscle cells has been suggested to inhibit Ca^{2+} release [21, 36, 37]. This observation is difficult to reconcile with the data presented herein for phosphorylation of $\text{S2}^- \text{InsP}_3\text{R-1}$ by PKA, since phosphorylation of either S1589 or S1755 resulted in potentiated release. Nevertheless, similar experiments were performed to elucidate the effect of PKG

phosphorylation of S2⁻ InsP₃R-1. Interestingly, no effect of 10 μM 8-Br cGMP treatment was observed in cells transfected with either wild-type (fig 6A and pooled data fig 6D), S1589A S2⁻ InsP₃R-1 (fig 6B and 6D) or S1755A S2⁻ InsP₃R-1 (fig 6C and 6D). However, in the same batches of cells transfected with wild-type S2⁻ InsP₃R-1, treatment with

5 forskolin resulted in the expected ~4 fold increase in the initial peak (n=5 cells). These data also reinforced the contention that 8-Br cGMP specifically activates PKG without altering PKA activity; the logic being that if, this was not the case, activation of PKA by 8-Br cGMP in S2⁻ InsP₃R-1 expressing cells would be expected to result in data similar to PKA activation shown in Fig 3.

10 134. The data demonstrated that PKA phosphorylation of either S1589 or S1755 resulted in enhanced Ca²⁺ release in the S2⁻ variant of the receptor (fig 3 A/B/C). Thus, PKG is simply not capable of *directly* phosphorylating this receptor. These data, although somewhat surprising, do not rule out the possibility that phosphorylation of an accessory protein termed IRAG [51, 52] may have an effect.

15 135. In conclusion, using mutational analysis in a *null* InsP₃R background this study has elucidated the serine residues in InsP₃R-1 functionally important for modulating Ca²⁺ release by cyclic nucleotide dependent protein kinases. An important finding of this study was that, although phosphorylation of either S1589 or S1755 can result in markedly enhanced Ca²⁺ release, the particular splice variant of InsP₃R-1 expressed dictated which

20 sites were susceptible to phosphorylation. Potentiation of Ca²⁺ release through InsP₃R-1 phosphorylation thus provided a powerful means of enhancing and amplifying Ca²⁺ signaling events when multiple signaling pathways are activated. Additionally, the evidence indicated that PKG appears not to directly regulate S2⁻ InsP₃R-1. Therefore, this splice variation defined which kinase is capable of phosphorylating the receptor at these sites and

25 thus the specificity of functional response.

Example 2: Acute Regulation of Secretion: Cross-Talk Between Signaling Molecules and Their Effectors

Effects on InsP₃-induced Ca²⁺ release

30 136. Phosphorylation of inositol 1,4,5 trisphosphate receptors (InsP₃R) is a major point of synergism between the Ca²⁺ and cAMP signaling systems [29]. Phosphorylation of InsP₃R in parotid acinar cells results in markedly enhanced Ca²⁺ release, an effect attributed to type-II InsP₃R [29]. The functionally important phosphorylation sites have recently been defined in the type-I receptor [57]. The experiments examine the potential for

“phosphomimetic” mutants of InsP₃R-1 to enhance Ca²⁺ signaling and the mechanism responsible for this augmentation of Ca²⁺ release in both the InsP₃R-I and InsP₃R-II. These constructs can be utilized in models of impaired fluid secretion to assess their ability to augment fluid secretion.

5 ***Fluid secretion in salivary acinar cells***

137. Appropriate control of salivary secretion is required for effective speech, mastication and general oral health [62-64]. Disruption of normal secretion is thus a significant health problem for affected individuals. The inability to produce an adequate salivary fluid secretion results in a variety of conditions that together comprise a major health problem for a significant proportion of the population [62, 63].

138. Fluid secretion in the salivary glands relies on the secondary active transepithelial transport of Cl⁻ [61, 65-68]. Briefly, Cl⁻ ions enter the cell across the basolateral membrane, in part via Cl⁻/HCO₃⁻ exchange but primarily by an electrically neutral Na⁺-K⁺-2Cl⁻ cotransport process [69-72]. The accumulated K⁺ ions recycle to the serosal side via basolateral K⁺ channels, whilst the accumulated Cl⁻ exit to the mucosal side via apical Cl⁻ channels. The resultant transepithelial movement of Cl⁻ generates an electrical potential gradient (lumen negative) sufficient to drive Na⁺ into the lumen via a paracellular pathway. The net result is the secretion of Na⁺ and Cl⁻, with water following osmotically [61, 65, 68]. The principal means of regulation of this fluid secretion involves stimulation via parasympathetic nerves supplying the glands [73]. It is generally acknowledged that the main component of this system involves neurally released acetylcholine (ACh) acting at muscarinic receptors on the acinar cells [74-76]. Activation of these receptors produces a rise in [Ca²⁺]_i as a result of an increased turnover of membrane phosphoinositides and the generation of inositol 1,4,5-trisphosphate (InsP₃) [77]. The elevated [Ca²⁺]_i in turn acts at membrane ion channels, specifically increasing basolateral K⁺ conductance and an apical Cl⁻ conductance [61, 65, 67, 68]. It is the increases in these conductance pathways that lead to the initiation of the secretion of ions and accompanying fluid. The rise in [Ca²⁺]_i also apparently has important additional effects including the stimulation of the activity of the basolateral Na⁺-K⁺-2Cl⁻ cotransport increasing the entry of Cl⁻ ions into the cell [78].

30 ***Ca²⁺ signaling in parotid acinar cells***

139. Many studies have investigated the characteristics of [Ca²⁺]_i signals in parotid acinar cells [79]. In common with other electrically non-excitable cells, cytosolic Ca²⁺ signals comprise both the release of Ca²⁺ from intracellular stores and the activation of pathways mediating the entry of Ca²⁺ from the extracellular space. It should be noted that while the

release of intracellular Ca^{2+} is capable of initiating fluid secretion in the salivary glands, the ability to produce a sustained secretion is known to be entirely dependent on the influx of Ca^{2+} from the extracellular medium [58-60]. Consequently, a thorough understanding of the processes leading to activation and modulation of both Ca^{2+} release and Ca^{2+} influx is
 5 fundamentally important for understanding fluid secretion.

140. The pathways involved in Ca^{2+} release are relatively well defined; the binding of secretagogues such as ACh, substance P, noradrenaline and ATP (acting at P2Y receptors) to plasma membrane receptors, couples to the heterotrimeric G protein $\text{G}\alpha_q/11$, resulting in activation of $\text{PLC}\beta$ and the subsequent formation of InsP_3 . All three isoforms of InsP_3R are
 10 expressed to varying degrees in rodent parotid tissue, with ~80% comprising the type-II ($\text{InsP}_3\text{R-II}$) or type-III isoform ($\text{InsP}_3\text{R-III}$) and with $\text{InsP}_3\text{R-II}$ constituting the absolute majority [80, 81]. Binding of InsP_3 to these receptors located in the endoplasmic reticulum results in explosive Ca^{2+} release into the cell cytoplasm. The vast majority of InsP_3R are expressed in the extreme apical pole of the cells and this localization reasonably explains
 15 why Ca^{2+} release is initiated in this region [82, 53]. Physiologically, the initial increase in $[\text{Ca}^{2+}]_i$ is ideally situated to activate Ca^{2+} -dependent Cl^- channels which are localized exclusively to the luminal membrane [54]. Subsequently, the $[\text{Ca}^{2+}]_i$ signal rapidly becomes “global”, facilitating the activation of basolateral Ca^{2+} -activated K^+ channels [80]. The process responsible for the extremely rapid globalization of the Ca^{2+} signal appears to be
 20 distinct from other exocrine cells, such as pancreatic acinar cells [80], in that the increase is much too rapid to be mediated by a classical Ca^{2+} wave propagated by sequentially Ca^{2+} -induced Ca^{2+} release from neighboring release sites. Instead, experimental evidence and mathematical modeling indicate that this phenomenon is best explained by largely
 25 autonomous, local Ca^{2+} release occurring throughout the cytoplasm mediated by both ryanodine receptors (RyR) and InsP_3R [80, 55].

141. Importantly this secretagogue-induced Ca^{2+} release is modulated in both mouse and human parotid acinar cells under conditions where cAMP is elevated. cAMP results in a substantial increase in the $[\text{Ca}^{2+}]_i$ signal upon muscarinic stimulation relative to stimulation in the absence of cAMP. In particular the initial increase in $[\text{Ca}^{2+}]_i$ was enhanced, sub-
 30 threshold stimulation was transformed to a measurable $[\text{Ca}^{2+}]_i$ increase and an oscillatory increase was converted to a sustained $[\text{Ca}^{2+}]_i$ increase, all consistent with a left shift in sensitivity to stimulation by Ca^{2+} mobilizing agonists. Although, there are obviously many potential molecular targets of cAMP, these studies indicated that modulation by cAMP of

PLC activity, pumping activity through PMCA or SERCA, and release through RyR did not appear to be responsible for the enhanced $[Ca^{2+}]_i$ signal [29, 57]. Instead the major effect appeared to be enhanced Ca^{2+} release through PKA phosphorylation of $InsP_3R$. Moreover, this effect was attributed in particular to the $InsP_3R$ -II since this isoform has the greatest sensitivity to $InsP_3$, is the most abundant in mouse parotid, and was shown to be specifically phosphorylated [29]. Since $InsP_3R$ are central to mobilizing $[Ca^{2+}]_i$ in parotid acinar cells, their regulation by phosphorylation provides a point of convergence whereby any secretagogues acting through Gq-PLC are subject to modulation. Indeed, this appears to be the case since Ca^{2+} release through P2Y purinoreceptors in mouse acini is also enhanced by cAMP treatment.

142. While the functional consequences of $InsP_3R$ phosphorylation appear to be sub-type specific, recent studies in heterologous expression systems have demonstrated that phosphorylation of $InsP_3R$ -I in addition to $InsP_3R$ -II also leads to markedly enhanced Ca^{2+} release. The particular sites within $InsP_3R$ -I which are functionally important for potentiated release have also been defined; two canonical PKA-phosphorylation motifs which are conserved from *Drosophila* to human are present in the $InsP_3R$ -1 sequence but are not present in either the $InsP_3R$ -II or $InsP_3R$ -III [12]. In the splice variant of the $InsP_3R$ -1 expressed in parotid acinar cells ($S2^-$ $InsP_3R$ -1 or “short form”) [7] phosphorylation of both sites occurs, resulting in $InsP_3R$ with an enhanced apparent sensitivity to $InsP_3$. Because potentiation of Ca^{2+} release at the level of $InsP_3R$ can be a nexus for interactions between the cAMP and Ca^{2+} signaling systems in parotid acinar cells, this project investigates the mechanism underpinning this effect by studying $InsP_3R$ with phosphomimetic mutations. These receptors can be used therapeutically to maximize $[Ca^{2+}]_i$ signals if expressed in diseased salivary tissue.

$InsP_3$ -dependent Ca^{2+} release: cAMP effects on Ca^{2+} release

143. In mouse parotid acinar cells raising cAMP profoundly potentiates muscarinic agonist-induced $[Ca^{2+}]_i$ signals [29, 83, 84]. A major mechanism underlying this phenomenon can be the PKA-dependent phosphorylation of $InsP_3R$ [29]. The primary evidence supporting this is that cAMP elevation results in both $InsP_3R$ phosphorylation and a marked potentiation of Ca^{2+} release in a PKA dependent manner [29]. Data, consistent with the idea that $InsP_3R$ are central to this effect, is presented in Fig. 7. First, Ca^{2+} release generated through other Gq/PLC-linked receptors, such as P2Y purinergic receptors were also enhanced by cAMP elevation (Fig. 7A). Secondly, the effect was not species specific since a similar marked potentiation of the CCh-induced elevation in $[Ca^{2+}]_i$ was observed in

human parotid acini incubated with either forskolin (Fig. 7B) or β -adrenergic agonist prior to stimulation. The effects of InsP_3R phosphorylation can be subtype-specific. Enhanced Ca^{2+} release is consistent with an effect on $\text{InsP}_3\text{R-II}$ as this InsP_3R is most abundant in parotid tissue and PKA-dependent phosphorylation of $\text{InsP}_3\text{R-II}$ has been shown to augment Ca^{2+} release in other tissues such as liver [30]. It should be noted however, that all three subtypes of InsP_3R are expressed in parotid tissue with similar localization to the apical domain of the cell.

144. Experiments expressing in the DT-40 3kocells a mutant $\text{InsP}_3\text{R-1}$ where serine residues at position 1589 and 1755 are mutated to glutamate as described above, result in markedly potentiated Ca^{2+} release (Fig. 8).

145. Phosphorylation of InsP_3R can alter apparent sensitivity to InsP_3 by a number of mechanisms. These include altering the sensitivity to InsP_3 itself, by changing the sensitivity of the receptor to its co-agonist Ca^{2+} or alternatively by modulating the interaction with other regulatory factors such as proteins or adenine nucleotides. Although studying Ca^{2+} release in DT-40 3ko cells as described above provides a powerful system to assess the net cellular effect of phosphorylation, a complimentary approach can be employed to study the biophysical properties of single InsP_3R channels in isolated nuclei from cells overexpressing InsP_3R and mutants. This technique relies on the fact that the outer nuclear membrane is continuous with the ER and can be patch clamped in the “on nucleus” configuration [11, 85-89]. Studies have successfully recorded InsP_3 dependent currents from isolated Cos-7 nuclei overexpressing $\text{InsP}_3\text{R-1}$ (Fig. 9). Because of the very low expression of endogenous InsP_3R in Cos-7 cells [11, 88] InsP_3 -dependent channel activity in untransfected/mock transfected cells has not been observed. In the example shown in Fig. 9, representative sweeps are shown from a single nucleus which was patched on 6 separate occasions; initially with saturating InsP_3 , subsequently with no InsP_3 , and then later again with InsP_3 in the patch pipette.

Example 3: Modulation of Ca^{2+} Release by Inositol 1,4,5-trisphosphate Receptor Phosphorylation

146. Inositol 1,4,5-trisphosphate receptors (InsP_3R) are the major route of intracellular calcium release in eukaryotic cells and thus are pivotal for stimulation of Ca^{2+} dependent effectors important for the control of numerous physiological processes (Figures 10 and 11). Modulation of Ca^{2+} release through InsP_3R is thus of general importance for defining the particular spatio-temporal characteristics of Ca^{2+} signals. While it is widely appreciated that

Ca^{2+} itself is an important regulator of InsP_3R , the receptor is also subject to modulation through numerous inputs, including protein-protein interactions, binding of adenine nucleotides and phosphorylation by multiple kinases. In this study, the effects on Ca^{2+} release of phosphorylation of InsP_3R by cyclic nucleotide-dependent protein kinases was studied.

147. To investigate the particular sites of phosphoregulation in an unambiguously homogenous population of homomeric receptors, type-1 InsP_3R ($\text{InsP}_3\text{R-I}$) were expressed in DT-40 cells devoid of endogenous InsP_3R (Figure 1A) (43). In cells expressing the neuronal, S2^+ splice variant of the $\text{InsP}_3\text{R-1}$, Ca^{2+} release was markedly enhanced when either PKA or PKG was activated (Figure 1B-D and as described above) (23). The sites of phosphorylation were investigated by mutation of serine residues present in two canonical phosphorylation sites present in the protein. Potentiated Ca^{2+} release was abolished when serine 1755 was mutated to alanine (S1755A) but was unaffected by a similar mutation of serine 1589 (S1589A) (Figures 3 and 12). These data demonstrate that S1755 is the functionally important residue for phosphoregulation by PKA and PKG in the neuronal variant of the $\text{InsP}_3\text{R-1}$. Activation of PKA also resulted in potentiated Ca^{2+} release in cells expressing the non-neuronal, S2^- splice variant of the $\text{InsP}_3\text{R-1}$. However, the PKA-induced potentiation was still evident in S1589A or S1755A $\text{InsP}_3\text{R-1}$ mutants. The effect was abolished in the double (S1589A/S1755A) mutant, indicating both sites are phosphorylated and contribute to the functional effect (Figure 8). Indeed, mimicking phosphorylation by changing either S1589 or S1755 to a positively charged glutamate residue (S1589E or S1755E) resulted in InsP_3R with apparent enhanced sensitivity to InsP_3 (Figures 8 and 13). Activation of PKG had no effect on Ca^{2+} release in cells expressing the S2^- variant of $\text{InsP}_3\text{R-1}$. Collectively these data indicated that phosphoregulation of $\text{InsP}_3\text{R-1}$ had dramatic effects on Ca^{2+} release and defined the molecular sites phosphorylated in the major variants expressed in neuronal and peripheral tissues.

148. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

149. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the

invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

5

REFERENCES

1. Berridge, M.J. (1993) *Nature*. **361**(6410), 315-25
- 10 2. Furuichi, T., S. Yoshikawa, A. Miyawaki, K. Wada, N. Maeda, and K. Mikoshiba. (1989) *Nature*. **342**(6245), 32-8
3. Furuichi, T., S. Yoshikawa, and K. Mikoshiba. (1989) *Nucleic Acids Res.* **17**(13), 5385-6
4. Sudhof, T.C., C.L. Newton, B.T. Archer, 3rd, Y.A. Ushkaryov, and G.A. Mignery.
- 15 (1991) *Embo J.* **10**(11), 3199-206
5. Maranto, A.R. (1994) *J Biol Chem.* **269**(2), 1222-30
6. Nakagawa, T., H. Okano, T. Furuichi, J. Aruga, and K. Mikoshiba. (1991) *Proc Natl Acad Sci U S A.* **88**(14), 6244-8
7. Danoff, S.K., C.D. Ferris, C. Donath, G.A. Fischer, S. Munemitsu, A. Ullrich, S.H.
- 20 Snyder, and C.A. Ross. (1991) *Proc Natl Acad Sci U S A.* **88**(7), 2951-5
8. Yoshikawa, F., M. Morita, T. Monkawa, T. Michikawa, T. Furuichi, and K. Mikoshiba. (1996) *J Biol Chem.* **271**(30), 18277-84
9. Mignery, G.A. and T.C. Sudhof. (1990) *Embo J.* **9**(12), 3893-8
10. Michikawa, T., H. Hamanaka, H. Otsu, A. Yamamoto, A. Miyawaki, T. Furuichi, Y.
- 25 Tashiro, and K. Mikoshiba. (1994) *J Biol Chem.* **269**(12), 9184-9
11. Boehning, D., D.O. Mak, J.K. Foskett, and S.K. Joseph. (2001) *J Biol Chem.* **276**(17), 13509-12
12. Patel, S., S.K. Joseph, and A.P. Thomas. (1999) *Cell Calcium.* **25**(3), 247-64
13. Berridge, M.J., P. Lipp, and M.D. Bootman. (2000) *Nat Rev Mol Cell Biol.* **1**(1), 11-
- 30 21
14. Bootman, M.D., T.J. Collins, C.M. Peppiatt, L.S. Prothero, L. MacKenzie, P. De Smet, M. Travers, S.C. Tovey, J.T. Seo, M.J. Berridge, F. Ciccolini, and P. Lipp. (2001) *Semin Cell Dev Biol.* **12**(1), 3-10

15. Mignery, G.A., P.A. Johnston, and T.C. Sudhof. (1992) *J Biol Chem.* **267**(11), 7450-5
16. Bezprozvanny, I., J. Watras, and B.E. Ehrlich. (1991) *Nature.* **351**(6329), 751-4
17. Iino, M. (1990) *J Gen Physiol.* **95**(6), 1103-22
- 5 18. Iino, M. (1991) *J Gen Physiol.* **98**(4), 681-98
19. Ehrlich, B.E. and J. Watras. (1988) *Nature.* **336**(6199), 583-6
20. Yamada, M., A. Miyawaki, K. Saito, T. Nakajima, M. Yamamoto-Hino, Y. Ryo, T. Furuichi, and K. Mikoshiba. (1995) *Biochem J.* **308** (Pt 1), 83-8
21. Tertyshnikova, S., X. Yan, and A. Fein. (1998) *J Physiol.* **512** (Pt 1), 89-96
- 10 22. Tertyshnikova, S. and A. Fein. (1998) *Proc Natl Acad Sci U S A.* **95**(4), 1613-7
23. Tang, T.S., H. Tu, Z. Wang, and I. Bezprozvanny. (2003) *J Neurosci.* **23**(2), 403-15
24. Nakade, S., S.K. Rhee, H. Hamanaka, and K. Mikoshiba. (1994) *J Biol Chem.* **269**(9), 6735-42
25. Supattapone, S., S.K. Danoff, A. Theibert, S.K. Joseph, J. Steiner, and S.H. Snyder. (1988) *Proc Natl Acad Sci U S A.* **85**(22), 8747-50
- 15 26. Wojcikiewicz, R.J. and S.G. Luo. (1998) *J Biol Chem.* **273**(10), 5670-7
27. Jayaraman, T., K. Ondrias, E. Ondriasova, and A.R. Marks. (1996) *Science.* **272**(5267), 1492-4
28. Giovannucci, D.R., G.E. Groblewski, J. Sneyd, and D.I. Yule. (2000) *J Biol Chem.* **275**(43), 33704-11
- 20 29. Bruce, J.I., T.J. Shuttleworth, D.R. Giovannucci, and D.I. Yule. (2002) *J Biol Chem.* **277**(2), 1340-8
30. Joseph, S.K. and S.V. Ryan. (1993) *J Biol Chem.* **268**(31), 23059-65
31. Ferris, C.D., R.L. Huganir, D.S. Bredt, A.M. Cameron, and S.H. Snyder. (1991) *Proc Natl Acad Sci U S A.* **88**(6), 2232-5
- 25 32. den Dekker, E., J.W. Heemskerk, G. Gorter, H. van der Vuurst, J. Donath, C. Kroner, K. Mikoshiba, and J.W. Akkerman. (2002) *Arterioscler Thromb Vasc Biol.* **22**(1), 179-86
33. DeSouza, N., S. Reiken, K. Ondrias, Y.M. Yang, S. Matkovich, and A.R. Marks. (2002) *J Biol Chem.* **277**(42), 39397-400
- 30 34. Ferris, C.D., A.M. Cameron, D.S. Bredt, R.L. Huganir, and S.H. Snyder. (1991) *Biochem Biophys Res Commun.* **175**(1), 192-8

35. Haug, L.S., V. Jensen, O. Hvalby, S.I. Walaas, and A.C. Ostvold. (1999) *J Biol Chem.* **274**(11), 7467-73
36. Komalavilas, P. and T.M. Lincoln. (1994) *J Biol Chem.* **269**(12), 8701-7
37. Komalavilas, P. and T.M. Lincoln. (1996) *J Biol Chem.* **271**(36), 21933-8
- 5 38. LeBeau, A.P., D.I. Yule, G.E. Groblewski, and J. Sneyd. (1999) *J Gen Physiol.* **113**(6), 851-72
39. Pieper, A.A., D.J. Brat, E. O'Hearn, D.K. Krug, A.I. Kaplin, K. Takahashi, J.H. Greenberg, D. Ginty, M.E. Molliver, and S.H. Snyder. (2001) *Neuroscience.* **102**(2), 433-44
40. Koga, T., Y. Yoshida, J.Q. Cai, M.O. Islam, and S. Imai. (1994) *J Biol Chem.*
10 **269**(15), 11640-7
41. Straub, S.V., D.R. Giovannucci, J.I. Bruce, and D.I. Yule. (2002) *J Biol Chem.* **277**(35), 31949-56
42. Miyakawa, T., A. Maeda, T. Yamazawa, K. Hirose, T. Kurosaki, and M. Iino. (1999) *Embo J.* **18**(5), 1303-8
- 15 43. Sugawara, H., M. Kurosaki, M. Takata, and T. Kurosaki. (1997) *Embo J.* **16**(11), 3078-88
44. Kubista, H., T. Hawkins, and S.E. Moss. (1998) *Biochim Biophys Acta.* **1448**(2), 299-310
45. Li, W., J. Llopis, M. Whitney, G. Zlokarnik, and R.Y. Tsien. (1998) *Nature.*
20 **392**(6679), 936-41
46. Cavallini, L., M. Coassin, A. Borean, and A. Alexandre. (1996) *J Biol Chem.* **271**(10), 5545-51
47. Wojcikiewicz, R.J. (1995) *J Biol Chem.* **270**(19), 11678-83
48. Rapoport, R.M., M.B. Draznin, and F. Murad. (1982) *Proc Natl Acad Sci U S A.*
25 **79**(21), 6470-4
49. Colbran, J.L., S.H. Francis, A.B. Leach, M.K. Thomas, H. Jiang, L.M. McAllister, and J.D. Corbin. (1992) *J Biol Chem.* **267**(14), 9589-94
50. Houslay, M.D. and G. Milligan. (1997) *Trends Biochem Sci.* **22**(6), 217-24
51. Ammendola, A., A. Geiselhoringer, F. Hofmann, and J. Schlossmann. (2001) *J Biol*
30 *Chem.* **276**(26), 24153-9
52. Schlossmann, J., A. Ammendola, K. Ashman, X. Zong, A. Huber, G. Neubauer, G.X. Wang, H.D. Allescher, M. Korth, M. Wilm, F. Hofmann, and P. Ruth. (2000) *Nature.* **404**(6774), 197-201

53. Nezu, A., et al., *Evidence that zymogen granules do not function as an intracellular Ca^{2+} store for the generation of the Ca^{2+} signal in rat parotid acinar cells.* Biochem J, 2002. **363**(Pt 1): p. 59-66.
54. Hassoni, A.A. and P.T. Gray, *Flash photolysis studies of the localization of calcium release sites in rat parotid isolated acinar cells.* J Physiol, 1994. **478 Pt 3**: p. 461-7.
55. Sneyd, J., et al., *A model of calcium waves in pancreatic and parotid acinar cells.* Biophys J, 2003. **85**(3): p. 1392-405.
56. Bruce, J.I., S.V. Straub, and D.I. Yule, *Crosstalk between cAMP and Ca^{2+} signaling in non-excitabile cells.* Cell Calcium, 2003. **34**(6): p. 431-44.
- 10 57. Bruce, J.I., D.I. Yule, and T.J. Shuttleworth, *Ca^{2+} -dependent protein kinase--a modulation of the plasma membrane Ca^{2+} -ATPase in parotid acinar cells.* J Biol Chem, 2002. **277**(50): p. 48172-81.
58. Mertz, L.M., B.J. Baum, and I.S. Ambudkar, *Refill status of the agonist-sensitive Ca^{2+} pool regulates Mn^{2+} influx into parotid acini.* 1990. **265**(25): p. 15010-15014.
- 15 59. Putney, J.W., Jr., *Biphasic modulation of potassium release in rat parotid gland by carbachol and phenylephrine.* 1976. **198**(2): p. 375-384.
60. Mertz, L.M., et al., *Calcium entry in rat parotid acini: activation by carbachol and aluminum fluoride.* 1990. **258**(4 Pt 1): p. C654-C661.
61. Turner, R.J., *Mechanisms of fluid secretion by salivary glands.* Ann N Y Acad Sci, 20 1993. **694**: p. 24-35.
62. Mandel, I.D., *The role of saliva in maintaining oral homeostasis.* J Am Dent Assoc, 1989. **119**(2): p. 298-304.
63. Atkinson, J.C. and P.C. Fox, *Salivary gland dysfunction.* Clin Geriatr Med, 1992. **8**(3): p. 499-511.
- 25 64. Baum, B.J., *Principles of saliva secretion.* Ann N Y Acad Sci, 1993. **694**: p. 17-23.
65. Petersen, O.H., *Stimulus-secretion coupling: cytoplasmic calcium signals and the control of ion channels in exocrine acinar cells.* J Physiol, 1992. **448**: p. 1-51.
66. Frizzell, R.A., M. Field, and S.G. Schultz, *Sodium-coupled chloride transport by epithelial tissues.* Am J Physiol, 1979. **236**(1): p. F1-8.
- 30 67. Melvin, J.E., *Chloride channels and salivary gland function.* Crit Rev Oral Biol Med, 1999. **10**(2): p. 199-209.
68. Nauntofte, B., *Regulation of electrolyte and fluid secretion in salivary acinar cells.* Am J Physiol, 1992. **263**(6 Pt 1): p. G823-37.

69. Evans, R.L., et al., *Severe impairment of salivation in Na⁺/K⁺/2Cl⁻ cotransporter (NKCC1)-deficient mice*. J Biol Chem, 2000. **275**(35): p. 26720-6.
70. Melvin, J.E. and R.J. Turner, *Cl⁻ fluxes related to fluid secretion by the rat parotid: involvement of Cl⁻-HCO₃⁻ exchange*. Am J Physiol, 1992. **262**(3 Pt 1): p. G393-8.
- 5 71. Turner, R.J. and J.N. George, *Cl⁻-HCO₃⁻ exchange is present with Na⁺-K⁺-Cl⁻ cotransport in rabbit parotid acinar basolateral membranes*. Am J Physiol, 1988. **254**(3 Pt 1): p. C391-6.
72. Turner, R.J., J.N. George, and B.J. Baum, *Evidence for a Na⁺/K⁺/Cl⁻ cotransport system in basolateral membrane vesicles from the rabbit parotid*. J Membr Biol, 1986.
10 **94**(2): p. 143-52.
73. Garrett, J.R. and A. Kidd, *The innervation of salivary glands as revealed by morphological methods*. Microsc Res Tech, 1993. **26**(1): p. 75-91.
74. Tojyo, Y., A. Tanimura, and Y. Matsumoto, *Imaging of intracellular Ca²⁺ waves induced by muscarinic receptor stimulation in rat parotid acinar cells*. Cell Calcium, 1997.
15 **22**(6): p. 455-62.
75. Watson, E.L., et al., *Identification of muscarinic receptor subtypes in mouse parotid gland*. Am J Physiol, 1996. **271**(3 Pt 1): p. C905-13.
76. Watson, E.L., J.A. Williams, and I.A. Siegel, *Calcium mediation of cholinergic-stimulated amylase release from mouse parotid gland*. Am J Physiol, 1979. **236**(5): p.
20 C233-7.
77. Sawaki, K., et al., *Involvement of G alpha q/11 in m3-muscarinic receptor stimulation of phosphatidylinositol 4,5 biphosphate-specific phospholipase C in rat parotid gland membranes*. Arch Biochem Biophys, 1993. **305**(2): p. 546-50.
78. Evans, R.L. and R.J. Turner, *Upregulation of Na⁽⁺⁾-K⁽⁺⁾-2Cl⁻ cotransporter activity in rat parotid acinar cells by muscarinic stimulation*. J Physiol, 1997. **499** (Pt 2): p.
25 351-9.
79. Ambudkar, I.S., *Regulation of calcium in salivary gland secretion*. 2000. **11**(1): p. 4-25.
80. Giovannucci, D.R., et al., *Cytosolic Ca⁽²⁺⁾ and Ca⁽²⁺⁾-activated Cl⁽⁻⁾ current dynamics: insights from two functionally distinct mouse exocrine cells*. J Physiol, 2002.
30 **540**(Pt 2): p. 469-84.
81. Zhang, X., et al., *Ryanodine and inositol trisphosphate receptors are differentially distributed and expressed in rat parotid gland*. Biochem J, 1999. **340** (Pt 2): p. 519-27.

82. Lee, M.G., et al., *Polarized expression of Ca²⁺ channels in pancreatic and salivary gland cells. Correlation with initiation and propagation of [Ca²⁺]_i waves.* J Biol Chem, 1997. **272**(25): p. 15765-70.
83. Tanimura, A., et al., *Isoproterenol potentiates alpha-adrenergic and muscarinic receptor-mediated Ca²⁺ response in rat parotid cells.* Am J Physiol, 1999. **276**(6 Pt 1): p. C1282-7.
84. Tanimura, A., Y. Matsumoto, and Y. Tojyo, *Evidence that isoproterenol-induced Ca²⁺(+)-mobilization in rat parotid acinar cells is not mediated by activation of beta-adrenoceptors.* Biochim Biophys Acta, 1990. **1055**(3): p. 273-7.
- 10 85. Mak, D.O. and J.K. Foskett, *Single-channel inositol 1,4,5-trisphosphate receptor currents revealed by patch clamp of isolated Xenopus oocyte nuclei.* J Biol Chem, 1994. **269**(47): p. 29375-8.
86. Mak, D.O., S. McBride, and J.K. Foskett, *ATP regulation of type 1 inositol 1,4,5-trisphosphate receptor channel gating by allosteric tuning of Ca²⁺ activation.* J Biol
15 Chem, 1999. **274**(32): p. 22231-7.
87. Mak, D.O., et al., *Single-channel properties in endoplasmic reticulum membrane of recombinant type 3 inositol trisphosphate receptor.* J Gen Physiol, 2000. **115**(3): p. 241-56.
88. Boehning, D., et al., *Single-channel recordings of recombinant inositol trisphosphate receptors in mammalian nuclear envelope.* Biophys J, 2001. **81**(1): p. 117-24.
- 20 89. Mak, D.O., S. McBride, and J.K. Foskett, *Regulation by Ca²⁺ and inositol 1,4,5-trisphosphate (InsP₃) of single recombinant type 3 InsP₃ receptor channels. Ca²⁺ activation uniquely distinguishes types 1 and 3 insp₃ receptors.* J Gen Physiol, 2001. **117**(5): p. 435-46.

IV. CLAIMS

What is claimed is:

1. A InsP_3R mutant, comprising at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site of a wild-type InsP_3R , wherein the mutant has an enhanced Ca^{2+} release function as compared to the wild-type InsP_3R .
2. The mutant of claim 1, wherein the Ca^{2+} release function is at least 5 times greater than the Ca^{2+} release function of the wild-type InsP_3R .
3. The mutant of claim 1, wherein the InsP_3R mutant is an $\text{InsP}_3\text{R-1}$ mutant and the wild-type InsP_3R is $\text{InsP}_3\text{R-1}$.
4. The mutant of claim 3, comprising at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site, wherein the phosphorylation site is selected from residue 1589 or 1755 of a wild-type $\text{InsP}_3\text{R-1}$ sequence.
5. The mutant of claim 4, wherein the substitution of serine for the negatively charged amino acid is at residue 1589.
6. The mutant of claim 4, wherein glutamate is substituted for serine at residue 1589.
7. The mutant of claim 6, wherein the mutant comprises the amino acid sequence of SEQ ID NO:1.
8. The mutant of claim 6, wherein the mutant comprises the amino acid sequence of SEQ ID NO:1 with one or more conservative amino acid substitutions.
9. The mutant of claim 6, wherein the mutant comprises the amino acid sequence of SEQ ID NO:2.
10. The mutant of claim 6, wherein the mutant comprises the amino acid sequence of SEQ ID NO:2 with one or more conservative amino acid substitutions.
11. The mutant of claim 4, wherein aspartate is substituted for serine at residue 1589.
12. The mutant of claim 11, wherein the mutant comprises the amino acid sequence of SEQ ID NO:3.
13. The mutant of claim 11, wherein the mutant comprises the amino acid sequence of SEQ ID NO:3 with one or more conservative amino acid substitutions.
14. The mutant of claim 11, wherein the mutant comprises the amino acid sequence of SEQ ID NO:4.
15. The mutant of claim 11, wherein the mutant comprises the amino acid sequence of SEQ ID NO:4 with one or more conservative amino acid substitutions.
16. The mutant of claim 4, wherein the substitution of serine for the negatively charged amino acid is at residue 1755.
17. The mutant of claim 16, wherein glutamate is substituted for serine at residue 1755.
18. The mutant of claim 17, wherein the mutant comprises the amino acid sequence of SEQ ID NO:5.
19. The mutant of claim 17, wherein the mutant comprises the amino acid sequence of SEQ ID NO:5 with one or more conservative amino acid substitutions.
20. The mutant of claim 17, wherein the mutant comprises the amino acid sequence of SEQ ID NO:6.
21. The mutant of claim 17, wherein the mutant comprises the amino acid sequence of SEQ ID NO:6 with one or more conservative amino acid substitutions.
22. The mutant of claim 16, wherein aspartate is substituted for serine at residue 1755.
23. The mutant of claim 22, wherein the mutant comprises the amino acid sequence of SEQ ID NO:7.
24. The mutant of claim 22, wherein the mutant comprises the amino acid sequence of SEQ ID NO:7 with one or more conservative amino acid substitutions.
25. The mutant of claim 22, wherein the mutant comprises the amino acid sequence of SEQ ID NO:8.

26. The mutant of claim 22, wherein the mutant comprises the amino acid sequence of SEQ ID NO:8 with one or more conservative amino acid substitutions.
27. The mutant of claim 4, wherein the substitutions of serine for the negatively charged amino acid is at residues 1589 and 1755.
- 5 28. The mutant of claim 27, wherein glutamate is substituted for serine at residues 1589 and 1755.
29. The mutant of claim 28, wherein the mutant comprises the amino acid sequence of SEQ ID NO:9.
30. The mutant of claim 28, wherein the mutant comprises the amino acid sequence of
10 SEQ ID NO:9 with one or more conservative amino acid substitutions.
31. The mutant of claim 28, wherein the mutant comprises the amino acid sequence of SEQ ID NO:10.
32. The mutant of claim 28, wherein the mutant comprises the amino acid sequence of SEQ ID NO:10 with one or more conservative amino acid substitutions.
- 15 33. The mutant of claim 27, wherein aspartate is substituted for serine at residues 1589 and 1755.
34. The mutant of claim 33, wherein the mutant comprises the amino acid sequence of SEQ ID NO:11.
35. The mutant of claim 33, wherein the mutant comprises the amino acid sequence of
20 SEQ ID NO:11 with one or more conservative amino acid substitutions.
36. The mutant of claim 33, wherein the mutant comprises the amino acid sequence of SEQ ID NO:12.
37. The mutant of claim 33, wherein the mutant comprises the amino acid sequence of SEQ ID NO:12 with one or more conservative amino acid substitutions.
- 25 38. The mutant of claim 27, wherein aspartate is substituted for serine at residue 1589 and glutamate is substituted for serine at residue 1755.
39. The mutant of claim 37, wherein the mutant comprises the amino acid sequence of SEQ ID NO:13.
40. The mutant of claim 37, wherein the mutant comprises the amino acid sequence of
30 SEQ ID NO:13 with one or more conservative amino acid substitutions.
41. The mutant of claim 37, wherein the mutant comprises the amino acid sequence of SEQ ID NO:14.
42. The mutant of claim 37, wherein the mutant comprises the amino acid sequence of SEQ ID NO:14 with one or more conservative amino acid substitutions.
- 35 43. The mutant of claim 25, wherein glutamate is substituted for serine at residue 1589 and aspartate is substituted for serine at residue 1755.
44. The mutant of claim 43, wherein the mutant comprises the amino acid sequence of SEQ ID NO:15.
45. The mutant of claim 43, wherein the mutant comprises the amino acid sequence of
40 SEQ ID NO:15 with one or more conservative amino acid substitutions.
46. The mutant of claim 43, wherein the mutant comprises the amino acid sequence of SEQ ID NO:16.
47. The mutant of claim 43, wherein the mutant comprises the amino acid sequence of SEQ ID NO:16 with one or more conservative amino acid substitutions.
- 45 48. A nucleic acid that encodes the mutant of claim 1-47.
49. An expression vector comprising the nucleic acid of claim 48 operable linked to an expression control sequence.
50. A cultured cell comprising the vector of claim 48.
51. The cell of claim 50, wherein the cell is a DT-40 cell.

52. The cell of claim 51, wherein the cell further comprises a nucleic acid that encodes an acetylcholine receptor.

53. The cell of claim 52, wherein the acetylcholine receptor is an M3 receptor.

54. An InsP₃R mutant, comprising at least one substitution of serine for an amino acid with an aliphatic side chain at a phosphorylation site of a wild-type InsP₃R, wherein the mutant is nonphosphorylatable.

55. The mutant of claim 50, wherein the nonphosphorylatable mutant is an InsP₃R-1 mutant.

56. The mutant of claim 50, wherein the nonphosphorylatable mutant of InsP₃R is selected from the group consisting of an S1755A, or S1589A/S1755A mutation.

57. A nucleic acid that encodes the mutant of claim 50.

58. An expression vector comprising the nucleic acid of claim 57 operable linked to an expression control sequence.

59. A cultured cell comprising the vector of claim 57.

60. The cell of claim 59, wherein the cell is a DT-40 cell.

61. The cell of claim 60 wherein the cell further comprises a nucleic acid that encodes an acetylcholine receptor.

62. The cell of claim 61, wherein the acetylcholine receptor is an M3 receptor.

63. A method of screening for an agent that preferentially modulates Ca²⁺ release by phosphorylated InsP₃R, comprising

a. contacting the cell of claim 50 with the agent to be screened, under conditions that allow Ca²⁺ release;

b. measuring Ca²⁺ release; and

c. comparing the amount of Ca²⁺ release in step b with a control cell, wherein the control cell comprises an un-phosphorylated InsP₃R and wherein the control cell is contacted with the agent to be screened, an increase or decrease in Ca²⁺ release as compared to a control cell indicating an agent that preferentially modulates unphosphorylated InsP₃R.

64. The method of claim 63, wherein the un-phosphorylated InsP₃R is a nonphosphorylatable mutant InsP₃R.

65. The method of claim 64, wherein the nonphosphorylatable mutant comprises a substitution of a serine at a phosphorylation site with an amino acid having an aliphatic side-chain.

66. The method of claim 65, wherein the amino acid having an aliphatic side chain is alanine.

67. The method of claim 65, wherein the phosphorylation site is either residue 1589 or 1755 or a combination thereof of wild-type InsP₃R.

68. A method of expressing a mutant InsP₃R in a cell *in vivo*, comprising

a. providing the expression vector of claim 48;

b. introducing the vector into a cell *in vivo*;

c. maintaining the cell under condition that permit expression of the mutant InsP₃R by the cell.

69. A method of treating a subject with xerostomia, comprising introducing into the subject the expression vector of claim 48 under conditions that an amount of InsP₃R mutant is expressed in an effective amount to alleviate the symptoms of xerostomia.

70. A method of treating a subject with cystic fibrosis, comprising introducing into the subject the expression vector of claim 48 under conditions that an amount of InsP₃R mutant is expressed in an effective amount to alleviate the symptoms of cystic fibrosis.

71. The mutant of claim 1, wherein the InsP₃R mutant is an InsP₃R-2 mutant and the wild-type InsP₃R is InsP₃R-2.

72. The mutant of claim 71, comprising at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site, wherein the phosphorylation site is selected from residue 766, 1772, 1856, 2058; 2227 of a wild-type InsP₃R-2 sequence.

5 73. The mutant of claim 72, wherein one or more serines are substituted with glutamate.

74. The mutant of claim 72, wherein one or more serines are substituted with aspartate.

75. The mutant of claim 72, wherein any combination of the serines are substituted with any combination of aspartate or glutamate.

10 76. The mutant of claim 1, wherein the InsP₃R mutant is an InsP₃R-3 mutant and the wild-type InsP₃R is InsP₃R-3.

77. The mutant of claim 76, comprising at least one substitution of serine for a negatively charged amino acid residue at a phosphorylation site, wherein the phosphorylation site is selected from residue 934, 1640, 1834, 2009, 2041, 2189 of a wild-type InsP₃R-3 sequence.

15 78. The mutant of claim 77, wherein one or more serines are substituted with glutamate.

79. The mutant of claim 77, wherein one or more serines are substituted with aspartate.

80. The mutant of claim 77, wherein any combination of the serines are substituted with any combination of aspartate or glutamate.

20




FIG. 1




FIG. 2




FIG. 3






FIG. 4

A



B



C




FIG. 5




FIG. 6




Figure 7





Figure 8






Figure 9



Adapted from Mikoshiba *TIPs*. 14(3):86-9, 1993

Figure 10



S2⁺=neuronal "long form"
 S2⁻=peripheral "short form"

Figure 11




Figure 12






Figure 13

DT-40 IP₃R-III cells



IP: type III InsP3R
 Probe: phospho Ser/Thr PKA

Forsk/dbcAMP	—	+	+
RpcAMP/H89	—	—	+

Figure 14





Figure 15




Figure 16

SEQUENCE LISTING

<110> Yule, D.I.

Wagner II, Larry

<120> Inositol 1,4,5-trisphosphate receptor
mutants and uses thereof

<130> 21108.0042U1

<160> 22

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2710

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 1

Met	Ser	Asp	Lys	Met	Ser	Ser	Phe	Leu	His	Ile	Gly	Asp	Ile	Cys	Ser	1	5	10	15
Leu	Tyr	Ala	Glu	Gly	Ser	Thr	Asn	Gly	Phe	Ile	Ser	Thr	Leu	Gly	Leu	20	25	30	
Val	Asp	Asp	Arg	Cys	Val	Val	Gln	Pro	Glu	Ala	Gly	Asp	Leu	Asn	Asn	35	40	45	
Pro	Pro	Lys	Lys	Phe	Arg	Asp	Cys	Leu	Phe	Lys	Leu	Cys	Pro	Met	Asn	50	55	60	
Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Ala	Lys	Pro	Gly	Ala	65	70	75	80
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala	85	90	95	
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly	100	105	110	
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser	115	120	125	
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys	130	135	140	
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp	145	150	155	160
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	165	170	175	
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	180	185	190	
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	195	200	205	
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	210	215	220	
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235	240
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	245	250	255	
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	260	265	270	

ATTORNEY DOCKET NO. 21108.0042U1

Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	
		275					280					285				
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	
	290					295					300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	
305					310					315					320	
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	
				325					330					335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	
		340						345					350			
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	
	355						360					365				
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	
	370					375					380					
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	
385					390					395					400	
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	
			405					410						415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
		420						425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
	435					440						445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
		500						505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
	515						520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565					570						575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
		580						585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
	595						600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645					650						655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
		660						665					670			
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
	675						680					685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695					700					
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725					730						735		
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	
		740						745					750			

Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	
	755						760					765				
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
	770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
				805					810					815		
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
			820					825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
	835						840					845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
	850					855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870					875					880	
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	
				885					890					895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	
		900						905					910			
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	
	915						920					925				
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	
	930					935					940					
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	
945					950					955					960	
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu	
			965					970						975		
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys	
		980						985					990			
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser	
	995						1000					1005				
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val	
	1010					1015					1020					
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile	
1025					1030					1035					1040	
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly	
			1045						1050					1055		
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr	
		1060						1065					1070			
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser	
	1075					1080					1085					
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val	
	1090					1095					1100					
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp	
1105					1110					1115					1120	
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly	
			1125						1130					1135		
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His	
		1140						1145					1150			
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr	
	1155						1160					1165				
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser	
	1170					1175					1180					
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln	
1185					1190					1195					1200	
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu	
			1205						1210					1215		
Leu	Leu	Gln	Ile	Pro	Tyr	Glu	Lys	Ala	Glu	Asp	Thr	Lys	Met	Gln	Glu	
		1220						1225					1230			

Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Glu Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710

Arg Arg Glu Ser Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190

Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525
 Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590
 Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
 2595 2600 2605
 Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
 2610 2615 2620
 Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
 2625 2630 2635 2640
 Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
 2645 2650 2655
 Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
 2660 2665 2670

Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
 2675 2680 2685
 Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
 2690 2695 2700
 Asn Pro Gln Gln Pro Ala
 2705 2710

<210> 2
 <211> 2749
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 2
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Ser His Gln Leu Val Asp Asn Pro Gly Cys Asn Glu
 195 200 205
 Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Val Leu Phe Met
 210 215 220
 Lys Trp Ser Asp Asn Lys Asp Asp Ile Leu Lys Gly Gly Asp Val Val
 225 230 235 240
 Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu His
 245 250 255
 Arg Lys Lys Gln His Val Phe Leu Arg Thr Thr Gly Arg Gln Ser Ala
 260 265 270
 Thr Ser Ala Thr Ser Ser Lys Ala Leu Trp Glu Val Glu Val Val Gln
 275 280 285
 His Asp Pro Cys Arg Gly Gly Ala Gly Tyr Trp Asn Ser Leu Phe Arg
 290 295 300
 Phe Lys His Leu Ala Thr Gly His Tyr Leu Ala Ala Glu Val Asp Pro
 305 310 315 320
 Asp Phe Glu Glu Glu Cys Leu Glu Phe Gln Pro Ser Val Asp Pro Asp
 325 330 335

Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val		
			340					345					350				
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe		
		355					360					365					
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
	370					375					380						
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395					400		
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu		
			405					410						415			
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
			420					425					430				
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
		435					440					445					
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
	450					455					460						
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480		
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu		
			485					490						495			
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu		
			500					505					510				
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr		
		515					520					525					
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln		
	530					535				540							
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu		
545					550					555					560		
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys		
			565					570						575			
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu		
			580					585					590				
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys		
		595					600					605					
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys		
	610					615					620						
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser		
625					630					635					640		
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val		
			645					650						655			
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu		
		660						665					670				
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu		
		675				680						685					
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn		
	690					695					700						
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys		
705					710					715					720		
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln		
			725					730						735			
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile		
		740						745					750				
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met		
		755				760						765					
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu		
	770					775					780						
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro		
785					790					795					800		
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile		
			805					810						815			

Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	820	825	830
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	835	840	845
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	850	855	860
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	865	870	875
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	885	890	895
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	900	905	910
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	915	920	925
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	930	935	940
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	945	950	955
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu	965	970	975
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys	980	985	990
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser	995	1000	1005
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val	1010	1015	1020
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile	1025	1030	1035
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly	1045	1050	1055
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr	1060	1065	1070
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser	1075	1080	1085
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val	1090	1095	1100
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp	1105	1110	1115
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly	1125	1130	1135
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His	1140	1145	1150
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr	1155	1160	1165
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser	1170	1175	1180
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln	1185	1190	1195
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu	1205	1210	1215
Leu	Leu	Gln	Ile	Pro	Tyr	Glu	Lys	Ala	Glu	Asp	Thr	Lys	Met	Gln	Glu	1220	1225	1230
Ile	Met	Arg	Leu	Ala	His	Glu	Phe	Leu	Gln	Asn	Phe	Cys	Ala	Gly	Asn	1235	1240	1245
Gln	Gln	Asn	Gln	Ala	Leu	Leu	His	Lys	His	Ile	Asn	Leu	Phe	Leu	Asn	1250	1255	1260
Pro	Gly	Ile	Leu	Glu	Ala	Val	Thr	Met	Gln	His	Ile	Phe	Met	Asn	Asn	1265	1270	1275
Phe	Gln	Leu	Cys	Ser	Glu	Ile	Asn	Glu	Arg	Val	Val	Gln	His	Phe	Val	1285	1290	1295

His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Glu Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695
 Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Ser Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775

Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790
 Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885
 Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255

Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu.
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560
 Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
 2565 2570 2575
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2580 2585 2590
 Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
 2595 2600 2605
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2610 2615 2620
 Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
 2625 2630 2635 2640
 Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
 2645 2650 2655
 Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
 2660 2665 2670
 Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
 2675 2680 2685
 Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2690 2695 2700
 Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
 2705 2710 2715 2720
 Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
 2725 2730 2735

His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
 2740 2745

<210> 3
 <211> 2710
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 3
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Ser His Gln Leu Val Asp Asn Pro Gly Cys Asn Glu
 195 200 205
 Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Val Leu Phe Met
 210 215 220
 Lys Trp Ser Asp Asn Lys Asp Asp Ile Leu Lys Gly Gly Asp Val Val
 225 230 235 240
 Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu His
 245 250 255
 Arg Lys Lys Gln His Val Phe Leu Arg Thr Thr Gly Arg Gln Ser Ala
 260 265 270
 Thr Ser Ala Thr Ser Ser Lys Ala Leu Trp Glu Val Glu Val Val Gln
 275 280 285
 His Asp Pro Cys Arg Gly Gly Ala Gly Tyr Trp Asn Ser Leu Phe Arg
 290 295 300
 Phe Lys His Leu Ala Thr Gly His Tyr Leu Ala Ala Glu Val Asp Pro
 305 310 315 320
 Asp Phe Glu Glu Glu Cys Leu Glu Phe Gln Pro Ser Val Asp Pro Asp
 325 330 335
 Gln Asp Ala Ser Arg Ser Arg Leu Arg Asn Ala Gln Glu Lys Met Val
 340 345 350
 Tyr Ser Leu Val Ser Val Pro Glu Gly Asn Asp Ile Ser Ser Ile Phe
 355 360 365

Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
370						375				380							
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395					400		
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Lys	Pro	Val	Met	Leu			
				405					410					415			
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
			420					425					430				
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
		435				440						445					
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
450					455					460							
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480		
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu		
				485					490					495			
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu		
			500					505					510				
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr		
		515					520					525					
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln		
530					535					540							
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu		
545					550					555					560		
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys		
				565					570					575			
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu		
			580					585					590				
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys		
		595					600					605					
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys		
610					615					620							
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser		
625					630					635					640		
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val		
				645					650					655			
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu		
			660					665					670				
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu		
		675					680					685					
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn		
690					695					700							
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys		
705					710					715					720		
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln		
				725					730					735			
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile		
			740					745					750				
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met		
		755					760					765					
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu		
		770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro		
785					790					795					800		
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile		
				805					810					815			
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg		
			820					825					830				
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val		
		835					840					845					

Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe		
850						855					860						
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn		
865					870					875					880		
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp		
				885					890						895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly		
			900					905					910				
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly		
		915					920					925					
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met		
930						935					940						
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro		
945					950					955					960		
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu		
				965					970						975		
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys		
			980					985					990				
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser		
		995					1000					1005					
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val		
1010						1015					1020						
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile		
1025					1030					1035					1040		
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly		
				1045					1050						1055		
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr		
			1060				1065						1070				
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser		
		1075					1080					1085					
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val		
1090						1095					1100						
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp		
1105					1110					1115					1120		
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly		
				1125					1130						1135		
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His		
			1140					1145					1150				
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr		
		1155					1160					1165					
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser		
		1170				1175					1180						
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln		
1185					1190					1195					1200		
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu		
				1205					1210						1215		
Leu	Leu	Gln	Ile	Pro	Tyr	Glu	Lys	Ala	Glu	Asp	Thr	Lys	Met	Gln	Glu		
			1220					1225					1230				
Ile	Met	Arg	Leu	Ala	His	Glu	Phe	Leu	Gln	Asn	Phe	Cys	Ala	Gly	Asn		
		1235					1240					1245					
Gln	Gln	Asn	Gln	Ala	Leu	Leu	His	Lys	His	Ile	Asn	Leu	Phe	Leu	Asn		
		1250				1255					1260						
Pro	Gly	Ile	Leu	Glu	Ala	Val	Thr	Met	Gln	His	Ile	Phe	Met	Asn	Asn		
1265					1270					1275					1280		
Phe	Gln	Leu	Cys	Ser	Glu	Ile	Asn	Glu	Arg	Val	Val	Gln	His	Phe	Val		
				1285					1290						1295		
His	Cys	Ile	Glu	Thr	His	Gly	Arg	Asn	Val	Gln	Tyr	Ile	Lys	Phe	Leu		
			1300					1305					1310				
Gln	Thr	Ile	Val	Lys	Ala	Glu	Gly	Lys	Phe	Ile	Lys	Lys	Cys	Gln	Asp		
			1315				1320					1325					

Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Ser Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805

Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285

Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525
 Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590
 Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
 2595 2600 2605
 Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
 2610 2615 2620
 Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
 2625 2630 2635 2640
 Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
 2645 2650 2655
 Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
 2660 2665 2670
 Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
 2675 2680 2685
 Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
 2690 2695 2700
 Asn Pro Gln Gln Pro Ala
 2705 2710

<210> 4

<211> 2749

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 4

Met	Ser	Asp	Lys	Met	Ser	Ser	Phe	Leu	His	Ile	Gly	Asp	Ile	Cys	Ser	1	5	10	15
Leu	Tyr	Ala	Glu	Gly	Ser	Thr	Asn	Gly	Phe	Ile	Ser	Thr	Leu	Gly	Leu	20	25	30	
Val	Asp	Asp	Arg	Cys	Val	Val	Gln	Pro	Glu	Ala	Gly	Asp	Leu	Asn	Asn	35	40	45	
Pro	Pro	Lys	Lys	Phe	Arg	Asp	Cys	Leu	Phe	Lys	Leu	Cys	Pro	Met	Asn	50	55	60	
Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Lys	Pro	Gly	Ala		65	70	75	80
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala	85	90	95	
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly	100	105	110	
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser	115	120	125	
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys	130	135	140	
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp	145	150	155	160
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	165	170	175	
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	180	185	190	
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	195	200	205	
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	210	215	220	
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235	240
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	245	250	255	
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	260	265	270	
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	275	280	285	
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300	
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	305	310	315	320
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	325	330	335	
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	340	345	350	
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365	
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380	
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395	400
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	405	410	415	
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430	
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445	

Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	465	470	475
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	485	490	495
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	500	505	510
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	515	520	525
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	530	535	540
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	580	585	590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	610	615	620
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	645	650	655
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	660	665	670
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	675	680	685
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	690	695	700
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	705	710	715
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	725	730	735
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	740	745	750
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	755	760	765
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	770	775	780
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	785	790	795
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	805	810	815
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	820	825	830
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	835	840	845
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	850	855	860
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	865	870	875
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	885	890	895
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	900	905	910
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	915	920	925

Glu Leu Met Thr Gln Val Val Leu Arg Gly Gly Gly Phe Leu Pro Met
 930 935 940
 Thr Pro Met Ala Ala Ala Pro Glu Gly Asn Val Lys Gln Ala Glu Pro
 945 950 955 960
 Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405

Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695
 Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Ser Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775
 Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790
 Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885

Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365

Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560
 Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
 2565 2570 2575
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2580 2585 2590
 Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
 2595 2600 2605
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2610 2615 2620
 Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
 2625 2630 2635 2640
 Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
 2645 2650 2655
 Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
 2660 2665 2670
 Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
 2675 2680 2685
 Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2690 2695 2700
 Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
 2705 2710 2715 2720
 Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
 2725 2730 2735
 His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
 2740 2745

<210> 5

<211> 2710

<212> PRT

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 5

Met	Ser	Asp	Lys	Met	Ser	Ser	Phe	Leu	His	Ile	Gly	Asp	Ile	Cys	Ser		
1				5					10					15			
Leu	Tyr	Ala	Glu	Gly	Ser	Thr	Asn	Gly	Phe	Ile	Ser	Thr	Leu	Gly	Leu		
		20						25					30				
Val	Asp	Asp	Arg	Cys	Val	Val	Gln	Pro	Glu	Ala	Gly	Asp	Leu	Asn	Asn		
		35					40					45					
Pro	Pro	Lys	Lys	Phe	Arg	Asp	Cys	Leu	Phe	Lys	Leu	Cys	Pro	Met	Asn		
	50					55					60						
Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Ala	Lys	Pro	Gly	Ala		
65					70				75					80			
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala		
				85					90					95			
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly		
		100					105						110				
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser		
		115					120					125					
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys		
	130					135					140						
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp		
145					150				155					160			
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val		
				165				170						175			
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro		
		180					185						190				
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu		
		195				200						205					
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met		
	210					215					220						
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val		
225				230					235					240			
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His		
				245					250					255			
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala		
			260					265					270				
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln		
		275				280						285					
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg		
	290				295						300						
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro		
305					310				315					320			
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp		
				325					330					335			
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val		
			340				345						350				
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe		
		355				360						365					
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
	370					375					380						
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395				400			
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Lys	Pro	Val	Met	Leu			
				405					410					415			
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
			420				425						430				
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
		435					440					445					
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
	450					455					460						
Ile	Thr	Gln	Asn	Glu	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu			
465					470				475					480			

Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
				485					490					495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
		515					520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
				565				570						575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
			580					585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
		595					600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
				645					650					655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
			660					665					670			
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
		675					680					685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695				700						
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725					730						735		
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	
			740					745					750			
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	
		755					760					765				
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
	770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
				805					810					815		
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
			820					825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
			835				840					845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
	850					855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870					875					880	
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	
				885					890					895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	
			900					905					910			
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	
		915					920					925				
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	
	930					935					940					
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	
945					950					955					960	

Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440

Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val	1445	1450	1455
Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp	1460	1465	1470
Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr	1475	1480	1485
Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr	1490	1495	1500
Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr	1505	1510	1515
His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys	1525	1530	1535
Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro	1540	1545	1550
Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn	1555	1560	1565
Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala	1570	1575	1580
Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile	1585	1590	1595
Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg	1605	1610	1615
Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg	1620	1625	1630
Pro Glu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu	1635	1640	1645
Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu	1650	1655	1660
Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg	1665	1670	1675
Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu	1685	1690	1695
Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly	1700	1705	1710
Arg Arg Glu Glu Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly	1715	1720	1725
Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser	1730	1735	1740
Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp	1745	1750	1755
Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser	1765	1770	1775
Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu	1780	1785	1790
Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr	1795	1800	1805
Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met	1810	1815	1820
Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser	1825	1830	1835
Asp Leu Gly Asn Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro	1845	1850	1855
Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val	1860	1865	1870
Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr	1875	1880	1885
Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu	1890	1895	1900
Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser	1905	1910	1915
			1920

Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400

```

Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
      2405                      2410                      2415
Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
      2420                      2425                      2430
Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
      2435                      2440                      2445
Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
      2450                      2455                      2460
Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
      2465                      2470                      2475                      2480
Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
      2485                      2490                      2495
Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
      2500                      2505                      2510
Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
      2515                      2520                      2525
Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
      2530                      2535                      2540
Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
      2545                      2550                      2555                      2560
Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
      2565                      2570                      2575
Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
      2580                      2585                      2590
Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
      2595                      2600                      2605
Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
      2610                      2615                      2620
Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
      2625                      2630                      2635                      2640
Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
      2645                      2650                      2655
Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
      2660                      2665                      2670
Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
      2675                      2680                      2685
Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
      2690                      2695                      2700
Asn Pro Gln Gln Pro Ala
      2705                      2710

```

<210> 6

<211> 2749

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 6

```

Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1          5          10          15
Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
      20          25          30
Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
      35          40          45
Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
      50          55          60

```

Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Ala	Lys	Pro	Gly	Ala	
65					70					75					80	
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala	
				85					90					95		
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly	
			100					105					110			
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser	
		115					120					125				
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys	
	130					135					140					
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp	
145					150					155					160	
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	
			165					170						175		
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	
			180					185					190			
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	
		195					200					205				
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	
	210					215					220					
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	
225					230					235					240	
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	
			245						250					255		
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	
			260					265					270			
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	
		275					280					285				
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	
	290					295					300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	
305					310					315					320	
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	
			325						330					335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	
			340					345					350			
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	
		355					360					365				
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	
	370					375					380					
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	
385					390					395					400	
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Lys	Pro	Val	Met	Leu		
			405						410					415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
			420					425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
		435					440					445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
		515					520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					

Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu
545					550					555					560
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys
				565					570						575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu
			580					585							590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys
		595					600					605			
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys
	610					615					620				
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser
625					630					635					640
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val
				645					650						655
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu
			660					665					670		
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu
		675					680					685			
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn
	690					695					700				
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys
705					710					715					720
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln
				725					730						735
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile
			740					745					750		
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met
		755					760					765			
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu
	770					775					780				
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro
785					790					795					800
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile
				805					810						815
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg
			820					825					830		
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val
			835				840					845			
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe
	850					855					860				
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn
865					870					875					880
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp
				885					890					895	
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly
			900					905					910		
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly
		915					920					925			
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met
	930					935						940			
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro
945					950					955					960
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu
				965					970						975
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys
			980					985					990		
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser
		995					1000					1005			
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val
	1010					1015					1020				

Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500

Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr	1505	1510	1515	1520
His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys	1525	1530	1535	
Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro	1540	1545	1550	
Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn	1555	1560	1565	
Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala	1570	1575	1580	
Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile	1585	1590	1595	1600
Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg	1605	1610	1615	
Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg	1620	1625	1630	
Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu	1635	1640	1645	
Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu	1650	1655	1660	
Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg	1665	1670	1675	1680
Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile	1685	1690	1695	
Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn	1700	1705	1710	
Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp	1715	1720	1725	
His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr	1730	1735	1740	
Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Glu Leu Thr Ser Phe Gly	1745	1750	1755	1760
Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly	1765	1770	1775	
Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala	1780	1785	1790	
Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile	1795	1800	1805	
Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile	1810	1815	1820	
Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His	1825	1830	1835	1840
Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe	1845	1850	1855	
Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala	1860	1865	1870	
Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp	1875	1880	1885	
Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr	1890	1895	1900	
Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala	1905	1910	1915	1920
Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp	1925	1930	1935	
Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala	1940	1945	1950	
Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile	1955	1960	1965	
Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln	1970	1975	1980	

Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys	1985	1990	1995	2000
Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly		2005	2010	2015
Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile		2020	2025	2030
Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His		2035	2040	2045
Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile		2050	2055	2060
Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg		2065	2070	2075
Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu		2085	2090	2095
Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu		2100	2105	2110
Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr		2115	2120	2125
Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly		2130	2135	2140
Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His		2145	2150	2155
Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly		2165	2170	2175
Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr		2180	2185	2190
Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val		2195	2200	2205
Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu		2210	2215	2220
Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn		2225	2230	2235
Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln		2245	2250	2255
Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met		2260	2265	2270
Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu		2275	2280	2285
Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu		2290	2295	2300
Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu		2305	2310	2315
Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile		2325	2330	2335
Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr		2340	2345	2350
Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu		2355	2360	2365
Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala		2370	2375	2380
Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile		2385	2390	2395
Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu		2405	2410	2415
Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser		2420	2425	2430
Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu		2435	2440	2445
Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp		2450	2455	2460

```

Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
2465                2470                2475                2480
Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
                2485                2490                2495
Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
                2500                2505                2510
Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
                2515                2520                2525
Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
                2530                2535                2540
Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
2545                2550                2555                2560
Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
                2565                2570                2575
Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
                2580                2585                2590
Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
                2595                2600                2605
Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
                2610                2615                2620
Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
2625                2630                2635                2640
Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
                2645                2650                2655
Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
                2660                2665                2670
Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
                2675                2680                2685
Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
                2690                2695                2700
Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
2705                2710                2715                2720
Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
                2725                2730                2735
His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
                2740                2745

```

<210> 7

<211> 2710

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 7

```

Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
1          5          10          15
Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
20          25          30
Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
35          40          45
Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
50          55          60
Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
65          70          75          80
Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
85          90          95

```

Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly		
			100						105				110				
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser		
		115							120				125				
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys		
		130							135				140				
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp		
145					150					155					160		
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val		
				165					170						175		
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro		
			180						185				190				
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu		
		195							200				205				
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met		
		210							215				220				
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val		
225					230					235					240		
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His		
				245					250						255		
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala		
			260						265						270		
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln		
		275							280						285		
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg		
		290							295			300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro		
305					310					315					320		
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp		
				325					330						335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val		
			340						345						350		
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe		
		355							360						365		
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
		370							375						380		
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395					400		
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu		
				405						410					415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
			420						425						430		
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
		435							440						445		
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
		450							455						460		
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480		
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu		
				485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu		
			500						505						510		
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr		
		515							520						525		
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln		
		530							535						540		
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu		
545					550					555					560		
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys		
				565					570						575		

Gln Phe Gly Phe Met Gln Lys Gln Ile Gly Tyr Asp Val Leu Ala Glu
 580 585 590
 Asp Thr Ile Thr Ala Leu Leu His Asn Asn Arg Lys Leu Leu Glu Lys
 595 600 605
 His Ile Thr Ala Ala Glu Ile Asp Thr Phe Val Ser Leu Val Arg Lys
 610 615 620
 Asn Arg Glu Pro Arg Phe Leu Asp Tyr Leu Ser Asp Leu Cys Val Ser
 625 630 635 640
 Met Asn Lys Ser Ile Pro Val Thr Gln Glu Leu Ile Cys Lys Ala Val
 645 650 655
 Leu Asn Pro Thr Asn Ala Asp Ile Leu Ile Glu Thr Lys Leu Val Leu
 660 665 670
 Ser Arg Phe Glu Phe Glu Gly Val Ser Thr Gly Glu Asn Ala Leu Glu
 675 680 685
 Ala Gly Glu Asp Glu Glu Glu Val Trp Leu Phe Trp Arg Asp Ser Asn
 690 695 700
 Lys Glu Ile Arg Ser Lys Ser Val Arg Glu Leu Ala Gln Asp Ala Lys
 705 710 715 720
 Glu Gly Gln Lys Glu Asp Arg Asp Val Leu Ser Tyr Tyr Arg Tyr Gln
 725 730 735
 Leu Asn Leu Phe Ala Arg Met Cys Leu Asp Arg Gln Tyr Leu Ala Ile
 740 745 750
 Asn Glu Ile Ser Gly Gln Leu Asp Val Asp Leu Ile Leu Arg Cys Met
 755 760 765
 Ser Asp Glu Asn Leu Pro Tyr Asp Leu Arg Ala Ser Phe Cys Arg Leu
 770 775 780
 Met Leu His Met His Val Asp Arg Asp Pro Gln Glu Gln Val Thr Pro
 785 790 795 800
 Val Lys Tyr Ala Arg Leu Trp Ser Glu Ile Pro Ser Glu Ile Ala Ile
 805 810 815
 Asp Asp Tyr Asp Ser Ser Gly Ala Ser Lys Asp Glu Ile Lys Glu Arg
 820 825 830
 Phe Ala Gln Thr Met Glu Phe Val Glu Glu Tyr Leu Arg Asp Val Val
 835 840 845
 Cys Gln Arg Phe Pro Phe Ser Asp Lys Glu Lys Asn Lys Leu Thr Phe
 850 855 860
 Glu Val Val Asn Leu Ala Arg Asn Leu Ile Tyr Phe Gly Phe Tyr Asn
 865 870 875 880
 Phe Ser Asp Leu Leu Arg Leu Thr Lys Ile Leu Leu Ala Ile Leu Asp
 885 890 895
 Cys Val His Val Thr Thr Ile Phe Pro Ile Ser Lys Met Thr Lys Gly
 900 905 910
 Glu Glu Asn Lys Gly Ser Asn Val Met Arg Ser Ile His Gly Val Gly
 915 920 925
 Glu Leu Met Thr Gln Val Val Leu Arg Gly Gly Gly Phe Leu Pro Met
 930 935 940
 Thr Pro Met Ala Ala Ala Pro Glu Gly Asn Val Lys Gln Ala Glu Pro
 945 950 955 960
 Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055

Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535

Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Asp Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015

Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495

```

Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
      2500                      2505                      2510
Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
      2515                      2520                      2525
Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
      2530                      2535                      2540
Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
      2545                      2550                      2555                      2560
Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
      2565                      2570                      2575
Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
      2580                      2585                      2590
Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
      2595                      2600                      2605
Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
      2610                      2615                      2620
Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
      2625                      2630                      2635                      2640
Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
      2645                      2650                      2655
Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
      2660                      2665                      2670
Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
      2675                      2680                      2685
Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
      2690                      2695                      2700
Asn Pro Gln Gln Pro Ala
      2705                      2710

```

<210> 8

<211> 2749

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 8

```

Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1          5          10          15
Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
      20          25          30
Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
      35          40          45
Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
      50          55          60
Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
      65          70          75          80
Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
      85          90          95
Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
      100         105         110
Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
      115         120         125
Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
      130         135         140
Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
      145         150         155         160

```

Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	165	170	175
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	180	185	190
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	195	200	205
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	210	215	220
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	245	250	255
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	260	265	270
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	275	280	285
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	305	310	315
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	325	330	335
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	340	345	350
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	405	410	415
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	465	470	475
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	485	490	495
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	500	505	510
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	515	520	525
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	530	535	540
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	580	585	590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	610	615	620
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635

Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val		
				645					650					655			
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu		
			660					665					670				
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu		
		675					680					685					
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn		
	690					695				700							
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys		
705					710				715						720		
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln		
			725					730						735			
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile		
		740						745					750				
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met		
	755					760						765					
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu		
	770					775				780							
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro		
785					790				795						800		
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile		
			805					810						815			
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg		
		820						825					830				
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val		
		835					840					845					
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe		
	850					855				860							
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn		
865					870				875						880		
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp		
			885					890						895			
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly		
		900						905					910				
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly		
	915					920						925					
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met		
	930					935					940						
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro		
945					950				955						960		
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu		
			965					970						975			
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys		
		980						985					990				
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser		
	995						1000					1005					
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val		
	1010				1015						1020						
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile		
1025					1030				1035						1040		
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly		
			1045					1050						1055			
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr		
		1060					1065						1070				
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser		
	1075					1080						1085					
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val		
	1090					1095					1100						
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp		
1105					1110					1115					1120		

Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600

Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695
 Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Asp Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775
 Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790
 Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885
 Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080

Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560


```
<220>
<223> Description of Artificial Sequence:/note =
        synthetic construct
```

48

Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	
		195					200					205				
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	
	210					215					220					
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	
225					230					235					240	
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	
				245					250					255		
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	
			260					265					270			
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	
	275						280					285				
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	
	290					295					300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	
305					310					315					320	
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	
				325					330					335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	
		340						345					350			
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	
	355						360					365				
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	
	370					375					380					
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	
385					390					395					400	
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	
			405					410						415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
	420							425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
	435						440					445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
	515						520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565						570					575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
			580					585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
	595						600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645						650					655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
			660					665					670			

Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
	675						680					685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695					700					
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725						730					735		
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	
			740					745					750			
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	
	755						760					765				
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
	770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
			805					810						815		
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
			820					825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
	835						840					845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
	850					855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870				875						880	
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	
			885					890						895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	
			900					905					910			
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	
	915						920					925				
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	
	930					935					940					
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	
945					950					955					960	
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu	
			965					970						975		
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys	
			980					985					990			
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser	
	995						1000					1005				
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val	
	1010					1015					1020					
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile	
1025					1030					1035					1040	
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly	
			1045					1050						1055		
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr	
			1060					1065					1070			
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser	
	1075						1080					1085				
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val	
	1090					1095					1100					
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp	
1105					1110					1115					1120	
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly	
			1125					1130						1135		
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His	
			1140					1145					1150			

Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Glu Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630

Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Glu Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110

Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525
 Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590

[illegible]

```
<220>
<223> Description of Artificial Sequence:/note =
        synthetic construct
```

54

Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	
			260					265					270			
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	
		275					280					285				
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	
	290					295					300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	
305					310					315					320	
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	
				325					330					335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	
			340					345					350			
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	
	355						360					365				
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	
	370					375					380					
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	
385					390					395					400	
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	
			405					410						415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
		420						425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
	435						440					445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
		500						505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
	515						520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565					570						575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
		580						585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
	595						600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645					650						655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
		660						665					670			
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
		675					680					685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695					700					
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725						730						735	

Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile		
			740					745					750				
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met		
		755					760					765					
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu		
		770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro		
785					790					795					800		
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile		
			805						810					815			
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg		
			820					825					830				
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val		
		835					840					845					
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe		
		850					855				860						
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn		
865					870					875					880		
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp		
			885						890					895			
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly		
			900					905					910				
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly		
		915					920					925					
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met		
		930				935					940						
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro		
945					950					955					960		
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu		
			965						970					975			
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys		
		980						985					990				
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser		
		995					1000					1005					
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val		
		1010				1015					1020						
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile		
1025					1030					1035					1040		
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly		
			1045						1050					1055			
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr		
			1060						1065				1070				
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser		
		1075				1080						1085					
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val		
		1090				1095					1100						
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp		
1105					1110					1115					1120		
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly		
			1125						1130					1135			
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His		
			1140					1145					1150				
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr		
		1155				1160						1165					
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser		
		1170				1175					1180						
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln		
1185					1190					1195					1200		
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu		
			1205						1210					1215			

Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Glu Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695

Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Glu Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775
 Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790
 Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885
 Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175

Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560
 Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
 2565 2570 2575
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2580 2585 2590
 Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
 2595 2600 2605
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2610 2615 2620
 Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
 2625 2630 2635 2640
 Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
 2645 2650 2655

Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
 2660 2665 2670
 Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
 2675 2680 2685
 Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2690 2695 2700
 Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
 2705 2710 2715 2720
 Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
 2725 2730 2735
 His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
 2740 2745

<210> 11
 <211> 2710
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 11
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Ser His Gln Leu Val Asp Asn Pro Gly Cys Asn Glu
 195 200 205
 Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Val Leu Phe Met
 210 215 220
 Lys Trp Ser Asp Asn Lys Asp Asp Ile Leu Lys Gly Gly Asp Val Val
 225 230 235 240
 Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu His
 245 250 255
 Arg Lys Lys Gln His Val Phe Leu Arg Thr Thr Gly Arg Gln Ser Ala
 260 265 270
 Thr Ser Ala Thr Ser Ser Lys Ala Leu Trp Glu Val Glu Val Val Gln
 275 280 285

His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	305	310	315
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	325	330	335
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	340	345	350
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	405	410	415
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	465	470	475
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	485	490	495
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	500	505	510
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	515	520	525
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	530	535	540
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	580	585	590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	610	615	620
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	645	650	655
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	660	665	670
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	675	680	685
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	690	695	700
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	705	710	715
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	725	730	735
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	740	745	750
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	755	760	765

Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
770						775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
				805					810						815	
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
			820					825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
			835					840				845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
850						855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870					875					880	
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	
				885					890						895	
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	
			900					905					910			
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	
			915					920					925			
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	
			930				935					940				
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	
945					950					955					960	
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu	
				965					970						975	
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys	
			980					985					990			
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser	
		995					1000					1005				
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val	
	1010					1015						1020				
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile	
1025					1030					1035					1040	
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly	
				1045					1050					1055		
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr	
			1060					1065					1070			
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser	
		1075					1080					1085				
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val	
	1090					1095					1100					
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp	
1105					1110					1115					1120	
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly	
				1125					1130						1135	
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His	
			1140					1145					1150			
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr	
		1155					1160					1165				
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser	
		1170				1175					1180					
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln	
1185					1190					1195					1200	
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu	
				1205					1210						1215	
Leu	Leu	Gln	Ile	Pro	Tyr	Glu	Lys	Ala	Glu	Asp	Thr	Lys	Met	Gln	Glu	
			1220					1225					1230			
Ile	Met	Arg	Leu	Ala	His	Glu	Phe	Leu	Gln	Asn	Phe	Cys	Ala	Gly	Asn	
			1235				1240					1245				

Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Asp Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725

Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205

Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525
 Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590
 Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
 2595 2600 2605
 Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
 2610 2615 2620
 Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
 2625 2630 2635 2640
 Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
 2645 2650 2655
 Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
 2660 2665 2670
 Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
 2675 2680 2685

ATTORNEY DOCKET NO. 21108.0042U1

Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
 2690 2695 2700
 Asn Pro Gln Gln Pro Ala
 2705 2710

<210> 12
 <211> 2749
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 12
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Ser His Gln Leu Val Asp Asn Pro Gly Cys Asn Glu
 195 200 205
 Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Val Leu Phe Met
 210 215 220
 Lys Trp Ser Asp Asn Lys Asp Asp Ile Leu Lys Gly Gly Asp Val Val
 225 230 235 240
 Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu His
 245 250 255
 Arg Lys Lys Gln His Val Phe Leu Arg Thr Thr Gly Arg Gln Ser Ala
 260 265 270
 Thr Ser Ala Thr Ser Ser Lys Ala Leu Trp Glu Val Glu Val Val Gln
 275 280 285
 His Asp Pro Cys Arg Gly Gly Ala Gly Tyr Trp Asn Ser Leu Phe Arg
 290 295 300
 Phe Lys His Leu Ala Thr Gly His Tyr Leu Ala Ala Glu Val Asp Pro
 305 310 315 320
 Asp Phe Glu Glu Glu Cys Leu Glu Phe Gln Pro Ser Val Asp Pro Asp
 325 330 335
 Gln Asp Ala Ser Arg Ser Arg Leu Arg Asn Ala Gln Glu Lys Met Val
 340 345 350

Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	405	410	415
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460
Ile	Thr	Gln	Asn	Glu	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		465	470	475
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	485	490	495
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	500	505	510
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	515	520	525
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	530	535	540
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	580	585	590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	610	615	620
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	645	650	655
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	660	665	670
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	675	680	685
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	690	695	700
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	705	710	715
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	725	730	735
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	740	745	750
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	755	760	765
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	770	775	780
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	785	790	795
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	805	810	815
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	820	825	830

Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val		
		835						840				845					
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe		
		850				855					860						
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn		
865						870				875					880		
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp		
				885					890						895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly		
			900					905					910				
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly		
		915					920					925					
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met		
930							935					940					
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro		
945						950					955				960		
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu		
				965					970						975		
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys		
			980					985					990				
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser		
		995					1000					1005					
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val		
	1010					1015					1020						
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile		
1025					1030				1035						1040		
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly		
				1045					1050						1055		
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr		
			1060						1065					1070			
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser		
		1075					1080					1085					
Gln	Arg	Gln	Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val		
	1090					1095					1100						
Thr	Ser	Gln	Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Gln	Asp	Leu	Asp		
1105					1110					1115					1120		
Gln	Leu	Arg	Ser	Ile	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Tyr	Lys	Gly		
				1125					1130						1135		
Gln	Gly	Pro	Asp	Glu	Pro	Met	Asp	Gly	Ala	Ser	Gly	Glu	Asn	Glu	His		
			1140					1145					1150				
Lys	Lys	Thr	Glu	Glu	Gly	Thr	Ser	Lys	Pro	Leu	Lys	His	Glu	Ser	Thr		
		1155					1160					1165					
Ser	Ser	Tyr	Asn	Tyr	Arg	Val	Val	Lys	Glu	Ile	Leu	Ile	Arg	Leu	Ser		
		1170				1175					1180						
Lys	Leu	Cys	Val	Gln	Glu	Ser	Ala	Ser	Val	Arg	Lys	Ser	Arg	Lys	Gln		
1185					1190					1195					1200		
Gln	Gln	Arg	Leu	Leu	Arg	Asn	Met	Gly	Ala	His	Ala	Val	Val	Leu	Glu		
				1205					1210						1215		
Leu	Leu	Gln	Ile	Pro	Tyr	Glu	Lys	Ala	Glu	Asp	Thr	Lys	Met	Gln	Glu		
			1220					1225					1230				
Ile	Met	Arg	Leu	Ala	His	Glu	Phe	Leu	Gln	Asn	Phe	Cys	Ala	Gly	Asn		
		1235					1240					1245					
Gln	Gln	Asn	Gln	Ala	Leu	Leu	His	Lys	His	Ile	Asn	Leu	Phe	Leu	Asn		
		1250				1255					1260						
Pro	Gly	Ile	Leu	Glu	Ala	Val	Thr	Met	Gln	His	Ile	Phe	Met	Asn	Asn		
1265					1270					1275					1280		
Phe	Gln	Leu	Cys	Ser	Glu	Ile	Asn	Glu	Arg	Val	Val	Gln	His	Phe	Val		
				1285					1290						1295		
His	Cys	Ile	Glu	Thr	His	Gly	Arg	Asn	Val	Gln	Tyr	Ile	Lys	Phe	Leu		
			1300					1305						1310			

Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695
 Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Asp Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775
 Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790

Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885
 Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270

Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560
 Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
 2565 2570 2575
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2580 2585 2590
 Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
 2595 2600 2605
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2610 2615 2620
 Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
 2625 2630 2635 2640
 Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
 2645 2650 2655
 Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
 2660 2665 2670
 Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
 2675 2680 2685
 Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2690 2695 2700
 Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
 2705 2710 2715 2720
 Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
 2725 2730 2735
 His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
 2740 2745

<210> 13
 <211> 2710
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 13
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Ser His Gln Leu Val Asp Asn Pro Gly Cys Asn Glu
 195 200 205
 Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Val Leu Phe Met
 210 215 220
 Lys Trp Ser Asp Asn Lys Asp Asp Ile Leu Lys Gly Gly Asp Val Val
 225 230 235 240
 Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu His
 245 250 255
 Arg Lys Lys Gln His Val Phe Leu Arg Thr Thr Gly Arg Gln Ser Ala
 260 265 270
 Thr Ser Ala Thr Ser Ser Lys Ala Leu Trp Glu Val Glu Val Val Gln
 275 280 285
 His Asp Pro Cys Arg Gly Gly Ala Gly Tyr Trp Asn Ser Leu Phe Arg
 290 295 300
 Phe Lys His Leu Ala Thr Gly His Tyr Leu Ala Ala Glu Val Asp Pro
 305 310 315 320
 Asp Phe Glu Glu Glu Cys Leu Glu Phe Gln Pro Ser Val Asp Pro Asp
 325 330 335
 Gln Asp Ala Ser Arg Ser Arg Leu Arg Asn Ala Gln Glu Lys Met Val
 340 345 350
 Tyr Ser Leu Val Ser Val Pro Glu Gly Asn Asp Ile Ser Ser Ile Phe
 355 360 365
 Glu Leu Asp Pro Thr Thr Leu Arg Gly Gly Asp Ser Leu Val Pro Arg
 370 375 380
 Asn Ser Tyr Val Arg Leu Arg His Leu Cys Thr Asn Thr Trp Val His
 385 390 395 400

Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	
				405					410					415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
			420					425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
		435					440					445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
		515					520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535				540						
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565					570						575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
		580						585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
	595						600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615				620						
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645					650						655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
		660						665					670			
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
		675				680						685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695				700						
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725					730						735		
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	
		740						745					750			
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	
	755					760						765				
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
	770					775				780						
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
			805					810						815		
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
		820						825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
		835					840					845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
	850					855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870					875					880	

Phe Ser Asp Leu Leu Arg Leu Thr Lys Ile Leu Leu Ala Ile Leu Asp
 885 890 895
 Cys Val His Val Thr Thr Ile Phe Pro Ile Ser Lys Met Thr Lys Gly
 900 905 910
 Glu Glu Asn Lys Gly Ser Asn Val Met Arg Ser Ile His Gly Val Gly
 915 920 925
 Glu Leu Met Thr Gln Val Val Leu Arg Gly Gly Gly Phe Leu Pro Met
 930 935 940
 Thr Pro Met Ala Ala Ala Pro Glu Gly Asn Val Lys Gln Ala Glu Pro
 945 950 955 960
 Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360

Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Glu Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840

Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950
 Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320

```

Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
      2325                      2330                      2335
Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
      2340                      2345                      2350
Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
      2355                      2360                      2365
His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
      2370                      2375                      2380
Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
2385                      2390                      2395                      2400
Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
      2405                      2410                      2415
Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
      2420                      2425                      2430
Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
      2435                      2440                      2445
Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
      2450                      2455                      2460
Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
2465                      2470                      2475                      2480
Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
      2485                      2490                      2495
Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
      2500                      2505                      2510
Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
      2515                      2520                      2525
Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
      2530                      2535                      2540
Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
2545                      2550                      2555                      2560
Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
      2565                      2570                      2575
Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
      2580                      2585                      2590
Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
      2595                      2600                      2605
Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
      2610                      2615                      2620
Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
2625                      2630                      2635                      2640
Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
      2645                      2650                      2655
Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
      2660                      2665                      2670
Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
      2675                      2680                      2685
Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
      2690                      2695                      2700
Asn Pro Gln Gln Pro Ala
2705                      2710

```

<210> 14

<211> 2749

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 14

Met	Ser	Asp	Lys	Met	Ser	Ser	Phe	Leu	His	Ile	Gly	Asp	Ile	Cys	Ser	1	5	10	15
Leu	Tyr	Ala	Glu	Gly	Ser	Thr	Asn	Gly	Phe	Ile	Ser	Thr	Leu	Gly	Leu	20	25	30	
Val	Asp	Asp	Arg	Cys	Val	Val	Gln	Pro	Glu	Ala	Gly	Asp	Leu	Asn	Asn	35	40	45	
Pro	Pro	Lys	Lys	Phe	Arg	Asp	Cys	Leu	Phe	Lys	Leu	Cys	Pro	Met	Asn	50	55	60	
Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Ala	Lys	Pro	Gly	Ala	65	70	75	80
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala	85	90	95	
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly	100	105	110	
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser	115	120	125	
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys	130	135	140	
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp	145	150	155	160
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	165	170	175	
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	180	185	190	
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	195	200	205	
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	210	215	220	
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235	240
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	245	250	255	
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	260	265	270	
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	275	280	285	
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300	
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	305	310	315	320
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	325	330	335	
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	340	345	350	
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365	
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380	
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395	400
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Lys	Pro	Val	Met	Leu		405	410	415	
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430	
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445	
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460	
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	465	470	475	480

Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
				485					490					495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
		515					520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535					540					
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565						570					575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
			580					585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
		595					600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645						650					655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
		660						665					670			
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	
		675					680					685				
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	
	690					695					700					
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	
705					710					715					720	
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	
			725						730					735		
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	
		740						745					750			
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	
	755						760					765				
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	
	770					775					780					
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	
785					790					795					800	
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	
			805						810					815		
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	
		820						825					830			
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	
		835					840					845				
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	
	850					855					860					
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	
865					870					875					880	
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	
			885						890					895		
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	
		900						905					910			
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	
		915					920					925				
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	
	930					935					940					
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	
945					950					955					960	


```

Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
      1445      1450      1455
Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
      1460      1465      1470
Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
      1475      1480      1485
Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
      1490      1495      1500
Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
1505      1510      1515      1520
His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
      1525      1530      1535
Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
      1540      1545      1550
Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
      1555      1560      1565
Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
      1570      1575      1580
Ala Arg Arg Asp Asp Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
1585      1590      1595      1600
Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
      1605      1610      1615
Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
      1620      1625      1630
Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
      1635      1640      1645
Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
      1650      1655      1660
Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
1665      1670      1675      1680
Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
      1685      1690      1695
Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
      1700      1705      1710
Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
      1715      1720      1725
His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
      1730      1735      1740
Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Glu Leu Thr Ser Phe Gly
1745      1750      1755      1760
Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
      1765      1770      1775
Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
      1780      1785      1790
Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
      1795      1800      1805
Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
      1810      1815      1820
Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
1825      1830      1835      1840
Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
      1845      1850      1855
Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
      1860      1865      1870
Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
      1875      1880      1885
Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
      1890      1895      1900
Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
1905      1910      1915      1920

```

Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400

```
<220>
<223> Description of Artificial Sequence:/note =
synthetic construct
```

83

Val	Asp	Asp	Arg	Cys	Val	Val	Gln	Pro	Glu	Ala	Gly	Asp	Leu	Asn	Asn		
	35						40					45					
Pro	Pro	Lys	Lys	Phe	Arg	Asp	Cys	Leu	Phe	Lys	Leu	Cys	Pro	Met	Asn		
	50					55					60						
Arg	Tyr	Ser	Ala	Gln	Lys	Gln	Phe	Trp	Lys	Ala	Ala	Lys	Pro	Gly	Ala		
65					70					75					80		
Asn	Ser	Thr	Thr	Asp	Ala	Val	Leu	Leu	Asn	Lys	Leu	His	His	Ala	Ala		
				85					90					95			
Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly		
			100					105					110				
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser		
	115					120						125					
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys		
	130					135					140						
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp		
145					150					155					160		
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val		
				165					170					175			
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro		
			180					185					190				
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu		
	195					200						205					
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met		
	210					215					220						
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val		
225					230					235					240		
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His		
				245					250					255			
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala		
			260					265					270				
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln		
	275					280						285					
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg		
	290					295					300						
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro		
305					310					315					320		
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp		
				325					330					335			
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val		
			340					345					350				
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe		
	355					360						365					
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
	370					375					380						
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395					400		
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu		
				405					410					415			
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
			420					425					430				
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
	435							440				445					
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
	450					455					460						
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480		
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu		
				485					490					495			
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu		
			500					505					510				

Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr		
		515					520					525					
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln		
		530				535					540						
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu		
545						550				555					560		
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys		
				565						570					575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu		
			580					585					590				
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys		
		595					600					605					
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys		
		610				615					620						
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser		
625						630				635					640		
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val		
				645					650					655			
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu		
			660					665					670				
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu		
		675					680					685					
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn		
		690				695					700						
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys		
705					710					715					720		
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln		
				725					730					735			
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile		
			740					745					750				
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met		
		755					760					765					
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu		
		770				775					780						
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro		
785					790					795					800		
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile		
				805					810					815			
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg		
			820					825					830				
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val		
		835						840				845					
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe		
		850				855					860						
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn		
865					870				875						880		
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp		
				885					890					895			
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly		
			900					905					910				
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly		
		915					920					925					
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met		
		930				935					940						
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro		
945					950					955					960		
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu		
				965					970					975			
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys		
			980					985						990			

Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470

Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Glu Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630
 Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu
 1685 1690 1695
 Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly
 1700 1705 1710
 Arg Arg Glu Asp Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly
 1715 1720 1725
 Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser
 1730 1735 1740
 Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp
 1745 1750 1755 1760
 Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser
 1765 1770 1775
 Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu
 1780 1785 1790
 Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr
 1795 1800 1805
 Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met
 1810 1815 1820
 Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser
 1825 1830 1835 1840
 Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro
 1845 1850 1855
 Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val
 1860 1865 1870
 Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr
 1875 1880 1885
 Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu
 1890 1895 1900
 Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser
 1905 1910 1915 1920
 Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu
 1925 1930 1935
 Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn
 1940 1945 1950

Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp
 1955 1960 1965
 Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr
 1970 1975 1980
 Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu
 1985 1990 1995 2000
 Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala
 2005 2010 2015
 Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn
 2020 2025 2030
 Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu
 2035 2040 2045
 Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430

Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525
 Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590
 Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
 2595 2600 2605
 Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
 2610 2615 2620
 Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
 2625 2630 2635 2640
 Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
 2645 2650 2655
 Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
 2660 2665 2670
 Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
 2675 2680 2685
 Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
 2690 2695 2700
 Asn Pro Gln Gln Pro Ala
 2705 2710

<210> 16
 <211> 2749
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 16
 Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95

Asp	Leu	Glu	Lys	Lys	Gln	Asn	Glu	Thr	Glu	Asn	Arg	Lys	Leu	Leu	Gly		
			100					105					110				
Thr	Val	Ile	Gln	Tyr	Gly	Asn	Val	Ile	Gln	Leu	Leu	His	Leu	Lys	Ser		
		115					120					125					
Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys		
	130					135				140							
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp		
145					150					155					160		
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val		
			165					170						175			
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro		
		180						185					190				
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu		
	195					200						205					
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met		
	210					215				220							
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val		
225					230					235					240		
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His		
			245						250					255			
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala		
		260						265					270				
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln		
	275					280					285						
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg		
	290					295				300							
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro		
305					310					315					320		
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp		
			325						330					335			
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val		
		340						345					350				
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe		
	355					360					365						
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg		
	370					375				380							
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His		
385					390					395					400		
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu		
			405					410						415			
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile		
		420						425					430				
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp		
	435					440						445					
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr		
	450					455				460							
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu		
465					470					475					480		
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu		
			485					490						495			
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu		
		500						505					510				
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr		
	515						520					525					
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln		
	530				535					540							
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu		
545					550					555					560		
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys		
			565						570					575			

Gln Phe Gly Phe Met Gln Lys Gln Ile Gly Tyr Asp Val Leu Ala Glu
 580 585 590
 Asp Thr Ile Thr Ala Leu Leu His Asn Asn Arg Lys Leu Leu Glu Lys
 595 600 605
 His Ile Thr Ala Ala Glu Ile Asp Thr Phe Val Ser Leu Val Arg Lys
 610 615 620
 Asn Arg Glu Pro Arg Phe Leu Asp Tyr Leu Ser Asp Leu Cys Val Ser
 625 630 635 640
 Met Asn Lys Ser Ile Pro Val Thr Gln Glu Leu Ile Cys Lys Ala Val
 645 650 655
 Leu Asn Pro Thr Asn Ala Asp Ile Leu Ile Glu Thr Lys Leu Val Leu
 660 665 670
 Ser Arg Phe Glu Phe Glu Gly Val Ser Thr Gly Glu Asn Ala Leu Glu
 675 680 685
 Ala Gly Glu Asp Glu Glu Glu Val Trp Leu Phe Trp Arg Asp Ser Asn
 690 695 700
 Lys Glu Ile Arg Ser Lys Ser Val Arg Glu Leu Ala Gln Asp Ala Lys
 705 710 715 720
 Glu Gly Gln Lys Glu Asp Arg Asp Val Leu Ser Tyr Tyr Arg Tyr Gln
 725 730 735
 Leu Asn Leu Phe Ala Arg Met Cys Leu Asp Arg Gln Tyr Leu Ala Ile
 740 745 750
 Asn Glu Ile Ser Gly Gln Leu Asp Val Asp Leu Ile Leu Arg Cys Met
 755 760 765
 Ser Asp Glu Asn Leu Pro Tyr Asp Leu Arg Ala Ser Phe Cys Arg Leu
 770 775 780
 Met Leu His Met His Val Asp Arg Asp Pro Gln Glu Gln Val Thr Pro
 785 790 795 800
 Val Lys Tyr Ala Arg Leu Trp Ser Glu Ile Pro Ser Glu Ile Ala Ile
 805 810 815
 Asp Asp Tyr Asp Ser Ser Gly Ala Ser Lys Asp Glu Ile Lys Glu Arg
 820 825 830
 Phe Ala Gln Thr Met Glu Phe Val Glu Glu Tyr Leu Arg Asp Val Val
 835 840 845
 Cys Gln Arg Phe Pro Phe Ser Asp Lys Glu Lys Asn Lys Leu Thr Phe
 850 855 860
 Glu Val Val Asn Leu Ala Arg Asn Leu Ile Tyr Phe Gly Phe Tyr Asn
 865 870 875 880
 Phe Ser Asp Leu Leu Arg Leu Thr Lys Ile Leu Leu Ala Ile Leu Asp
 885 890 895
 Cys Val His Val Thr Thr Ile Phe Pro Ile Ser Lys Met Thr Lys Gly
 900 905 910
 Glu Glu Asn Lys Gly Ser Asn Val Met Arg Ser Ile His Gly Val Gly
 915 920 925
 Glu Leu Met Thr Gln Val Val Leu Arg Gly Gly Gly Phe Leu Pro Met
 930 935 940
 Thr Pro Met Ala Ala Ala Pro Glu Gly Asn Val Lys Gln Ala Glu Pro
 945 950 955 960
 Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055

Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535

Ile Arg Val	Leu Ser Asp	Val Ala Lys	Ser Arg Ala	Ile Ala Ile	Pro	
	1540		1545		1550	
Val Asp Leu	Asp Ser Gln	Val Asn Asn	Leu Phe Leu	Lys Ser His	Asn	
	1555		1560		1565	
Ile Val Gln	Lys Thr Ala	Met Asn Trp	Arg Leu Ser	Ala Arg Asn	Ala	
	1570		1575		1580	
Ala Arg Arg	Asp Glu Val	Leu Ala Ala	Ser Arg Asp	Tyr Arg Asn	Ile	
	1585		1590		1595	
Ile Glu Arg	Leu Gln Asp	Ile Val Ser	Ala Leu Glu	Asp Arg Leu	Arg	
	1605		1610		1615	
Pro Leu Val	Gln Ala Glu	Leu Ser Val	Leu Val Asp	Val Leu His	Arg	
	1620		1625		1630	
Pro Glu Leu	Phe Pro Glu	Asn Thr Asp	Ala Arg Arg	Lys Cys Glu		
	1635		1640		1645	
Ser Gly Arg	Phe Ile Cys	Lys Leu Ile	Lys His Thr	Lys Gln Leu	Leu	
	1650		1655		1660	
Glu Glu Asn	Glu Glu Lys	Leu Cys Ile	Lys Val Leu	Gln Thr Leu	Arg	
	1665		1670		1675	
Glu Met Met	Thr Lys Asp	Arg Gly Tyr	Gly Glu Lys	Gln Ile Ser	Ile	
	1685		1690		1695	
Asp Glu Leu	Glu Asn Ala	Glu Leu Pro	Gln Pro Pro	Glu Ala Glu	Asn	
	1700		1705		1710	
Ser Thr Glu	Glu Leu Glu	Pro Ser Pro	Pro Leu Arg	Gln Leu Glu	Asp	
	1715		1720		1725	
His Lys Arg	Gly Glu Ala	Leu Arg Gln	Ile Leu Val	Asn Arg Tyr	Tyr	
	1730		1735		1740	
Gly Asn Ile	Arg Pro Ser	Gly Arg Arg	Glu Asp Leu	Thr Ser Phe	Gly	
	1745		1750		1755	
Asn Gly Pro	Leu Ser Pro	Gly Gly Pro	Ser Lys Pro	Gly Gly Gly	Gly	
	1765		1770		1775	
Gly Gly Pro	Gly Ser Gly	Ser Thr Ser	Arg Gly Glu	Met Ser Leu	Ala	
	1780		1785		1790	
Glu Val Gln	Cys His Leu	Asp Lys Glu	Gly Ala Ser	Asn Leu Val	Ile	
	1795		1800		1805	
Asp Leu Ile	Met Asn Ala	Ser Ser Asp	Arg Val Phe	His Glu Ser	Ile	
	1810		1815		1820	
Leu Leu Ala	Ile Ala Leu	Leu Glu Gly	Gly Asn Thr	Thr Ile Gln	His	
	1825		1830		1835	
Ser Phe Phe	Cys Arg Leu	Thr Glu Asp	Lys Lys Ser	Glu Lys Phe	Phe	
	1845		1850		1855	
Lys Val Phe	Tyr Asp Arg	Met Lys Val	Ala Gln Gln	Glu Ile Lys	Ala	
	1860		1865		1870	
Thr Val Thr	Val Asn Thr	Ser Asp Leu	Gly Asn Lys	Lys Lys Asp	Asp	
	1875		1880		1885	
Glu Val Asp	Arg Asp Ala	Pro Ser Arg	Lys Lys Ala	Lys Glu Pro	Thr	
	1890		1895		1900	
Thr Gln Ile	Thr Glu Glu	Val Arg Asp	Gln Leu Leu	Glu Ala Ser	Ala	
	1905		1910		1915	
Ala Thr Arg	Lys Ala Phe	Thr Thr Phe	Arg Arg Glu	Ala Asp Pro	Asp	
	1925		1930		1935	
Asp His Tyr	Gln Ser Gly	Glu Gly Thr	Gln Ala Thr	Thr Asp Lys	Ala	
	1940		1945		1950	
Lys Asp Asp	Leu Glu Met	Ser Ala Val	Ile Thr Ile	Met Gln Pro	Ile	
	1955		1960		1965	
Leu Arg Phe	Leu Gln Leu	Leu Cys Glu	Asn His Asn	Arg Asp Leu	Gln	
	1970		1975		1980	
Asn Phe Leu	Arg Cys Gln	Asn Asn Lys	Thr Asn Tyr	Asn Leu Val	Cys	
	1985		1990		1995	
Glu Thr Leu	Gln Phe Leu	Asp Cys Ile	Cys Gly Ser	Thr Thr Gly	Gly	
	2005		2010		2015	

Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110
 Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495

```

Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
      2500                      2505                      2510
Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
      2515                      2520                      2525
Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
      2530                      2535                      2540
Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
2545                      2550                      2555                      2560
Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Leu Phe Phe Phe Met Val
      2565                      2570                      2575
Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
      2580                      2585                      2590
Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
      2595                      2600                      2605
Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
      2610                      2615                      2620
Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
2625                      2630                      2635                      2640
Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
      2645                      2650                      2655
Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
      2660                      2665                      2670
Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
      2675                      2680                      2685
Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
      2690                      2695                      2700
Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
2705                      2710                      2715                      2720
Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
      2725                      2730                      2735
His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
      2740                      2745

```

```

<210> 17
<211> 2710
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence:/note =
      synthetic construct

```

```

<400> 17
Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1          5          10          15
Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
      20          25          30
Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
      35          40          45
Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
      50          55          60
Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
65          70          75          80
Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
      85          90          95
Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
      100         105         110
Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
      115         120         125

```


Asn	Lys	Tyr	Leu	Thr	Val	Asn	Lys	Arg	Leu	Pro	Ala	Leu	Leu	Glu	Lys	130	135	140
Asn	Ala	Met	Arg	Val	Thr	Leu	Asp	Glu	Ala	Gly	Asn	Glu	Gly	Ser	Trp	145	150	155
Phe	Tyr	Ile	Gln	Pro	Phe	Tyr	Lys	Leu	Arg	Ser	Ile	Gly	Asp	Ser	Val	165	170	175
Val	Ile	Gly	Asp	Lys	Val	Val	Leu	Asn	Pro	Val	Asn	Ala	Gly	Gln	Pro	180	185	190
Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	195	200	205
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	210	215	220
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	245	250	255
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	260	265	270
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	275	280	285
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	305	310	315
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	325	330	335
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	340	345	350
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	355	360	365
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	370	375	380
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	385	390	395
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	405	410	415
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	420	425	430
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	435	440	445
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	450	455	460
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	465	470	475
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	485	490	495
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	500	505	510
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	515	520	525
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	530	535	540
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	580	585	590
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605

His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	610	615	620
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	645	650	655
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	660	665	670
Ser	Arg	Phe	Glu	Phe	Glu	Gly	Val	Ser	Thr	Gly	Glu	Asn	Ala	Leu	Glu	675	680	685
Ala	Gly	Glu	Asp	Glu	Glu	Glu	Val	Trp	Leu	Phe	Trp	Arg	Asp	Ser	Asn	690	695	700
Lys	Glu	Ile	Arg	Ser	Lys	Ser	Val	Arg	Glu	Leu	Ala	Gln	Asp	Ala	Lys	705	710	715
Glu	Gly	Gln	Lys	Glu	Asp	Arg	Asp	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	725	730	735
Leu	Asn	Leu	Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	740	745	750
Asn	Glu	Ile	Ser	Gly	Gln	Leu	Asp	Val	Asp	Leu	Ile	Leu	Arg	Cys	Met	755	760	765
Ser	Asp	Glu	Asn	Leu	Pro	Tyr	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	770	775	780
Met	Leu	His	Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Gln	Val	Thr	Pro	785	790	795
Val	Lys	Tyr	Ala	Arg	Leu	Trp	Ser	Glu	Ile	Pro	Ser	Glu	Ile	Ala	Ile	805	810	815
Asp	Asp	Tyr	Asp	Ser	Ser	Gly	Ala	Ser	Lys	Asp	Glu	Ile	Lys	Glu	Arg	820	825	830
Phe	Ala	Gln	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Arg	Asp	Val	Val	835	840	845
Cys	Gln	Arg	Phe	Pro	Phe	Ser	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	850	855	860
Glu	Val	Val	Asn	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Asn	865	870	875
Phe	Ser	Asp	Leu	Leu	Arg	Leu	Thr	Lys	Ile	Leu	Leu	Ala	Ile	Leu	Asp	885	890	895
Cys	Val	His	Val	Thr	Thr	Ile	Phe	Pro	Ile	Ser	Lys	Met	Thr	Lys	Gly	900	905	910
Glu	Glu	Asn	Lys	Gly	Ser	Asn	Val	Met	Arg	Ser	Ile	His	Gly	Val	Gly	915	920	925
Glu	Leu	Met	Thr	Gln	Val	Val	Leu	Arg	Gly	Gly	Gly	Phe	Leu	Pro	Met	930	935	940
Thr	Pro	Met	Ala	Ala	Ala	Pro	Glu	Gly	Asn	Val	Lys	Gln	Ala	Glu	Pro	945	950	955
Glu	Lys	Glu	Asp	Ile	Met	Val	Met	Asp	Thr	Lys	Leu	Lys	Ile	Ile	Glu	965	970	975
Ile	Leu	Gln	Phe	Ile	Leu	Asn	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Cys	980	985	990
Leu	Leu	Cys	Ile	Phe	Lys	Arg	Glu	Phe	Asp	Glu	Ser	Asn	Ser	Gln	Ser	995	1000	1005
Ser	Glu	Thr	Ser	Ser	Gly	Asn	Ser	Ser	Gln	Glu	Gly	Pro	Ser	Asn	Val	1010	1015	1020
Pro	Gly	Ala	Leu	Asp	Phe	Glu	His	Ile	Glu	Glu	Gln	Ala	Glu	Gly	Ile	1025	1030	1035
Phe	Gly	Gly	Ser	Glu	Glu	Asn	Thr	Pro	Leu	Asp	Leu	Asp	Asp	His	Gly	1045	1050	1055
Gly	Arg	Thr	Phe	Leu	Arg	Val	Leu	Leu	His	Leu	Thr	Met	His	Asp	Tyr	1060	1065	1070
Pro	Pro	Leu	Val	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Arg	His	Phe	Ser	1075	1080	1085

Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150
 Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565

Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala	1570	1575	1580
Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile	1585	1590	1595
Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg	1605	1610	1615
Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg	1620	1625	1630
Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu	1635	1640	1645
Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu	1650	1655	1660
Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg	1665	1670	1675
Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gly Glu Ala Leu	1685	1690	1695
Arg Gln Ile Leu Val Asn Arg Tyr Tyr Gly Asn Ile Arg Pro Ser Gly	1700	1705	1710
Arg Arg Glu Ser Leu Thr Ser Phe Gly Asn Gly Pro Leu Ser Pro Gly	1715	1720	1725
Gly Pro Ser Lys Pro Gly Gly Gly Gly Gly Gly Pro Gly Ser Gly Ser	1730	1735	1740
Thr Ser Arg Gly Glu Met Ser Leu Ala Glu Val Gln Cys His Leu Asp	1745	1750	1755
Lys Glu Gly Ala Ser Asn Leu Val Ile Asp Leu Ile Met Asn Ala Ser	1765	1770	1775
Ser Asp Arg Val Phe His Glu Ser Ile Leu Leu Ala Ile Ala Leu Leu	1780	1785	1790
Glu Gly Gly Asn Thr Thr Ile Gln His Ser Phe Phe Cys Arg Leu Thr	1795	1800	1805
Glu Asp Lys Lys Ser Glu Lys Phe Phe Lys Val Phe Tyr Asp Arg Met	1810	1815	1820
Lys Val Ala Gln Gln Glu Ile Lys Ala Thr Val Thr Val Asn Thr Ser	1825	1830	1835
Asp Leu Gly Asn Lys Lys Lys Asp Asp Glu Val Asp Arg Asp Ala Pro	1845	1850	1855
Ser Arg Lys Lys Ala Lys Glu Pro Thr Thr Gln Ile Thr Glu Glu Val	1860	1865	1870
Arg Asp Gln Leu Leu Glu Ala Ser Ala Ala Thr Arg Lys Ala Phe Thr	1875	1880	1885
Thr Phe Arg Arg Glu Ala Asp Pro Asp Asp His Tyr Gln Ser Gly Glu	1890	1895	1900
Gly Thr Gln Ala Thr Thr Asp Lys Ala Lys Asp Asp Leu Glu Met Ser	1905	1910	1915
Ala Val Ile Thr Ile Met Gln Pro Ile Leu Arg Phe Leu Gln Leu Leu	1925	1930	1935
Cys Glu Asn His Asn Arg Asp Leu Gln Asn Phe Leu Arg Cys Gln Asn	1940	1945	1950
Asn Lys Thr Asn Tyr Asn Leu Val Cys Glu Thr Leu Gln Phe Leu Asp	1955	1960	1965
Cys Ile Cys Gly Ser Thr Thr Gly Gly Leu Gly Leu Leu Gly Leu Tyr	1970	1975	1980
Ile Asn Glu Lys Asn Val Ala Leu Ile Asn Gln Thr Leu Glu Ser Leu	1985	1990	1995
Thr Glu Tyr Cys Gln Gly Pro Cys His Glu Asn Gln Asn Cys Ile Ala	2005	2010	2015
Thr His Glu Ser Asn Gly Ile Asp Ile Ile Thr Ala Leu Ile Leu Asn	2020	2025	2030
Asp Ile Asn Pro Leu Gly Lys Lys Arg Met Asp Leu Val Leu Glu Leu	2035	2040	2045

Lys Asn Asn Ala Ser Lys Leu Leu Leu Ala Ile Met Glu Ser Arg His
 2050 2055 2060
 Asp Ser Glu Asn Ala Glu Arg Ile Leu Tyr Asn Met Arg Pro Lys Glu
 2065 2070 2075 2080
 Leu Val Glu Val Ile Lys Lys Ala Tyr Met Gln Gly Glu Val Glu Phe
 2085 2090 2095
 Glu Asp Gly Glu Asn Gly Glu Asp Gly Ala Ala Ser Pro Arg Asn Val
 2100 2105 2110
 Gly His Asn Ile Tyr Ile Leu Ala His Gln Leu Ala Arg His Asn Lys
 2115 2120 2125
 Glu Leu Gln Thr Met Leu Lys Pro Gly Gly Gln Val Asp Gly Asp Glu
 2130 2135 2140
 Ala Leu Glu Phe Tyr Ala Lys His Thr Ala Gln Ile Glu Ile Val Arg
 2145 2150 2155 2160
 Leu Asp Arg Thr Met Glu Gln Ile Val Phe Pro Val Pro Ser Ile Cys
 2165 2170 2175
 Glu Phe Leu Thr Lys Glu Ser Lys Leu Arg Ile Tyr Tyr Thr Thr Glu
 2180 2185 2190
 Arg Asp Glu Gln Gly Ser Lys Ile Asn Asp Phe Phe Leu Arg Ser Glu
 2195 2200 2205
 Asp Leu Phe Asn Glu Met Asn Trp Gln Lys Lys Leu Arg Ala Gln Pro
 2210 2215 2220
 Val Leu Tyr Trp Cys Ala Arg Asn Met Ser Phe Trp Ser Ser Ile Ser
 2225 2230 2235 2240
 Phe Asn Leu Ala Val Leu Met Asn Leu Leu Val Ala Phe Phe Tyr Pro
 2245 2250 2255
 Phe Lys Gly Val Arg Gly Gly Thr Leu Glu Pro His Trp Ser Gly Leu
 2260 2265 2270
 Leu Trp Thr Ala Met Leu Ile Ser Leu Ala Ile Val Ile Ala Leu Pro
 2275 2280 2285
 Lys Pro His Gly Ile Arg Ala Leu Ile Ala Ser Thr Ile Leu Arg Leu
 2290 2295 2300
 Ile Phe Ser Val Gly Leu Gln Pro Thr Leu Phe Leu Leu Gly Ala Phe
 2305 2310 2315 2320
 Asn Val Cys Asn Lys Ile Ile Phe Leu Met Ser Phe Val Gly Asn Cys
 2325 2330 2335
 Gly Thr Phe Thr Arg Gly Tyr Arg Ala Met Val Leu Asp Val Glu Phe
 2340 2345 2350
 Leu Tyr His Leu Leu Tyr Leu Leu Ile Cys Ala Met Gly Leu Phe Val
 2355 2360 2365
 His Glu Phe Phe Tyr Ser Leu Leu Leu Phe Asp Leu Val Tyr Arg Glu
 2370 2375 2380
 Glu Thr Leu Leu Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Pro
 2385 2390 2395 2400
 Ile Ile Leu Thr Ala Ala Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser
 2405 2410 2415
 Ile Val Gly Tyr Leu Phe Phe Lys Asp Asp Phe Ile Leu Glu Val Asp
 2420 2425 2430
 Arg Leu Pro Asn Glu Thr Ala Gly Pro Glu Thr Gly Glu Ser Leu Ala
 2435 2440 2445
 Asn Asp Phe Leu Tyr Ser Asp Val Cys Arg Val Glu Thr Gly Glu Asn
 2450 2455 2460
 Cys Thr Ser Pro Ala Pro Lys Glu Glu Leu Leu Pro Val Glu Glu Thr
 2465 2470 2475 2480
 Glu Gln Asp Lys Glu His Thr Cys Glu Thr Leu Leu Met Cys Ile Val
 2485 2490 2495
 Thr Val Leu Ser His Gly Leu Arg Ser Gly Gly Gly Val Gly Asp Val
 2500 2505 2510
 Leu Arg Lys Pro Ser Lys Glu Glu Pro Leu Phe Ala Ala Arg Val Ile
 2515 2520 2525

Tyr Asp Leu Leu Phe Phe Phe Met Val Ile Ile Ile Val Leu Asn Leu
 2530 2535 2540
 Ile Phe Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys
 2545 2550 2555 2560
 Gln Lys Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu
 2565 2570 2575
 Glu Arg Asp Lys Phe Asp Asn Lys Thr Val Thr Phe Glu Glu His Ile
 2580 2585 2590
 Lys Glu Glu His Asn Met Trp His Tyr Leu Cys Phe Ile Val Leu Val
 2595 2600 2605
 Lys Val Lys Asp Ser Thr Glu Tyr Thr Gly Pro Glu Ser Tyr Val Ala
 2610 2615 2620
 Glu Met Ile Arg Glu Arg Asn Leu Asp Trp Phe Pro Arg Met Arg Ala
 2625 2630 2635 2640
 Met Ser Leu Val Ser Ser Asp Ser Glu Gly Glu Gln Asn Glu Leu Arg
 2645 2650 2655
 Asn Leu Gln Glu Lys Leu Glu Ser Thr Met Lys Leu Val Thr Asn Leu
 2660 2665 2670
 Ser Gly Gln Leu Ser Glu Leu Lys Asp Gln Met Thr Glu Gln Arg Lys
 2675 2680 2685
 Gln Lys Gln Arg Ile Gly Leu Leu Gly His Pro Pro His Met Asn Val
 2690 2695 2700
 Asn Pro Gln Gln Pro Ala
 2705 2710

<210> 18

<211> 2749

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 18

Met Ser Asp Lys Met Ser Ser Phe Leu His Ile Gly Asp Ile Cys Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Thr Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val Gln Pro Glu Ala Gly Asp Leu Asn Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Leu Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Phe Trp Lys Ala Ala Lys Pro Gly Ala
 65 70 75 80
 Asn Ser Thr Thr Asp Ala Val Leu Leu Asn Lys Leu His His Ala Ala
 85 90 95
 Asp Leu Glu Lys Lys Gln Asn Glu Thr Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Thr Val Ile Gln Tyr Gly Asn Val Ile Gln Leu Leu His Leu Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Thr Leu Asp Glu Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile Gln Pro Phe Tyr Lys Leu Arg Ser Ile Gly Asp Ser Val
 165 170 175
 Val Ile Gly Asp Lys Val Val Leu Asn Pro Val Asn Ala Gly Gln Pro
 180 185 190

Leu	His	Ala	Ser	Ser	His	Gln	Leu	Val	Asp	Asn	Pro	Gly	Cys	Asn	Glu	
		195					200					205				
Val	Asn	Ser	Val	Asn	Cys	Asn	Thr	Ser	Trp	Lys	Ile	Val	Leu	Phe	Met	
		210				215					220					
Lys	Trp	Ser	Asp	Asn	Lys	Asp	Asp	Ile	Leu	Lys	Gly	Gly	Asp	Val	Val	
225					230					235					240	
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Glu	His	
				245					250					255		
Arg	Lys	Lys	Gln	His	Val	Phe	Leu	Arg	Thr	Thr	Gly	Arg	Gln	Ser	Ala	
			260					265					270			
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Val	Glu	Val	Val	Gln	
		275					280					285				
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Tyr	Trp	Asn	Ser	Leu	Phe	Arg	
	290					295					300					
Phe	Lys	His	Leu	Ala	Thr	Gly	His	Tyr	Leu	Ala	Ala	Glu	Val	Asp	Pro	
305					310					315					320	
Asp	Phe	Glu	Glu	Glu	Cys	Leu	Glu	Phe	Gln	Pro	Ser	Val	Asp	Pro	Asp	
				325					330					335		
Gln	Asp	Ala	Ser	Arg	Ser	Arg	Leu	Arg	Asn	Ala	Gln	Glu	Lys	Met	Val	
		340						345					350			
Tyr	Ser	Leu	Val	Ser	Val	Pro	Glu	Gly	Asn	Asp	Ile	Ser	Ser	Ile	Phe	
		355					360					365				
Glu	Leu	Asp	Pro	Thr	Thr	Leu	Arg	Gly	Gly	Asp	Ser	Leu	Val	Pro	Arg	
	370					375					380					
Asn	Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	His	
385					390					395					400	
Ser	Thr	Asn	Ile	Pro	Ile	Asp	Lys	Glu	Glu	Glu	Lys	Pro	Val	Met	Leu	
			405					410						415		
Lys	Ile	Gly	Thr	Ser	Pro	Leu	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	
		420						425					430			
Val	Pro	Val	Ser	Pro	Ala	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	
		435				440						445				
Ala	Ser	Lys	Val	Leu	Gly	Ser	Ile	Ala	Gly	Lys	Leu	Glu	Lys	Gly	Thr	
	450					455					460					
Ile	Thr	Gln	Asn	Glu	Arg	Arg	Ser	Val	Thr	Lys	Leu	Leu	Glu	Asp	Leu	
465					470					475					480	
Val	Tyr	Phe	Val	Thr	Gly	Gly	Thr	Asn	Ser	Gly	Gln	Asp	Val	Leu	Glu	
			485					490						495		
Val	Val	Phe	Ser	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	
			500					505					510			
Gln	Asn	Ile	Leu	Lys	Gln	Ile	Phe	Lys	Leu	Leu	Gln	Ala	Pro	Phe	Thr	
		515					520					525				
Asp	Cys	Gly	Asp	Gly	Pro	Met	Leu	Arg	Leu	Glu	Glu	Leu	Gly	Asp	Gln	
	530					535				540						
Arg	His	Ala	Pro	Phe	Arg	His	Ile	Cys	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	
			565						570					575		
Gln	Phe	Gly	Phe	Met	Gln	Lys	Gln	Ile	Gly	Tyr	Asp	Val	Leu	Ala	Glu	
			580					585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
		595					600					605				
His	Ile	Thr	Ala	Ala	Glu	Ile	Asp	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Met	Asn	Lys	Ser	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Ala	Val	
			645						650					655		
Leu	Asn	Pro	Thr	Asn	Ala	Asp	Ile	Leu	Ile	Glu	Thr	Lys	Leu	Val	Leu	
			660					665					670			

Ser Arg Phe Glu Phe Glu Gly Val Ser Thr Gly Glu Asn Ala Leu Glu
 675 680 685
 Ala Gly Glu Asp Glu Glu Glu Val Trp Leu Phe Trp Arg Asp Ser Asn
 690 695 700
 Lys Glu Ile Arg Ser Lys Ser Val Arg Glu Leu Ala Gln Asp Ala Lys
 705 710 715 720
 Glu Gly Gln Lys Glu Asp Arg Asp Val Leu Ser Tyr Tyr Arg Tyr Gln
 725 730 735
 Leu Asn Leu Phe Ala Arg Met Cys Leu Asp Arg Gln Tyr Leu Ala Ile
 740 745 750
 Asn Glu Ile Ser Gly Gln Leu Asp Val Asp Leu Ile Leu Arg Cys Met
 755 760 765
 Ser Asp Glu Asn Leu Pro Tyr Asp Leu Arg Ala Ser Phe Cys Arg Leu
 770 775 780
 Met Leu His Met His Val Asp Arg Asp Pro Gln Glu Gln Val Thr Pro
 785 790 795 800
 Val Lys Tyr Ala Arg Leu Trp Ser Glu Ile Pro Ser Glu Ile Ala Ile
 805 810 815
 Asp Asp Tyr Asp Ser Ser Gly Ala Ser Lys Asp Glu Ile Lys Glu Arg
 820 825 830
 Phe Ala Gln Thr Met Glu Phe Val Glu Glu Tyr Leu Arg Asp Val Val
 835 840 845
 Cys Gln Arg Phe Pro Phe Ser Asp Lys Glu Lys Asn Lys Leu Thr Phe
 850 855 860
 Glu Val Val Asn Leu Ala Arg Asn Leu Ile Tyr Phe Gly Phe Tyr Asn
 865 870 875 880
 Phe Ser Asp Leu Leu Arg Leu Thr Lys Ile Leu Leu Ala Ile Leu Asp
 885 890 895
 Cys Val His Val Thr Thr Ile Phe Pro Ile Ser Lys Met Thr Lys Gly
 900 905 910
 Glu Glu Asn Lys Gly Ser Asn Val Met Arg Ser Ile His Gly Val Gly
 915 920 925
 Glu Leu Met Thr Gln Val Val Leu Arg Gly Gly Gly Phe Leu Pro Met
 930 935 940
 Thr Pro Met Ala Ala Ala Pro Glu Gly Asn Val Lys Gln Ala Glu Pro
 945 950 955 960
 Glu Lys Glu Asp Ile Met Val Met Asp Thr Lys Leu Lys Ile Ile Glu
 965 970 975
 Ile Leu Gln Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Cys
 980 985 990
 Leu Leu Cys Ile Phe Lys Arg Glu Phe Asp Glu Ser Asn Ser Gln Ser
 995 1000 1005
 Ser Glu Thr Ser Ser Gly Asn Ser Ser Gln Glu Gly Pro Ser Asn Val
 1010 1015 1020
 Pro Gly Ala Leu Asp Phe Glu His Ile Glu Glu Gln Ala Glu Gly Ile
 1025 1030 1035 1040
 Phe Gly Gly Ser Glu Glu Asn Thr Pro Leu Asp Leu Asp Asp His Gly
 1045 1050 1055
 Gly Arg Thr Phe Leu Arg Val Leu Leu His Leu Thr Met His Asp Tyr
 1060 1065 1070
 Pro Pro Leu Val Ser Gly Ala Leu Gln Leu Leu Phe Arg His Phe Ser
 1075 1080 1085
 Gln Arg Gln Glu Val Leu Gln Ala Phe Lys Gln Val Gln Leu Leu Val
 1090 1095 1100
 Thr Ser Gln Asp Val Asp Asn Tyr Lys Gln Ile Lys Gln Asp Leu Asp
 1105 1110 1115 1120
 Gln Leu Arg Ser Ile Val Glu Lys Ser Glu Leu Trp Val Tyr Lys Gly
 1125 1130 1135
 Gln Gly Pro Asp Glu Pro Met Asp Gly Ala Ser Gly Glu Asn Glu His
 1140 1145 1150

Lys Lys Thr Glu Glu Gly Thr Ser Lys Pro Leu Lys His Glu Ser Thr
 1155 1160 1165
 Ser Ser Tyr Asn Tyr Arg Val Val Lys Glu Ile Leu Ile Arg Leu Ser
 1170 1175 1180
 Lys Leu Cys Val Gln Glu Ser Ala Ser Val Arg Lys Ser Arg Lys Gln
 1185 1190 1195 1200
 Gln Gln Arg Leu Leu Arg Asn Met Gly Ala His Ala Val Val Leu Glu
 1205 1210 1215
 Leu Leu Gln Ile Pro Tyr Glu Lys Ala Glu Asp Thr Lys Met Gln Glu
 1220 1225 1230
 Ile Met Arg Leu Ala His Glu Phe Leu Gln Asn Phe Cys Ala Gly Asn
 1235 1240 1245
 Gln Gln Asn Gln Ala Leu Leu His Lys His Ile Asn Leu Phe Leu Asn
 1250 1255 1260
 Pro Gly Ile Leu Glu Ala Val Thr Met Gln His Ile Phe Met Asn Asn
 1265 1270 1275 1280
 Phe Gln Leu Cys Ser Glu Ile Asn Glu Arg Val Val Gln His Phe Val
 1285 1290 1295
 His Cys Ile Glu Thr His Gly Arg Asn Val Gln Tyr Ile Lys Phe Leu
 1300 1305 1310
 Gln Thr Ile Val Lys Ala Glu Gly Lys Phe Ile Lys Lys Cys Gln Asp
 1315 1320 1325
 Met Val Met Ala Glu Leu Val Asn Ser Gly Glu Asp Val Leu Val Phe
 1330 1335 1340
 Tyr Asn Asp Arg Ala Ser Phe Gln Thr Leu Ile Gln Met Met Arg Ser
 1345 1350 1355 1360
 Glu Arg Asp Arg Met Asp Glu Asn Ser Pro Leu Phe Met Tyr His Ile
 1365 1370 1375
 His Leu Val Glu Leu Leu Ala Val Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Glu Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Ile
 1410 1415 1420
 Asn Phe Leu Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Met Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Ile Cys Arg Ala Cys Asn Asn Thr Ser Asp Arg Lys His Ala Asp
 1460 1465 1470
 Ser Val Leu Glu Lys Tyr Val Thr Glu Ile Val Met Ser Ile Val Thr
 1475 1480 1485
 Thr Phe Ser Ser Pro Phe Ser Asp Gln Ser Thr Thr Leu Gln Thr
 1490 1495 1500
 Arg Gln Pro Val Phe Val Gln Leu Leu Gln Gly Val Phe Arg Val Tyr
 1505 1510 1515 1520
 His Cys Asn Trp Leu Met Pro Ser Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Val Leu Ser Asp Val Ala Lys Ser Arg Ala Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Asn Leu Phe Leu Lys Ser His Asn
 1555 1560 1565
 Ile Val Gln Lys Thr Ala Met Asn Trp Arg Leu Ser Ala Arg Asn Ala
 1570 1575 1580
 Ala Arg Arg Asp Ser Val Leu Ala Ala Ser Arg Asp Tyr Arg Asn Ile
 1585 1590 1595 1600
 Ile Glu Arg Leu Gln Asp Ile Val Ser Ala Leu Glu Asp Arg Leu Arg
 1605 1610 1615
 Pro Leu Val Gln Ala Glu Leu Ser Val Leu Val Asp Val Leu His Arg
 1620 1625 1630

Pro Glu Leu Leu Phe Pro Glu Asn Thr Asp Ala Arg Arg Lys Cys Glu
 1635 1640 1645
 Ser Gly Gly Phe Ile Cys Lys Leu Ile Lys His Thr Lys Gln Leu Leu
 1650 1655 1660
 Glu Glu Asn Glu Glu Lys Leu Cys Ile Lys Val Leu Gln Thr Leu Arg
 1665 1670 1675 1680
 Glu Met Met Thr Lys Asp Arg Gly Tyr Gly Glu Lys Gln Ile Ser Ile
 1685 1690 1695
 Asp Glu Leu Glu Asn Ala Glu Leu Pro Gln Pro Pro Glu Ala Glu Asn
 1700 1705 1710
 Ser Thr Glu Glu Leu Glu Pro Ser Pro Pro Leu Arg Gln Leu Glu Asp
 1715 1720 1725
 His Lys Arg Gly Glu Ala Leu Arg Gln Ile Leu Val Asn Arg Tyr Tyr
 1730 1735 1740
 Gly Asn Ile Arg Pro Ser Gly Arg Arg Glu Ser Leu Thr Ser Phe Gly
 1745 1750 1755 1760
 Asn Gly Pro Leu Ser Pro Gly Gly Pro Ser Lys Pro Gly Gly Gly Gly
 1765 1770 1775
 Gly Gly Pro Gly Ser Gly Ser Thr Ser Arg Gly Glu Met Ser Leu Ala
 1780 1785 1790
 Glu Val Gln Cys His Leu Asp Lys Glu Gly Ala Ser Asn Leu Val Ile
 1795 1800 1805
 Asp Leu Ile Met Asn Ala Ser Ser Asp Arg Val Phe His Glu Ser Ile
 1810 1815 1820
 Leu Leu Ala Ile Ala Leu Leu Glu Gly Gly Asn Thr Thr Ile Gln His
 1825 1830 1835 1840
 Ser Phe Phe Cys Arg Leu Thr Glu Asp Lys Lys Ser Glu Lys Phe Phe
 1845 1850 1855
 Lys Val Phe Tyr Asp Arg Met Lys Val Ala Gln Gln Glu Ile Lys Ala
 1860 1865 1870
 Thr Val Thr Val Asn Thr Ser Asp Leu Gly Asn Lys Lys Lys Asp Asp
 1875 1880 1885
 Glu Val Asp Arg Asp Ala Pro Ser Arg Lys Lys Ala Lys Glu Pro Thr
 1890 1895 1900
 Thr Gln Ile Thr Glu Glu Val Arg Asp Gln Leu Leu Glu Ala Ser Ala
 1905 1910 1915 1920
 Ala Thr Arg Lys Ala Phe Thr Thr Phe Arg Arg Glu Ala Asp Pro Asp
 1925 1930 1935
 Asp His Tyr Gln Ser Gly Glu Gly Thr Gln Ala Thr Thr Asp Lys Ala
 1940 1945 1950
 Lys Asp Asp Leu Glu Met Ser Ala Val Ile Thr Ile Met Gln Pro Ile
 1955 1960 1965
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1970 1975 1980
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1985 1990 1995 2000
 Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly Gly
 2005 2010 2015
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu Ile
 2020 2025 2030
 Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 2035 2040 2045
 Glu Asn Gln Asn Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp Ile
 2050 2055 2060
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Asn Pro Leu Gly Lys Lys Arg
 2065 2070 2075 2080
 Met Asp Leu Val Leu Glu Leu Lys Asn Asn Ala Ser Lys Leu Leu Leu
 2085 2090 2095
 Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2100 2105 2110

Tyr Asn Met Arg Pro Lys Glu Leu Val Glu Val Ile Lys Lys Ala Tyr
 2115 2120 2125
 Met Gln Gly Glu Val Glu Phe Glu Asp Gly Glu Asn Gly Glu Asp Gly
 2130 2135 2140
 Ala Ala Ser Pro Arg Asn Val Gly His Asn Ile Tyr Ile Leu Ala His
 2145 2150 2155 2160
 Gln Leu Ala Arg His Asn Lys Glu Leu Gln Thr Met Leu Lys Pro Gly
 2165 2170 2175
 Gly Gln Val Asp Gly Asp Glu Ala Leu Glu Phe Tyr Ala Lys His Thr
 2180 2185 2190
 Ala Gln Ile Glu Ile Val Arg Leu Asp Arg Thr Met Glu Gln Ile Val
 2195 2200 2205
 Phe Pro Val Pro Ser Ile Cys Glu Phe Leu Thr Lys Glu Ser Lys Leu
 2210 2215 2220
 Arg Ile Tyr Tyr Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys Ile Asn
 2225 2230 2235 2240
 Asp Phe Phe Leu Arg Ser Glu Asp Leu Phe Asn Glu Met Asn Trp Gln
 2245 2250 2255
 Lys Lys Leu Arg Ala Gln Pro Val Leu Tyr Trp Cys Ala Arg Asn Met
 2260 2265 2270
 Ser Phe Trp Ser Ser Ile Ser Phe Asn Leu Ala Val Leu Met Asn Leu
 2275 2280 2285
 Leu Val Ala Phe Phe Tyr Pro Phe Lys Gly Val Arg Gly Gly Thr Leu
 2290 2295 2300
 Glu Pro His Trp Ser Gly Leu Leu Trp Thr Ala Met Leu Ile Ser Leu
 2305 2310 2315 2320
 Ala Ile Val Ile Ala Leu Pro Lys Pro His Gly Ile Arg Ala Leu Ile
 2325 2330 2335
 Ala Ser Thr Ile Leu Arg Leu Ile Phe Ser Val Gly Leu Gln Pro Thr
 2340 2345 2350
 Leu Phe Leu Leu Gly Ala Phe Asn Val Cys Asn Lys Ile Ile Phe Leu
 2355 2360 2365
 Met Ser Phe Val Gly Asn Cys Gly Thr Phe Thr Arg Gly Tyr Arg Ala
 2370 2375 2380
 Met Val Leu Asp Val Glu Phe Leu Tyr His Leu Leu Tyr Leu Leu Ile
 2385 2390 2395 2400
 Cys Ala Met Gly Leu Phe Val His Glu Phe Phe Tyr Ser Leu Leu Leu
 2405 2410 2415
 Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val Ile Lys Ser
 2420 2425 2430
 Val Thr Arg Asn Gly Arg Pro Ile Ile Leu Thr Ala Ala Leu Ala Leu
 2435 2440 2445
 Ile Leu Val Tyr Leu Phe Ser Ile Val Gly Tyr Leu Phe Phe Lys Asp
 2450 2455 2460
 Asp Phe Ile Leu Glu Val Asp Arg Leu Pro Asn Glu Thr Ala Gly Pro
 2465 2470 2475 2480
 Glu Thr Gly Glu Ser Leu Ala Asn Asp Phe Leu Tyr Ser Asp Val Cys
 2485 2490 2495
 Arg Val Glu Thr Gly Glu Asn Cys Thr Ser Pro Ala Pro Lys Glu Glu
 2500 2505 2510
 Leu Leu Pro Val Glu Glu Thr Glu Gln Asp Lys Glu His Thr Cys Glu
 2515 2520 2525
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Ser His Gly Leu Arg Ser
 2530 2535 2540
 Gly Gly Gly Val Gly Asp Val Leu Arg Lys Pro Ser Lys Glu Glu Pro
 2545 2550 2555 2560
 Leu Phe Ala Ala Arg Val Ile Tyr Asp Leu Phe Phe Phe Met Val
 2565 2570 2575
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2580 2585 2590

Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Glu Ile Leu Lys Thr
 2595 2600 2605
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2610 2615 2620
 Val Thr Phe Glu Glu His Ile Lys Glu Glu His Asn Met Trp His Tyr
 2625 2630 2635 2640
 Leu Cys Phe Ile Val Leu Val Lys Val Lys Asp Ser Thr Glu Tyr Thr
 2645 2650 2655
 Gly Pro Glu Ser Tyr Val Ala Glu Met Ile Arg Glu Arg Asn Leu Asp
 2660 2665 2670
 Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Ser Asp Ser Glu
 2675 2680 2685
 Gly Glu Gln Asn Glu Leu Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2690 2695 2700
 Met Lys Leu Val Thr Asn Leu Ser Gly Gln Leu Ser Glu Leu Lys Asp
 2705 2710 2715 2720
 Gln Met Thr Glu Gln Arg Lys Gln Lys Gln Arg Ile Gly Leu Leu Gly
 2725 2730 2735
 His Pro Pro His Met Asn Val Asn Pro Gln Gln Pro Ala
 2740 2745

<210> 19
 <211> 2701
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 19
 Met Ser Asp Lys Met Ser Ser Phe Leu Tyr Ile Gly Asp Ile Val Ser
 1 5 10 15
 Leu Tyr Ala Glu Gly Ser Val Asn Gly Phe Ile Ser Thr Leu Gly Leu
 20 25 30
 Val Asp Asp Arg Cys Val Val His Pro Glu Ala Gly Asp Leu Thr Asn
 35 40 45
 Pro Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Val Cys Pro Met Asn
 50 55 60
 Arg Tyr Ser Ala Gln Lys Gln Tyr Trp Lys Ala Lys Gln Ala Lys Gln
 65 70 75 80
 Gly Asn His Thr Glu Ala Ala Leu Leu Lys Lys Leu Gln His Ala Ala
 85 90 95
 Glu Leu Glu Gln Lys Gln Asn Glu Ser Glu Asn Arg Lys Leu Leu Gly
 100 105 110
 Glu Ile Val Lys Tyr Ser Lys Val Ile Gln Leu Leu His Ile Lys Ser
 115 120 125
 Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu Lys
 130 135 140
 Asn Ala Met Arg Val Ser Leu Asp Ala Ala Gly Asn Glu Gly Ser Trp
 145 150 155 160
 Phe Tyr Ile His Pro Phe Trp Lys Leu Arg Ser Glu Gly Asp Asn Ile
 165 170 175
 Val Val Gly Asp Lys Val Val Leu Met Pro Val Asn Ala Gly Gln Pro
 180 185 190
 Leu His Ala Ser Asn Val Glu Leu Leu Asp Asn Pro Gly Cys Lys Glu
 195 200 205
 Val Asn Ala Val Asn Cys Asn Thr Ser Trp Lys Ile Thr Leu Phe Met
 210 215 220

Lys	Phe	Ser	Ser	Tyr	Arg	Glu	Asp	Val	Leu	Lys	Gly	Gly	Asp	Val	Val	225	230	235	240
Arg	Leu	Phe	His	Ala	Glu	Gln	Glu	Lys	Phe	Leu	Thr	Cys	Asp	Asp	Tyr	245	250	255	
Glu	Lys	Lys	Gln	His	Ile	Phe	Leu	Arg	Thr	Thr	Leu	Arg	Gln	Ser	Ala	260	265	270	
Thr	Ser	Ala	Thr	Ser	Ser	Lys	Ala	Leu	Trp	Glu	Ile	Glu	Val	Val	His	275	280	285	
His	Asp	Pro	Cys	Arg	Gly	Gly	Ala	Gly	Gln	Trp	Asn	Ser	Leu	Phe	Arg	290	295	300	
Phe	Lys	His	Leu	Ala	Thr	Gly	Asn	Tyr	Leu	Ala	Ala	Glu	Leu	Asn	Pro	305	310	315	320
Asp	Tyr	Arg	Asp	Ala	Gln	Asn	Glu	Gly	Lys	Thr	Val	Arg	Asp	Gly	Glu	325	330	335	
Leu	Pro	Thr	Ser	Lys	Lys	Lys	His	Gln	Ala	Gly	Glu	Lys	Ile	Met	Tyr	340	345	350	
Thr	Leu	Val	Ser	Val	Pro	His	Gly	Asn	Asp	Ile	Ala	Ser	Leu	Phe	Glu	355	360	365	
Leu	Asp	Ala	Thr	Thr	Leu	Gln	Arg	Ala	Asp	Cys	Leu	Val	Pro	Arg	Asn	370	375	380	
Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Val	Thr	Ser	385	390	395	400
Thr	Ser	Ile	Pro	Ile	Asp	Thr	Glu	Glu	Glu	Arg	Pro	Val	Met	Leu	Lys	405	410	415	
Ile	Gly	Thr	Cys	Gln	Thr	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	Val	420	425	430	
Cys	Val	Pro	Leu	Ser	Glu	Val	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	Ala	435	440	445	
Asn	Lys	Val	Leu	Ala	Thr	Thr	Val	Lys	Lys	Leu	Glu	Asn	Gly	Ser	Ile	450	455	460	
Thr	Gln	Asn	Glu	Arg	Arg	Phe	Val	Thr	Lys	Leu	Glu	Asp	Leu	Ile		465	470	475	480
Phe	Phe	Val	Ala	Asp	Val	Thr	Asn	Asn	Gly	Gln	Asp	Val	Leu	Asp	Val	485	490	495	
Val	Ile	Thr	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Glu	Gln	500	505	510	
Asn	Ile	Leu	Ala	Gln	Val	Phe	Gly	Ile	Leu	Lys	Ala	Pro	Phe	Lys	Glu	515	520	525	
Lys	Ala	Gly	Glu	Gly	Ser	Met	Leu	Arg	Leu	Glu	Asp	Leu	Gly	Asp	Gln	530	535	540	
Arg	Tyr	Ala	Pro	Tyr	Lys	Tyr	Val	Leu	Arg	Leu	Cys	Tyr	Arg	Val	Leu	545	550	555	560
Arg	His	Ser	Gln	Gln	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	Tyr	Ile	Ala	Lys	565	570	575	
Asn	Phe	Cys	Val	Met	Gln	Ser	Gln	Ile	Gly	Tyr	Asp	Ile	Leu	Ala	Glu	580	585	590	
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	595	600	605	
His	Ile	Thr	Ala	Lys	Glu	Ile	Glu	Thr	Phe	Val	Ser	Leu	Leu	Arg	Arg	610	615	620	
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	625	630	635	640
Asn	Ser	Thr	Ala	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Phe	Met	645	650	655	
Leu	Ser	Pro	Gly	Asn	Ala	Asp	Ile	Leu	Ile	Gln	Thr	Lys	Leu	Val	Ser	660	665	670	
Met	Gln	Val	Glu	Asn	Pro	Met	Glu	Ser	Ser	Ile	Leu	Pro	Asp	Asp	Ile	675	680	685	
Asp	Asp	Glu	Glu	Val	Trp	Leu	Tyr	Trp	Ile	Asp	Ser	Asn	Lys	Glu	Pro	690	695	700	

His 705	Gly	Lys	Ala	Ile	Arg 710	His	Leu	Ala	Gln	Glu 715	Ala	Arg	Glu	Gly	Thr 720
Lys	Ala	Asp	Leu	Glu	Val	Leu	Thr	Tyr	Tyr	Arg	Tyr	Gln	Leu	Asn	Leu 735
Phe	Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	Asn	Gln	Ile 750
Ser	Thr	Gln	Leu	Ser	Val	Asp	Leu	Ile	Leu	Arg	Cys	Val	Ser	Asp	Glu 765
Ser	Leu	Pro	Phe	Asp	Leu	Arg	Ala	Ser	Phe	Cys	Arg	Leu	Met	Leu	His 780
Met	His	Val	Asp	Arg	Asp	Pro	Gln	Glu	Ser	Val	Val	Pro	Val	Arg	Tyr 800
Ala	Arg	Leu	Trp	Thr	Glu	Ile	Pro	Thr	Lys	Ile	Thr	Ile	His	Glu	Tyr 815
Asp	Ser	Ile	Thr	Asp	Ser	Ser	Arg	Asn	Asp	Met	Lys	Arg	Lys	Phe	Ala 830
Leu	Thr	Met	Glu	Phe	Val	Glu	Glu	Tyr	Leu	Lys	Glu	Val	Val	Asn	Gln 845
Pro	Phe	Pro	Phe	Gly	Asp	Lys	Glu	Lys	Asn	Lys	Leu	Thr	Phe	Glu	Val 860
Val	His	Leu	Ala	Arg	Asn	Leu	Ile	Tyr	Phe	Gly	Phe	Tyr	Ser	Phe	Ser 880
Glu	Leu	Leu	Arg	Leu	Thr	Arg	Thr	Leu	Leu	Ala	Ile	Leu	Asp	Ile	Val 895
Gln	Ala	Pro	Met	Ser	Ser	Tyr	Phe	Glu	Arg	Leu	Ser	Lys	Phe	Gln	Asp 910
Gly	Ser	Asn	Asn	Val	Met	Arg	Thr	Ile	His	Gly	Val	Gly	Glu	Met	Met 925
Thr	Gln	Met	Val	Leu	Ser	Arg	Gly	Ser	Ile	Phe	Pro	Val	Ser	Trp	Pro 940
Asp	Ala	Gln	Pro	Ser	Val	His	Pro	Ser	Lys	Gln	Ala	Ser	Pro	Gly	Glu 960
Gln	Glu	Asp	Val	Thr	Val	Met	Asp	Thr	Lys	Leu	Lys	Val	Ile	Glu	Ile 975
Leu	Gln	Phe	Ile	Leu	Ser	Val	Arg	Leu	Asp	Tyr	Arg	Ile	Ser	Tyr	Met 990
Leu	Ser	Ile	Tyr	Lys	Lys	Glu	Phe	Gly	Glu	Asn	Asp	Gly	Asn	Gly	Asp 1005
Pro	Ser	Ala	Ser	Gly	Thr	Pro	Glu	Thr	Leu	Leu	Pro	Ser	Ala	Leu	Val 1020
Pro	Asp	Ile	Asp	Glu	Ile	Ala	Ala	Gln	Ala	Glu	Thr	Met	Phe	Ala	Gly 1040
Arg	Lys	Glu	Lys	Thr	Pro	Val	Gln	Leu	Asp	Asp	Glu	Gly	Gly	Arg	Thr 1055
Phe	Leu	Arg	Val	Leu	Ile	His	Leu	Ile	Met	His	Asp	Tyr	Ala	Pro	Leu 1070
Leu	Ser	Gly	Ala	Leu	Gln	Leu	Leu	Phe	Lys	His	Phe	Ser	Gln	Arg	Ala 1085
Glu	Val	Leu	Gln	Ala	Phe	Lys	Gln	Val	Gln	Leu	Leu	Val	Ser	Asn	Gln 1100
Asp	Val	Asp	Asn	Tyr	Lys	Gln	Ile	Lys	Ala	Asp	Leu	Asp	Gln	Leu	Arg 1120
Leu	Thr	Val	Glu	Lys	Ser	Glu	Leu	Trp	Val	Glu	Lys	Ser	Gly	Ser	Tyr 1135
Glu	Asn	Gly	Asp	Met	Gly	Glu	Gly	Gln	Ala	Lys	Gly	Gly	Glu	Glu	Ala 1150
Asn	Glu	Glu	Ser	Asn	Leu	Leu	Ser	Pro	Val	Gln	Asp	Gly	Ala	Lys	Thr 1165
Pro	Gln	Ile	Asp	Ser	Asn	Lys	Gly	Asn	Asn	Tyr	Arg	Ile	Val	Lys	Glu 1180

Ile Leu Ile Arg Leu Ser Lys Leu Cys Val Gln Asn Lys Lys Cys Arg
 1185 1190 1195 1200
 Asn Gln His Gln Arg Leu Leu Lys Asn Met Gly Ala His Ser Val Val
 1205 1210 1215
 Leu Asp Leu Leu Gln Ile Pro Tyr Glu Lys Thr Asp Glu Lys Met Asn
 1220 1225 1230
 Glu Val Met Asp Leu Ala His Thr Phe Leu Gln Asn Phe Cys Arg Gly
 1235 1240 1245
 Asn Pro Gln Asn Gln Val Leu Leu His Lys His Leu Asn Leu Phe Leu
 1250 1255 1260
 Thr Pro Gly Leu Leu Glu Ala Glu Thr Met Arg His Ile Phe Met Asn
 1265 1270 1275 1280
 Asn Tyr His Leu Cys Asn Glu Ile Ser Glu Arg Val Val Gln His Phe
 1285 1290 1295
 Val His Cys Ile Glu Thr His Gly Arg His Val Glu Tyr Leu Arg Phe
 1300 1305 1310
 Leu Gln Thr Ile Val Lys Ala Asp Gly Lys Tyr Val Lys Lys Cys Gln
 1315 1320 1325
 Asp Met Val Met Thr Glu Leu Ile Asn Gly Gly Glu Asp Val Leu Ile
 1330 1335 1340
 Phe Tyr Asn Asp Arg Ala Ser Phe Pro Ile Leu Leu Asn Met Met Cys
 1345 1350 1355 1360
 Ser Glu Arg Ala Arg Gly Asp Glu Ser Gly Pro Leu Ala Tyr His Ile
 1365 1370 1375
 Thr Leu Val Glu Leu Leu Ala Ala Cys Thr Glu Gly Lys Asn Val Tyr
 1380 1385 1390
 Thr Glu Ile Lys Cys Asn Ser Leu Leu Pro Leu Asp Asp Ile Val Arg
 1395 1400 1405
 Val Val Thr His Asp Asp Cys Ile Pro Glu Val Lys Ile Ala Tyr Val
 1410 1415 1420
 Asn Phe Val Asn His Cys Tyr Val Asp Thr Glu Val Glu Met Lys Glu
 1425 1430 1435 1440
 Ile Tyr Thr Ser Asn His Ile Trp Lys Leu Phe Glu Asn Phe Leu Val
 1445 1450 1455
 Asp Met Ala Arg Val Cys Asn Thr Thr Thr Asp Arg Lys His Ala Asp
 1460 1465 1470
 Thr Phe Leu Glu Arg Cys Val Thr Glu Ser Val Met Asn Ile Val Ser
 1475 1480 1485
 Gly Phe Phe Asn Ser Pro Phe Ser Asp Asn Ser Thr Ser Leu Gln Thr
 1490 1495 1500
 His Gln Pro Val Phe Ile Gln Leu Leu Gln Ser Ala Phe Arg Ile Tyr
 1505 1510 1515 1520
 Asn Cys Thr Trp Pro Asn Pro Ala Gln Lys Ala Ser Val Glu Ser Cys
 1525 1530 1535
 Ile Arg Ala Leu Ala Glu Val Ala Lys Asn Arg Gly Ile Ala Ile Pro
 1540 1545 1550
 Val Asp Leu Asp Ser Gln Val Asn Thr Leu Phe Met Lys Asn His Ser
 1555 1560 1565
 Ser Thr Val Gln Arg Ala Ala Met Gly Trp Arg Leu Ser Ala Arg Ser
 1570 1575 1580
 Gly Pro Arg Phe Lys Glu Ala Leu Gly Gly Pro Ala Trp Asp Tyr Arg
 1585 1590 1595 1600
 Asn Ile Ile Glu Lys Leu Gln Asp Val Val Ala Ser Leu Glu Gln Gln
 1605 1610 1615
 Phe Ser Pro Met Met Gln Ala Glu Phe Ser Val Leu Val Asp Val Leu
 1620 1625 1630
 Tyr Ser Pro Glu Leu Leu Phe Pro Glu Gly Ser Asp Ala Arg Ile Arg
 1635 1640 1645
 Cys Gly Ala Phe Met Ser Lys Leu Ile Asn His Thr Lys Lys Leu Met
 1650 1655 1660

Glu Lys Glu Glu Lys Leu Cys Ile Lys Ile Leu Gln Thr Leu Arg Glu 1665 1670 1675 1680
 Met Leu Glu Lys Lys Asp Ser Phe Met Glu Glu Ser Ser Thr Leu Arg 1685 1690 1695
 Lys Ile Leu Leu Asn Arg Tyr Phe Lys Gly Asp His Ser Val Gly Val 1700 1705 1710
 Asn Gly Pro Leu Ser Gly Ala Tyr Ala Lys Thr Ala Gln Val Gly Gly 1715 1720 1725
 Gly Phe Thr Gly Gln Asp Ala Asp Lys Thr Gly Ile Ser Met Ser Asp 1730 1735 1740
 Ile Gln Cys Leu Leu Asp Lys Glu Gly Ala Ser Glu Leu Val Ile Asp 1745 1750 1755 1760
 Val Ile Val Asn Thr Lys Asn Asp Arg Ile Phe Ser Glu Gly Ile Leu 1765 1770 1775
 Leu Gly Ile Ala Leu Leu Glu Gly Gly Asn Thr Gln Thr Gln Asn Ser 1780 1785 1790
 Phe Tyr Gln Gln Leu His Glu Gln Lys Lys Ser Glu Lys Phe Phe Lys 1795 1800 1805
 Val Leu Tyr Asp Arg Met Lys Ala Ala Gln Lys Glu Ile Arg Ser Thr 1810 1815 1820
 Val Thr Val Asn Thr Ile Asp Leu Gly Ser Lys Lys Arg Glu Glu Asp 1825 1830 1835 1840
 Ser Asp Leu Met Ala Leu Gly Pro Arg Met Arg Val Arg Asp Ser Ser 1845 1850 1855
 Leu His Leu Lys Glu Gly Met Lys Gly Gln Leu Thr Glu Ala Ser Ser 1860 1865 1870
 Ala Thr Ser Lys Ala Tyr Cys Val Tyr Arg Arg Glu Met Asp Pro Asp 1875 1880 1885
 Ile Asp Thr Met Cys Pro Gly Gln Glu Ala Gly Ser Ala Glu Glu Lys 1890 1895 1900
 Ser Ala Glu Glu Val Thr Met Ser Pro Ala Ile Thr Ile Met Arg Pro 1905 1910 1915 1920
 Ile Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Glu Leu 1925 1930 1935
 Gln Asn Phe Leu Arg Asn Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val 1940 1945 1950
 Cys Glu Thr Leu Gln Phe Leu Asp Cys Ile Cys Gly Ser Thr Thr Gly 1955 1960 1965
 Gly Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Lys Asn Val Ala Leu 1970 1975 1980
 Val Asn Gln Thr Leu Glu Ser Leu Thr Glu Tyr Cys Gln Gly Pro Cys 1985 1990 1995 2000
 His Glu Asn Gln Thr Cys Ile Ala Thr His Glu Ser Asn Gly Ile Asp 2005 2010 2015
 Ile Ile Ile Ala Leu Ile Leu Ser Asp Ile Asn Pro Leu Gly Lys Tyr 2020 2025 2030
 Arg Met Asp Leu Val Leu Gln Leu Lys Asn Asn Ala Ser Lys Leu Leu 2035 2040 2045
 Leu Ala Ile Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile 2050 2055 2060
 Leu Phe Asn Met Arg Pro Lys Glu Leu Val Asp Val Met Lys Asn Ala 2065 2070 2075 2080
 Tyr Asn Gln Gly Leu Glu Cys Asn His Gly Asp Glu Glu Gly Gly Asp 2085 2090 2095
 Asp Gly Val Ser Pro Lys Asp Val Gly His Asn Ile Tyr Ile Leu Ala 2100 2105 2110
 His Gln Leu Ala Arg His Asn Lys Leu Leu Gln Gln Met Leu Lys Pro 2115 2120 2125
 Gly Ser Asp Pro Glu Glu Gly Asp Glu Ala Leu Lys Tyr Tyr Ala Asn 2130 2135 2140

His Thr Ala Gln Ile Glu Ile Val Arg His Asp Arg Thr Met Glu Gln
 2145 2150 2155 2160
 Ile Val Phe Pro Val Pro Asn Ile Cys Glu Phe Leu Thr Arg Glu Ser
 2165 2170 2175
 Lys Tyr Arg Val Phe Asn Thr Thr Glu Arg Asp Glu Gln Gly Ser Lys
 2180 2185 2190
 Val Asn Asp Phe Phe Gln Gln Thr Glu Asp Leu Tyr Asn Glu Met Lys
 2195 2200 2205
 Trp Gln Lys Lys Ile Arg Asn Asn Pro Ala Leu Phe Trp Phe Ser Arg
 2210 2215 2220
 His Ile Ser Leu Trp Gly Ser Ile Ser Phe Asn Leu Ala Val Phe Ile
 2225 2230 2235 2240
 Asn Leu Ala Val Ala Leu Phe Tyr Pro Phe Gly Asp Asp Gly Asp Glu
 2245 2250 2255
 Gly Thr Leu Ser Pro Leu Phe Ser Ala Leu Leu Trp Val Ala Val Ala
 2260 2265 2270
 Ile Cys Thr Ser Met Leu Phe Phe Phe Ser Lys Pro Val Gly Ile Arg
 2275 2280 2285
 Pro Phe Leu Val Ser Ile Met Leu Arg Ser Ile Tyr Thr Ile Gly Leu
 2290 2295 2300
 Gly Pro Thr Leu Ile Leu Leu Gly Ala Ala Asn Leu Cys Asn Lys Ile
 2305 2310 2315 2320
 Val Phe Leu Val Ser Phe Val Gly Asn Arg Gly Thr Phe Thr Arg Gly
 2325 2330 2335
 Tyr Arg Ala Val Ile Leu Asp Met Ala Phe Leu Tyr His Val Ala Tyr
 2340 2345 2350
 Val Leu Val Cys Met Leu Gly Leu Phe Val His Glu Phe Phe Tyr Ser
 2355 2360 2365
 Phe Leu Leu Phe Asp Leu Val Tyr Arg Glu Glu Thr Leu Leu Asn Val
 2370 2375 2380
 Ile Lys Ser Val Thr Arg Asn Gly Arg Ser Ile Ile Leu Thr Ala Val
 2385 2390 2395 2400
 Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser Ile Ile Gly Phe Leu Phe
 2405 2410 2415
 Leu Lys Asp Asp Phe Thr Met Glu Val Asp Arg Leu Lys Asn Arg Thr
 2420 2425 2430
 Pro Val Thr Gly Asn Asp Gly Val Pro Thr Met Thr Leu Thr Ser Met
 2435 2440 2445
 Leu Gly Thr Cys Pro Lys Glu Asn Cys Ser Pro Thr Ile Pro Ser Ser
 2450 2455 2460
 Asn Ala Ala Gly Glu Gly Gly Glu Asp Gly Ile Glu Arg Thr Cys Asp
 2465 2470 2475 2480
 Thr Leu Leu Met Cys Ile Val Thr Val Leu Asn Gln Gly Leu Arg Asn
 2485 2490 2495
 Gly Gly Gly Val Gly Asp Val Leu Arg Arg Pro Ser Lys Asp Glu Pro
 2500 2505 2510
 Leu Phe Ala Ala Arg Val Val Tyr Asp Leu Leu Phe Phe Phe Ile Val
 2515 2520 2525
 Ile Ile Ile Val Leu Asn Leu Ile Phe Gly Val Ile Ile Asp Thr Phe
 2530 2535 2540
 Ala Asp Leu Arg Ser Glu Lys Gln Lys Lys Glu Lys Ile Leu Lys Thr
 2545 2550 2555 2560
 Thr Cys Phe Ile Cys Gly Leu Glu Arg Asp Lys Phe Asp Asn Lys Thr
 2565 2570 2575
 Val Ser Phe Glu Glu His Ile Lys Ser Glu His Asn Met Trp His Tyr
 2580 2585 2590
 Leu Tyr Phe Ile Val Leu Val Lys Val Lys Asp Pro Thr Glu Tyr Thr
 2595 2600 2605
 Gly Pro Glu Ser Tyr Val Ala Gln Met Ile Thr Glu Lys Asn Leu Asp
 2610 2615 2620

Trp Phe Pro Arg Met Arg Ala Met Ser Leu Val Ser Asn Glu Gly Asp
 2625 2630 2635 2640
 Ser Glu Gln Asn Glu Ile Arg Asn Leu Gln Glu Lys Leu Glu Ser Thr
 2645 2650 2655
 Met Ser Leu Val Lys Gln Leu Ser Gly Gln Leu Ala Glu Leu Lys Glu
 2660 2665 2670
 Gln Met Thr Glu Gln Arg Lys Asn Lys Gln Arg Leu Gly Phe Leu Gly
 2675 2680 2685
 Ser Asn Thr Pro His Glu Asn His His Met Pro Pro His
 2690 2695 2700

<210> 20
 <211> 2670
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:/note =
 synthetic construct

<400> 20
 Met Asn Glu Met Ser Ser Phe Leu His Ile Gly Asp Ile Val Ser Leu
 1 5 10 15
 Tyr Ala Glu Gly Ser Val Asn Gly Phe Ile Ser Thr Leu Gly Leu Val
 20 25 30
 Asp Asp Arg Cys Val Val Glu Pro Ala Ala Gly Asp Leu Asp Asn Pro
 35 40 45
 Pro Lys Lys Phe Arg Asp Cys Leu Phe Lys Val Cys Pro Met Asn Arg
 50 55 60
 Tyr Ser Ala Gln Lys Gln Tyr Trp Lys Ala Lys Gln Thr Lys Gln Asp
 65 70 75 80
 Lys Glu Lys Ile Ala Asp Val Val Leu Leu Gln Lys Leu Gln His Ala
 85 90 95
 Ala Gln Met Glu Gln Lys Gln Asn Asp Thr Glu Asn Lys Lys Val His
 100 105 110
 Gly Asp Val Val Lys Tyr Gly Ser Val Ile Gln Leu Leu His Met Lys
 115 120 125
 Ser Asn Lys Tyr Leu Thr Val Asn Lys Arg Leu Pro Ala Leu Leu Glu
 130 135 140
 Lys Asn Ala Met Arg Val Thr Leu Asp Ala Thr Gly Asn Glu Gly Ser
 145 150 155 160
 Trp Leu Phe Ile Gln Pro Phe Trp Lys Leu Arg Ser Asn Gly Asp Asn
 165 170 175
 Val Val Val Gly Asp Lys Val Ile Leu Asn Pro Val Asn Ala Gly Gln
 180 185 190
 Pro Leu His Ala Ser Asn Tyr Glu Leu Ser Asp Asn Val Gly Cys Lys
 195 200 205
 Glu Val Asn Ser Val Asn Cys Asn Thr Ser Trp Lys Ile Asn Leu Phe
 210 215 220
 Met Gln Phe Arg Asp His Leu Glu Glu Val Leu Lys Gly Gly Asp Val
 225 230 235 240
 Val Arg Leu Phe His Ala Glu Gln Glu Lys Phe Leu Thr Cys Asp Glu
 245 250 255
 Tyr Arg Gly Lys Leu Gln Val Phe Leu Arg Thr Thr Leu Arg Gln Ser
 260 265 270
 Ala Thr Ser Ala Thr Ser Ser Asn Ala Leu Trp Glu Val Glu Val Val
 275 280 285
 His His Asp Pro Cys Arg Gly Gly Ala Gly His Trp Asn Gly Leu Tyr
 290 295 300

Arg	Phe	Lys	His	Leu	Ala	Thr	Gly	Asn	Tyr	Leu	Ala	Ala	Glu	Glu	Asn	
305					310					315					320	
Pro	Ser	Tyr	Lys	Gly	Asp	Val	Ser	Asp	Pro	Lys	Ala	Ala	Gly	Pro	Gly	
				325					330					335		
Ala	Gln	Ser	Arg	Thr	Gly	Arg	Arg	Asn	Ala	Gly	Glu	Lys	Ile	Lys	Tyr	
			340					345					350			
Arg	Leu	Val	Ala	Val	Pro	His	Gly	Asn	Asp	Ile	Ala	Ser	Leu	Phe	Glu	
		355					360					365				
Leu	Asp	Pro	Thr	Thr	Leu	Gln	Lys	Thr	Asp	Ser	Phe	Val	Pro	Arg	Asn	
	370					375					380					
Ser	Tyr	Val	Arg	Leu	Arg	His	Leu	Cys	Thr	Asn	Thr	Trp	Ile	Gln	Ser	
385					390					395					400	
Thr	Asn	Ala	Pro	Ile	Asp	Val	Glu	Glu	Glu	Arg	Pro	Ile	Arg	Leu	Met	
				405					410					415		
Leu	Gly	Thr	Cys	Pro	Thr	Lys	Glu	Asp	Lys	Glu	Ala	Phe	Ala	Ile	Val	
			420					425					430			
Ser	Val	Pro	Val	Ser	Glu	Ile	Arg	Asp	Leu	Asp	Phe	Ala	Asn	Asp	Ala	
		435					440				445					
Ser	Ser	Met	Leu	Ala	Ser	Ala	Val	Glu	Lys	Leu	Asn	Glu	Gly	Phe	Ile	
	450					455					460					
Ser	Gln	Asn	Asp	Arg	Arg	Phe	Val	Ile	Gln	Leu	Leu	Glu	Asp	Leu	Val	
465					470					475					480	
Phe	Phe	Val	Ser	Asp	Val	Pro	Asn	Asn	Gly	Gln	Asn	Val	Leu	Asp	Ile	
				485					490					495		
Met	Val	Thr	Lys	Pro	Asn	Arg	Glu	Arg	Gln	Lys	Leu	Met	Arg	Asp	Glu	
			500					505					510			
Asn	Ile	Leu	Lys	Gln	Ile	Phe	Gly	Ile	Leu	Lys	Ala	Pro	Phe	Arg	Asp	
		515					520					525				
Lys	Gly	Gly	Glu	Gly	Pro	Leu	Val	Arg	Leu	Glu	Glu	Leu	Ser	Asp	Gln	
	530					535					540					
Lys	Asn	Ala	Pro	Tyr	Gln	Tyr	Met	Phe	Arg	Leu	Cys	Tyr	Arg	Val	Leu	
545					550					555					560	
Arg	His	Ser	Gln	Glu	Asp	Tyr	Arg	Lys	Asn	Gln	Glu	His	Ile	Ala	Lys	
				565					570					575		
Gln	Phe	Gly	Met	Met	Gln	Ser	Gln	Ile	Gly	Tyr	Asp	Ile	Leu	Ala	Glu	
			580					585					590			
Asp	Thr	Ile	Thr	Ala	Leu	Leu	His	Asn	Asn	Arg	Lys	Leu	Leu	Glu	Lys	
		595					600					605				
His	Ile	Thr	Lys	Thr	Glu	Val	Glu	Thr	Phe	Val	Ser	Leu	Val	Arg	Lys	
	610					615					620					
Asn	Arg	Glu	Pro	Arg	Phe	Leu	Asp	Tyr	Leu	Ser	Asp	Leu	Cys	Val	Ser	
625					630					635					640	
Asn	Arg	Ile	Ala	Ile	Pro	Val	Thr	Gln	Glu	Leu	Ile	Cys	Lys	Cys	Val	
				645					650					655		
Leu	Asp	Pro	Lys	Asn	Ser	Asp	Ile	Leu	Ile	Gln	Thr	Glu	Leu	Arg	Pro	
		660						665					670			
Val	Lys	Glu	Met	Ala	Gln	Ser	His	Glu	Tyr	Leu	Ser	Ile	Glu	Tyr	Ser	
		675						680					685			
Glu	Glu	Glu	Val	Trp	Leu	Thr	Trp	Thr	Asp	Arg	Asn	Asn	Glu	His	His	
	690					695					700					
Glu	Lys	Ser	Val	Arg	Gln	Leu	Ala	Gln	Glu	Ala	Arg	Ala	Gly	Asn	Ala	
705					710					715					720	
His	Asp	Glu	Asn	Val	Leu	Ser	Tyr	Tyr	Arg	Tyr	Gln	Leu	Lys	Leu	Phe	
				725					730					735		
Ala	Arg	Met	Cys	Leu	Asp	Arg	Gln	Tyr	Leu	Ala	Ile	Asp	Glu	Ile	Ser	
			740					745					750			
Lys	Gln	Leu	Gly	Val	Glu	Leu	Leu	Phe	Leu	Cys	Met	Ala	Asp	Glu	Met	
		755					760					765				
Leu	Pro	Phe	Asp	Leu	Arg	Ala	Ser	Phe	Cys	His	Leu	Met	Leu	His	Val	
	770					775					780					

His Val Asp Arg Asp Pro Gln Glu Leu Val Thr Pro Val Lys Phe Ala	785	790	795	800
Arg Leu Trp Thr Glu Ile Pro Thr Ala Ile Thr Ile Lys Asp Tyr Asp		805	810	815
Ser Asn Leu Asn Ala Ser Arg Asp Asp Lys Lys Asn Lys Phe Ala Ser		820	825	830
Thr Met Glu Phe Val Glu Asp Tyr Leu Asn Asn Val Val Gly Glu Ala		835	840	845
Val Pro Phe Ala Asn Asp Glu Lys Asn Ile Leu Thr Phe Glu Val Val		850	855	860
Ser Leu Ala His Asn Leu Ile Tyr Phe Gly Phe Tyr Ser Phe Ser Glu		865	870	875
Leu Leu Arg Leu Thr Arg Thr Leu Leu Gly Ile Ile Asp Cys Ile Gln		885	890	895
Ala Pro Ala Ala Val Leu Gln Ala Tyr Glu Glu Pro Gly Gly Lys Asn		900	905	910
Val Arg Arg Ser Ile Gln Gly Val Gly His Met Met Ser Thr Met Val		915	920	925
Leu Ser Arg Lys Gln Ser Val Phe Gly Ala Ser Ser Leu Pro Thr Gly		930	935	940
Val Gly Val Pro Glu Gln Leu Asp Arg Ser Lys Phe Glu Asp Asn Glu		945	950	955
His Thr Val Val Met Glu Thr Lys Leu Lys Ile Leu Glu Ile Leu Gln		965	970	975
Phe Ile Leu Asn Val Arg Leu Asp Tyr Arg Ile Ser Tyr Leu Leu Ser		980	985	990
Val Phe Lys Lys Glu Phe Val Glu Val Phe Pro Met Gln Asp Ser Gly		995	1000	1005
Ala Asp Gly Thr Ala Pro Ala Phe Asp Ser Ser Thr Ala Asn Met Asn		1010	1015	1020
Leu Asp Arg Ile Gly Glu Gln Ala Glu Ala Met Phe Gly Val Gly Lys		1025	1030	1035
Thr Ser Ser Met Leu Glu Val Asp Asp Glu Gly Gly Arg Met Phe Leu		1045	1050	1055
Arg Val Leu Leu His Leu Thr Met His Asp Tyr Pro Pro Leu Val Ser		1060	1065	1070
Gly Ala Leu Gln Leu Leu Phe Lys His Phe Ser Gln Arg Gln Glu Ala		1075	1080	1085
Met His Thr Phe Lys Gln Val Gln Leu Leu Ile Ser Ala Gln Asp Val		1090	1095	1100
Glu Asn Tyr Lys Val Ile Lys Ser Glu Leu Asp Arg Leu Arg Thr Met		1105	1110	1115
Val Glu Lys Ser Glu Leu Trp Val Asp Lys Lys Gly Ser Val Lys Gly		1125	1130	1135
Glu Glu Gly Glu Ala Gly Ala Ser Lys Asp Lys Lys Glu Arg Pro Ser		1140	1145	1150
Asp Glu Glu Gly Phe Leu Gln Pro His Gly Glu Lys Ser Ser Glu Asn		1155	1160	1165
Tyr Gln Ile Val Lys Gly Ile Leu Glu Arg Leu Asn Lys Met Cys Gly		1170	1175	1180
Val Gly Glu Gln Met Arg Lys Lys Gln Gln Arg Leu Leu Lys Asn Met		1185	1190	1195
Asp Ala His Lys Val Met Leu Asp Leu Leu Gln Ile Pro Tyr Asp Lys		1205	1210	1215
Asn Asp Asn Lys Met Met Glu Ile Leu Arg Tyr Thr His Gln Phe Leu		1220	1225	1230
Gln Lys Phe Cys Ala Gly Asn Pro Gly Asn Gln Ala Leu Leu His Lys		1235	1240	1245
His Leu Gln Leu Phe Leu Thr Pro Gly Leu Leu Glu Ala Glu Thr Met		1250	1255	1260

Gln His Ile Phe Leu Asn Asn Tyr Gln Leu Cys Ser Glu Ile Ser Glu
 1265 1270 1275 1280
 Pro Val Leu Gln His Phe Val His Cys Trp Pro Thr His Gly Arg His
 1285 1290 1295
 Val Gln Tyr Leu Asp Phe Leu His Thr Val Ile Lys Ala Glu Gly Lys
 1300 1305 1310
 Tyr Val Lys Lys Cys Gln Asp Met Ile Met Thr Glu Leu Thr Asn Ala
 1315 1320 1325
 Gly Asp Asp Val Val Val Phe Tyr Asn Asp Lys Ala Ser Leu Ala His
 1330 1335 1340
 Leu Leu Asp Met Met Lys Ala Ala Arg Asp Gly Val Glu Asp His Ser
 1345 1350 1355 1360
 Pro Leu Met Tyr His Ile Ser Leu Val Asp Leu Leu Ala Ala Cys Ala
 1365 1370 1375
 Glu Gly Lys Asn Val Tyr Thr Glu Ile Lys Cys Thr Ser Leu Leu Pro
 1380 1385 1390
 Leu Glu Asp Val Val Ser Val Val Thr His Glu Asp Cys Ile Thr Glu
 1395 1400 1405
 Val Lys Met Ala Tyr Val Asn Phe Val Asn His Cys Tyr Val Asp Thr
 1410 1415 1420
 Glu Val Glu Met Lys Glu Ile Tyr Thr Ser Asn His Ile Trp Thr Leu
 1425 1430 1435 1440
 Phe Glu Asn Phe Thr Leu Asp Met Ala Leu Val Cys Asn Lys Arg Glu
 1445 1450 1455
 Lys Arg Leu Ser Asp Pro Thr Leu Glu Lys Tyr Val Leu Thr Val Val
 1460 1465 1470
 Leu Asp Thr Ile Ser Ala Phe Phe Ser Ser Pro Phe Ser Glu Asn Ser
 1475 1480 1485
 Thr Ser Leu Gln Thr His Gln Thr Ile Val Val Gln Leu Leu Gln Ser
 1490 1495 1500
 Thr Thr Arg Leu Leu Glu Cys Pro Trp Leu Gln Gln His Lys Gly
 1505 1510 1515 1520
 Ser Val Glu Ala Cys Val Arg Thr Leu Ala Met Val Ala Lys Ser Arg
 1525 1530 1535
 Ala Ile Leu Leu Pro Met Asp Leu Asp Ala His Met Ser Ala Leu Leu
 1540 1545 1550
 Ser Ser Gly Gly Ser Cys Ser Ala Ala Ala Gln Arg Ser Ala Ala Asn
 1555 1560 1565
 Tyr Lys Thr Ala Thr Arg Thr Phe Pro Arg Val Ile Pro Thr Ala Asn
 1570 1575 1580
 Gln Trp Asp Tyr Lys Asn Ile Ile Glu Lys Leu Gln Asp Ile Ile Thr
 1585 1590 1595 1600
 Ala Leu Glu Glu Arg Leu Lys Pro Leu Val Gln Ala Glu Leu Ser Val
 1605 1610 1615
 Leu Val Asp Met Leu His Trp Pro Glu Leu Leu Phe Leu Glu Gly Ser
 1620 1625 1630
 Glu Ala Tyr Gln Arg Cys Glu Ser Gly Gly Phe Leu Ser Lys Leu Ile
 1635 1640 1645
 Arg His Thr Lys Gly Leu Met Glu Ser Glu Glu Lys Leu Cys Val Lys
 1650 1655 1660
 Val Leu Arg Thr Leu Gln Met Leu Gln Lys Lys Ser Lys Tyr Gly
 1665 1670 1675 1680
 Asp Arg Gly Asn Gln Leu Arg Lys Met Leu Leu Gln Asn Tyr Leu Gln
 1685 1690 1695
 Asn Arg Lys Ser Gly Pro Arg Gly Glu Leu Thr Asp Pro Thr Gly Ser
 1700 1705 1710
 Gly Val Asp Gln Asp Trp Ser Ala Ile Ala Ala Thr Gln Cys Arg Leu
 1715 1720 1725
 Asp Lys Glu Gly Ala Thr Lys Leu Val Cys Asp Leu Ile Thr Ser Thr
 1730 1735 1740

Lys Asn Glu Lys Ile Phe Gln Glu Ser Ile Gly Leu Ala Ile Arg Leu
 1745 1750 1755 1760
 Leu Asp Gly Gly Asn Thr Glu Ile Gln Lys Ser Phe Tyr Asn Leu Met
 1765 1770 1775
 Thr Ser Asp Lys Lys Ser Glu Arg Phe Phe Lys Val Leu His Asp Arg
 1780 1785 1790
 Met Lys Arg Ala Gln Gln Glu Thr Lys Ser Thr Val Ala Val Asn Met
 1795 1800 1805
 Ser Asp Leu Gly Ser Gln Pro Arg Glu Asp Arg Glu Pro Ala Asp Pro
 1810 1815 1820
 Thr Thr Lys Gly Arg Val Ser Ser Phe Ser Met Pro Ser Ser Ser Arg
 1825 1830 1835 1840
 Tyr Ser Leu Gly Pro Gly Leu His Arg Gly His Asp Val Ser Glu Arg
 1845 1850 1855
 Ala Gln Asn Asn Glu Met Gly Thr Ser Val Leu Ile Met Arg Pro Ile
 1860 1865 1870
 Leu Arg Phe Leu Gln Leu Leu Cys Glu Asn His Asn Arg Asp Leu Gln
 1875 1880 1885
 Asn Phe Leu Arg Cys Gln Asn Asn Lys Thr Asn Tyr Asn Leu Val Cys
 1890 1895 1900
 Glu Thr Leu Gln Phe Leu Asp Ile Met Cys Gly Ser Thr Thr Gly Gly
 1905 1910 1915 1920
 Leu Gly Leu Leu Gly Leu Tyr Ile Asn Glu Asp Asn Val Gly Leu Val
 1925 1930 1935
 Ile Gln Thr Leu Glu Thr Leu Thr Glu Tyr Cys Gln Gly Pro Cys His
 1940 1945 1950
 Glu Asn Gln Thr Cys Ile Val Thr His Glu Ser Asn Gly Ile Asp Ile
 1955 1960 1965
 Ile Thr Ala Leu Ile Leu Asn Asp Ile Ser Pro Leu Cys Lys Tyr Arg
 1970 1975 1980
 Met Asp Leu Val Leu Gln Leu Lys Asp Asn Ala Ser Lys Leu Leu Leu
 1985 1990 1995 2000
 Ala Leu Met Glu Ser Arg His Asp Ser Glu Asn Ala Glu Arg Ile Leu
 2005 2010 2015
 Ile Ser Leu Arg Pro Gln Glu Leu Val Asp Val Ile Lys Lys Ala Tyr
 2020 2025 2030
 Leu Gln Glu Glu Glu Arg Glu Asn Ser Glu Val Ser Pro Arg Glu Val
 2035 2040 2045
 Gly His Asn Ile Tyr Ile Leu Ala Leu Gln Leu Ser Arg His Asn Lys
 2050 2055 2060
 Gln Leu Gln His Leu Leu Lys Pro Val Lys Arg Ile Gln Glu Glu Glu
 2065 2070 2075 2080
 Ala Glu Gly Ile Ser Ser Met Leu Ser Leu Asn Asn Lys Gln Leu Ser
 2085 2090 2095
 Gln Met Leu Lys Ser Ser Ala Pro Ala Gln Glu Glu Glu Glu Asp Pro
 2100 2105 2110
 Leu Ala Tyr Tyr Glu Asn His Thr Ser Gln Ile Glu Ile Val Arg Gln
 2115 2120 2125
 Asp Arg Ser Met Glu Gln Ile Val Phe Pro Val Pro Ala Ile Cys Gln
 2130 2135 2140
 Phe Leu Thr Glu Glu Thr Lys His Arg Leu Phe Thr Thr Thr Glu Gln
 2145 2150 2155 2160
 Asp Glu Gln Gly Ser Lys Val Ser Asp Phe Phe Asp Gln Ser Ser Phe
 2165 2170 2175
 Leu His Asn Glu Met Glu Trp Gln Arg Arg Leu Arg Ser Met Pro Leu
 2180 2185 2190
 Ile Tyr Trp Phe Ser Arg Arg Met Thr Leu Trp Gly Ser Ile Ser Phe
 2195 2200 2205
 Asn Leu Ala Val Phe Ile Asn Ile Ile Ile Ala Phe Phe Tyr Pro Tyr
 2210 2215 2220

Val Glu Gly Ala Ser Thr Gly Val Leu Gly Ser Pro Leu Ile Ser Leu
 2225 2230 2235 2240
 Leu Phe Trp Ile Leu Ile Cys Phe Ser Ile Ala Ala Leu Phe Thr Lys
 2245 2250 2255
 His Tyr Ser Val Arg Pro Leu Ile Val Ala Leu Val Leu Arg Ser Ile
 2260 2265 2270
 Tyr Tyr Leu Gly Ile Gly Pro Thr Leu Asn Ile Leu Gly Ala Leu Asn
 2275 2280 2285
 Leu Thr Asn Lys Ile Val Phe Val Val Ser Phe Val Gly Asn Arg Gly
 2290 2295 2300
 Thr Phe Ile Arg Gly Tyr Lys Ala Met Val Met Asp Met Glu Phe Leu
 2305 2310 2315 2320
 Tyr His Val Gly Tyr Ile Leu Thr Ser Val Leu Gly Leu Phe Ala His
 2325 2330 2335
 Glu Leu Phe Tyr Ser Ile Leu Leu Phe Asp Leu Ile Tyr Arg Glu Glu
 2340 2345 2350
 Thr Leu Phe Asn Val Ile Lys Ser Val Thr Arg Asn Gly Arg Ser Ile
 2355 2360 2365
 Leu Leu Thr Ala Leu Leu Ala Leu Ile Leu Val Tyr Leu Phe Ser Ile
 2370 2375 2380
 Val Gly Phe Leu Phe Leu Lys Asp Asp Phe Ile Leu Glu Val Asp Arg
 2385 2390 2395 2400
 Leu Pro Gly Asn His Ser Arg Ala Ser Thr Leu Gly Met Pro His Gly
 2405 2410 2415
 Ala Ala Thr Phe Met Gly Thr Cys Ser Gly Asp Lys Met Asp Cys Val
 2420 2425 2430
 Ser Glu Val Ser Val Pro Glu Ile Leu Glu Glu Asp Glu Glu Leu Asp
 2435 2440 2445
 Ser Thr Glu Arg Ala Cys Asp Thr Leu Leu Met Cys Ile Val Thr Val
 2450 2455 2460
 Met Asn His Gly Leu Arg Asn Gly Gly Gly Val Gly Asp Ile Leu Arg
 2465 2470 2475 2480
 Lys Pro Ser Lys Asp Glu Ser Leu Phe Pro Ala Arg Val Val Tyr Asp
 2485 2490 2495
 Leu Leu Phe Phe Phe Ile Val Ile Ile Ile Val Leu Asn Leu Ile Phe
 2500 2505 2510
 Gly Val Ile Ile Asp Thr Phe Ala Asp Leu Arg Ser Glu Lys Gln Lys
 2515 2520 2525
 Lys Glu Glu Ile Leu Lys Thr Thr Cys Phe Ile Cys Gly Leu Glu Arg
 2530 2535 2540
 Asp Lys Phe Asp Asn Lys Thr Val Ser Phe Glu Glu His Ile Lys Leu
 2545 2550 2555 2560
 Glu His Asn Met Trp Asn Tyr Leu Tyr Phe Ile Val Leu Val Arg Val
 2565 2570 2575
 Lys Asn Lys Thr Asp Tyr Thr Gly Pro Glu Ser Tyr Val Ala Gln Met
 2580 2585 2590
 Ile Lys Asn Lys Asn Leu Asp Trp Phe Pro Arg Met Arg Ala Met Ser
 2595 2600 2605
 Leu Val Ser Gly Glu Gly Glu Gly Glu Gln Asn Glu Ile Arg Ile Leu
 2610 2615 2620
 Gln Glu Lys Leu Gly Ser Thr Met Lys Leu Val Ser His Leu Thr Ala
 2625 2630 2635 2640
 Gln Leu Asn Glu Leu Lys Glu Gln Met Thr Glu Gln Arg Lys Arg Arg
 2645 2650 2655
 Gln Arg Leu Gly Phe Val Asp Val Gln Asn Cys Met Ser Arg
 2660 2665 2670

<210> 21
 <211> 4
 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<221> VARIANT

<222> 2, 3

<223> Xaa = Any amino acid

<400> 21

Arg Xaa Xaa Ser

1

<210> 22

<211> 9759

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:/note =
synthetic construct

<400> 22

gagagaaagc	gcacgcccag	aggaggtgtg	ggtgttccgc	tcccatacta	acggaacgag	60
ctccctcttc	goggacatgg	gattgcccag	cggctgctaa	cccctgtcct	ggtcctgac	120
cctcaaaccg	gcgtggctcc	ccggtcacca	aggagctgac	tacaaaggat	ttgcatcctt	180
ggctgggagt	ccattggcta	cagagtgcct	gacctgggtc	aggcttttca	acaaggacat	240
gtctgacaaa	atgtctagtt	tcctacatat	cggagacatt	tgttctctgt	atgcagaggg	300
atctacgaat	ggattttatca	gcaccttggg	cttggttgat	gaccgttgcg	ttgtacagcc	360
agaagctggg	gaccttaaca	atccacccaa	gaaattcaga	gactgcctct	ttaagctatg	420
tcctatgaat	cgatattctg	cacagaagca	gttctggaaa	gctgctaagc	ccggggccaa	480
cagtacaaca	gatgcggtgc	tgctcaacaa	attgcatcat	gctgcagact	tggaaaagaa	540
gcagaatgag	acagaaaaca	ggaaattgct	ggggacggtc	atccagtatg	gcaacgtgat	600
ccagctccta	catttgaaaa	gcaataaata	cttaactgtg	aataagaggc	ttcctgccct	660
gctggagaag	aacgccatga	gagtgcggtt	ggatgaggct	ggaaatgaag	ggtcttggtt	720
ttacattcag	ccgttctaca	agctccgctc	catcggagac	agtgtggtca	taggtgacaa	780
ggtagttttg	aaccctgtca	atgctgggca	gccgctacat	gccagcagcc	atcagctggt	840
ggataaccgg	ggctgcaatg	aggtcaactc	cgtcaactgt	aacacaagct	ggaaaatagt	900
gcttttcatg	aaatggagtg	ataacaaaga	tgacattcta	aaaggagggtg	atgtggtaag	960
actcttccat	gctgagcaag	agaagtttct	cacgtgcgat	gagcacagga	agaagcagca	1020
cgtcttccctg	aggacaaccg	gcagacagtc	agccacgtcg	gccaccagct	ccaaagccct	1080
gtgggaagtg	gaggtagtc	agcatgaccc	atgtcggggt	ggagctgggt	actggaatag	1140
cctcttccgg	ttcaagcacc	tggtacaggg	gcattacttg	gcagcagagg	tagaccctga	1200
ctttgaggaa	gaatgcctgg	agtttcagcc	ctcagtggtg	cctgatcagg	acgcatctcg	1260
gagcaggttg	agaaatgccc	aagaaaaaat	ggtgtactct	ctggtctctg	tgccctgagg	1320
caacgacatc	tcctccatct	ttgagctaga	ccccacaact	ctacgtggag	gtgacagcct	1380
tgtcccgaag	aactcctatg	tccggctcag	acacctgtgt	acaaacacct	gggttcacag	1440
cacaaacatc	cccattgaca	aggaagagga	aaaacctgtc	atgctgaaga	ttggtacctc	1500
tcccctgaag	gaggacaagg	aagctttttg	catagtcccc	gtttctctctg	ctgagggttcg	1560
ggacctggac	tttgccaatg	atgccagcaa	ggtgtctggc	tccatcgctg	ggaagttgga	1620
aaagggcacc	atcaccacga	atgagagaag	gtctgtcacc	aagctgctgg	aagacttgggt	1680
ttactttgtc	acgggtggaa	cgaactctgg	ccaagacgtg	cttgaagtag	tcttctctaa	1740
gcccacccga	gagcggcaga	agctgatgag	ggaacagaat	attctcaagc	agatcttcaa	1800
gctttttgcag	gcccccttca	cggactgcgg	ggatggccca	atgcttcggc	tggaggagct	1860
gggggaccag	cggcacgctc	ctttcagaca	catttgccga	ctctgctaca	gggtcctgag	1920
acactcacag	caagactaca	ggaagaacca	ggagtacata	gccaaagcag	ttggcttcat	1980
gcagaagcag	attggctatg	atgtgctggc	cgaagacacc	atcactgccc	tgctccacaa	2040
caaccgaaag	ctcctggaaa	agcacatcac	cgcagcagag	attgacacgt	ttgtcagcct	2100

ggtgcgaaag	aacaggggagc	ccaggttctt	ggattacctc	tctgacctct	gtgtatccat	2160
gaataagtca	atccctgtga	cccaggagct	catttgtaaa	gctgtgctga	atccccacaa	2220
tgctgacatc	ctgattgaga	ccaagttggt	tctttctcgt	tttgagtttg	aaggcgtttc	2280
caccggagag	aatgctctgg	aagctgggga	agatgaggaa	gaggtgtggc	tgttctggag	2340
ggacagcaac	aaagagatcc	gtagcaagag	tgtagggaa	ttggcacaag	atgctaaaga	2400
gggacagaag	gaagacaggg	atgtcctcag	ctactacagg	tatcagctga	acctctttgc	2460
aaggatgtgt	ctggaccgcc	agtacctggc	catcaatgaa	atatccgggc	agctggatgt	2520
tgacctcatc	ctccgctgca	tgtccgatga	gaacctcccc	tatgacctca	gagcatcctt	2580
ttgccgcctc	atgcttcaca	tgcattgtga	ccgagatccc	caggagcagg	tgacctctgt	2640
gaaatacgcc	cgtctgtggt	cagaaattcc	ctccgagatc	gccattgacg	actatgacag	2700
cagtggagca	tcgaaggatg	aaatcaagga	gaggtttgct	cagacgatgg	agtttgtgga	2760
ggagtacctg	agagatgtgg	tttgtcaaaag	attccccctt	tctgataagg	agaaaaataa	2820
gctcacattt	gaggttgtga	acttagccag	gaacctcata	tactttggct	tctacaactt	2880
ttctgacctt	ctccgattaa	ccaagatcct	cttggaatc	ttagactgtg	ttcatgtgac	2940
aaccatcttc	cccattagca	agatgacgaa	aggcgaagag	aataaaggca	gcaacgtgat	3000
gagatctatc	catggagtgg	gggagctcat	gacctagggtg	gtgcttcggg	gaggagctct	3060
tttgcccatg	actcctatgg	ctgctgcccc	tgaaggaaat	gtgaagcagg	cagagccaga	3120
gaaagaggat	atcatggtca	tggacaccaa	gttaaagatc	attgaaatac	tccagtttat	3180
tttgaatgtg	agattggatt	ataggatctc	ctgctcctcg	tgtatattta	agcgggagtt	3240
tgatgaaagc	aattcccagt	catcagaaac	atcctccgga	aacagcagcc	aagaaggggc	3300
aagtaatgta	ccaggtgctc	ttgactttga	acacattgaa	gagcaagcag	aaggcatcct	3360
tgggggaagt	gaggagaaca	cacctctgga	cttggaatgat	catggtggca	gaaccttctt	3420
cagggctctg	ctccacttga	caatgcatga	ttaccacccc	ctgggtgtctg	gggccctgca	3480
gctcctcttc	cggcatttca	gccagaggca	ggaggctcct	caggccttca	aacaggttca	3540
actgctggtt	actagccaag	atgtggacaa	ctacaacacag	atcaagcaag	acttggacca	3600
gctaagatcc	atcgttgaga	agtctgagct	ctgggtatac	aaaggccagg	gtcccagatga	3660
gcctatggac	ggagcctctg	gtgaaaacga	acataagaaa	actgaggagg	ggaccagtaa	3720
gccactgaag	cacgaaagca	ccagcagcta	caactaccga	gtggtgaaag	agattctgat	3780
tcgacttagc	aagctctgtg	ttcaagagag	cgcgtcgggtg	aggaagagca	ggaagcagca	3840
gcagcgactg	ctgaggaaca	tgggtgcccc	tgctgtgggtg	ctggagctgc	tgcagatccc	3900
ctatgagaag	gccgaagata	ccaagatgca	ggagatcatg	aggctggctc	acgaatttct	3960
gcagaatttc	tgcgcaggca	accagcagaa	ccaagctttg	ctacataaac	acataaacct	4020
gtttctcaac	ccagggatcc	tggaaagcag	gaccatgcag	cacatcttca	tgaacaactt	4080
ccagctgtgc	agtgagatca	acgagagagt	ggtccagcat	ttcgttccact	gcataagac	4140
ccacggtcga	aatgtccagt	atatcaagtt	tctccagact	attgtcaagg	ccgaagggaa	4200
attcattaaa	aagtgccaaag	acatggtcat	ggctgagctt	gtcaattctg	gagaggacgt	4260
cctcgtgttc	tacaatgaca	gagcctcttt	ccagactctg	atccagatga	tgcggtccga	4320
gcgtgaccgg	atggatgaga	acagccctct	catgtaccac	atccatctgg	tggagctctt	4380
ggctgtgtgc	acagagggca	agaatgtgta	cacagagatc	aagtgcact	ccctgctccc	4440
gctcgatgac	atcggttcgtg	tggctactca	tgaagactgt	atccccgagg	ttaagattgc	4500
ttacatcaac	ttcctgaatc	actgctatgt	ggacactgag	gtggagatga	aggagattta	4560
cacaagtaat	cacatgtgga	agttgtttga	gaatttcttc	gtggacatct	gcagggcctg	4620
taacaacaca	agtgcacga	agcatgcaga	ctcggttctg	gagaagtacg	tcactgaaat	4680
cgtgatgagc	attgtcacca	ccttcttcag	ctctcccttc	tcagaccaga	gtccactctt	4740
gcagactcgc	cagcctgtct	ttgtgcagct	cctgcaaggc	gtgttccgag	tttaccactg	4800
caactgggtg	atgccgagcc	agaaagcctc	ggtggagagc	tgtatccgcg	tgctctctga	4860
cgtagccaag	agccggggcca	tagccattcc	tgttgacctc	gacagccaag	tcaacaacct	4920
cttctgaag	tcccacaaca	ttgtgcagaa	aacagccatg	aactggcggt	tatcagcccg	4980
caacgctgct	cgtagagact	ctgtcctggc	agcttccaga	gactaccgaa	atattattga	5040
gaggttacag	gacatcgtgt	ctgccctgga	ggaccgactc	aggccccctg	tccaggccga	5100
gctgtctgtg	ctcgtggatg	ttctacacag	accggaactg	cttttccctg	agaacacgga	5160
tgccaggagg	aaatgcgaaa	gtggaggttt	catctgcaag	ctcataaaac	acaccaagca	5220
gctgctagag	gagaactgag	agaaaactgtg	atttaaagtc	ttacagaccc	tcagggaat	5280
gatgacaaa	gatagaggct	atggagaaaa	gcaaatttcc	attgatgaat	tggaaaatgc	5340
cgagctgcca	cagccaccgg	aagctgagaa	ctccacagag	caggagcttg	aaccaagtcc	5400
acccctgagg	caactggaag	accataaaag	gggtgaggca	ctccggcaaa	ttttgggtcaa	5460
ccgttactat	ggaaacatca	gaccttcagg	aagaagagag	agccttacca	gctttggcaa	5520
tggtccacta	tcaccaggag	gacctcagaa	gcctggggga	ggaggggggag	gtcctgggtc	5580
cggctccaca	agccgggggtg	agatgagcct	ggctgaggtt	caatgtcatc	tcgacaagga	5640
aggcgccctc	aatctggtca	tcgacctcat	aatgaatgca	tccagcgacc	gagtattcca	5700
cgaagcatt	ctcctggcca	tcgcacttct	ggaaggaggc	aacaccacta	tccagcactc	5760

atTTTTctgc	cggttgacgg	aagataagaa	atcagagaag	ttcttcaagg	tcttttacga	5820
tcgaatgaag	gtggcccagc	aggaaatcaa	ggcgacagtg	accgtgaaca	ccagcgattt	5880
gggaaacaaa	aagaaagatg	atgaagtgga	ccgggatgcc	ccatcccgga	agaaagccaa	5940
agagcccaca	acacagataa	cagaagaggt	ccgggatcag	ctcttggaag	catctgctgc	6000
caccagaaaa	gcctttacca	ccttccggag	ggaggccgac	cctgatgacc	attaccaatc	6060
tggggagggc	acccaggcta	caacggacaa	agccaaggat	gacctagaga	tgagtgcagt	6120
catcaccatc	atgcagccta	tctgcgcctt	cctgcagctc	ctgtgtgaaa	accacaaccg	6180
cgatctgcag	aatttccctt	gttgccaaaa	taataagacc	aactacaact	tggtgtgtga	6240
gacactgcag	tttctggact	gtatctgtgg	gagcacaact	ggaggccttg	gtcttctcgg	6300
actgtacata	aatgaaaaga	atgtagctct	tatcaaccaa	accctggaga	gtctgactga	6360
gtactgtcaa	gggccttgcc	atgaaaacca	gaactgcata	gccaccacag	agtccaatgg	6420
catcgatatc	atcacagccc	tcatccttaa	cgatatcaac	cctctgggga	agaaacggat	6480
ggacctggtg	ttagaactga	agaacaatgc	ttcaaagcta	ctcctggcca	tcatggaaag	6540
cagacacgat	agtgaaaatg	cagagaggat	cctgtacaac	atgaggccca	aggagctggt	6600
ggaagtgate	aagaaggcct	acatgcaagg	cgaagtggag	tttgaggatg	gggagaacgg	6660
tgaggatgga	gcagcctccc	ccaggaaact	gggccataac	atctacatcc	tcgctcacca	6720
gttggtcctg	cataacaaag	aacttcaaac	catgtctgaa	cctggaggcc	aggtggatgg	6780
cgatgaagct	ctggagttct	atgcgaagca	cacagcacia	attgagattg	tcagactgga	6840
ccgaactatg	gaacagattg	tcttccctgt	gccagcctc	tgtgaatttc	tgactaagga	6900
atcgaaactt	cgaatatatt	acaccacaga	gagggatgag	caaggcagca	agatcaatga	6960
cttcttctct	cgctccgagg	acctctttaa	tgagatgaac	tggcagaaga	aacttcgagc	7020
ccagcctgtc	ttgtactggt	gcgcccgaag	catgtctttc	tgagagcagca	tctccttcaa	7080
cctggccgtc	ctgatgaacc	tgctggtggc	gtttttctac	ccattttaaag	gagtgaaggg	7140
aggaacacta	gagccgcact	ggtccggcct	cctgtggaca	gccatgctca	tctctctggc	7200
aattgtcatt	gcgctgcccc	agccccatgg	catccgggcc	ttaattgctt	ctacaatcct	7260
acgactgata	tttccagttg	gattacagcc	cacactgttt	ctgctgggag	ctttcaatgt	7320
ctgcaataaa	atcatcttcc	tgatgagctt	tgtgggcaac	tgtgggacct	tcaccagagg	7380
ctaccgagcc	atggttctgg	acgttgagtt	cctctatcat	ttgctgtatc	tactgatctg	7440
tgccatgggc	ctcttcgtac	atgagttttt	ctatagtttg	ctgctttttg	atttagtgta	7500
cagagaggag	actttgctta	atgtcattaa	aagtgtcacc	cgcaatggac	ggtccatcat	7560
cttgacagcg	gtcctggctc	tgattctggt	ttacctgttc	tcaattgtgg	gctacctgtt	7620
cttcaaggat	gactttatct	tggaagtaga	caggttgccc	aatgagacag	ctggtccaga	7680
aactggtgag	agtttggtcca	acgatttccct	gtactctgat	gtgtgccggg	tagagacggg	7740
ggagaactgc	acctctccgg	cacccaaaga	agagctgctc	cctgtggaag	aaacggaaca	7800
ggataaggag	cacacgtgtg	agacactgct	catgtgcata	gtcacogttc	tgagtccagg	7860
gctgcggagt	gggggcgagg	taggagatgt	gctcaggaag	ccatccaaag	aggagcctct	7920
gtttgtctga	agggtgatct	atgacctcct	cttcttcttc	atgggtcatca	tcattgtcct	7980
gaacctcatt	tttggggtca	tcatcgacac	ctttgctgac	ctgaggagtg	agaagcagaa	8040
gaaggaagag	atcttaaaaa	ccacgtgctt	catttgtggc	ttggaaaggg	acaagtttga	8100
caataagacc	gtcacctttg	aagagcacat	taaggaagaa	cacaacatgt	ggcactatct	8160
gtgcttcata	gtgctggtga	aagtgaagga	ctccaccgag	tacaccgggc	ccgagagcta	8220
cgtggcagag	atgatcaggg	aaagaaacct	tgatttggtc	cccaggatga	gagccatgtc	8280
cctggtcagc	agtgactctg	aaggggaaca	gaacgagctg	aggaacctgc	aggagaagct	8340
ggagtccacc	atgaagctgg	tcaccaatct	ttctggccag	ctgtcagaac	taaaggacca	8400
gatgacagaa	caaagggaag	agaaacaaag	aattggcctt	ctaggacatc	ctcctcacat	8460
gaatgtcaac	ccacagcagc	cagcctaagc	aaatgagacg	gagggactgt	actcaacctt	8520
ttttaaatta	ttgtcagcgt	gggtctggct	cttggttctg	atctgccctc	taaggttaca	8580
tgtgcgctta	gtacatttgt	aaatactcgg	ttttgtattg	tatgtatatg	attgcaattc	8640
tcagaggttt	ggactttcgt	attgtaatta	gctctgttgg	catggtgact	tgtcactcct	8700
gccaaaaata	ttaaaaatgc	cttttttgga	aggactacag	aaagtacctg	atttgcactt	8760
gaaccagatt	atagattttaa	aagtatatga	catgtatttt	gtatttaaaa	ctagaatagc	8820
cagtatttat	gtttttttata	aaactgtgca	atacaaatga	tgcaatcacc	ataactctgt	8880
aactcctgag	tgtcttaagg	gagtgcgcct	ctttggaagct	gatctgttaa	tacttatgta	8940
ataaatgggt	aaatatcaaaa	tgatgatgct	gctgccaaaa	ttatattaat	agcaagtttc	9000
tggccccctg	gcaattttgt	accttgtaat	tatcctatgg	tgatgctgtt	tctcgttgct	9060
aatggcatta	gtgcctcgta	tcctagtgat	aactccaggt	ctgtgaacca	ttcaaacaac	9120
attcattttt	gagacaaagc	aacttttagtt	tcaagggtta	ttttaagctt	caaaattaat	9180
cattttaaagt	atttcttttaa	gagagccatg	tttagaggctc	acacggttagc	ttgaaaggag	9240
tcgatgaaat	aatttttttta	aagggaactt	tttacacgac	gttttgaata	acagcatatt	9300
gctgaccagt	cagtgtcatc	tcccagggtga	atttttagtgt	cacgttatag	tcaaatgagc	9360
tagctgatgg	tttctagatt	ctcttcatct	gaaccaacat	gatgcagtag	gtgagaagtt	9420

```
attatgcata tatacacata tacatccata taaggcaaag taggagctgt ccccttagga 9480
tgcatagctg ccccttagg gtgcagagct caacactgac agtgctgttc tgagagagcc 9540
acgtttgggt tttatttctt tgtcacatga tttcttttct ggatgtgtgc aagtataaca 9600
ggaagtgttt totacctgtt gcttgttttg tacctgggtc tcgttttact agaccatctc 9660
tgcacaaaag tttaaaaaat gaaccgtaag cagagttctg aagcaagtca agtttgtaag 9720
tgcatacctg aaattattta ataaatgacg cagaatact 9759
```